FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Djogbenou, LS
   Assogba, B
   Essandoh, J
   Constant, EAV
   Makoutode, M
   Akogbeto, M
   Donnelly, MJ
   Weetman, D
AF Djogbenou, Luc S.
   Assogba, Benoit
   Essandoh, John
   Constant, Edi A. V.
   Makoutode, Michel
   Akogbeto, Martin
   Donnelly, Martin J.
   Weetman, David
TI Estimation of allele-specific Ace-1 duplication in insecticide-resistant
   Anopheles mosquitoes from West Africa
SO MALARIA JOURNAL
LA English
DT Article
ID COPY NUMBER VARIATION; DROPLET DIGITAL PCR; CULEX-PIPIENS; HUMAN GENOME;
   STRUCTURAL VARIATION; QUANTITATIVE PCR; GENE DUPLICATION; COTE-DIVOIRE;
   GAMBIAE; MUTATION
AB Background: Identification of variation in Ace-1 copy number and G119S mutation genotype from samples of Anopheles gambiae and Anopheles coluzzii across West Africa are important diagnostics of carbamate and organophosphate resistance at population and individual levels. The most widespread and economical method, PCR-RFLP, suffers from an inability to discriminate true heterozygotes from heterozygotes with duplication.
   Methods: In addition to PCR-RFLP, in this study three different molecular techniques were applied on the same mosquito specimens: TaqMan qPCR, qRTPCR and ddPCR. To group heterozygous individuals recorded from the PCR-RFLP analysis into different assumptive genotypes K-means clustering was applied on the Z-scores of data obtained from both the TaqMan and ddPCR methods. The qRTPCR analysis was used for absolute quantification of copy number variation.
   Results: The results indicate that most heterozygotes are duplicated and that G119S mutation must now be regarded as a complex genotype ranging from primarily single-copy susceptible Glycine homozygotes to balanced and imbalanced heterozygotes, and multiply-amplified resistant Serine allele homozygotes. Whilst qRTPCR-based gene copy analysis suffers from some imprecision, it clearly illustrates differences in copy number among genotype groups identified by TaqMan or ddPCR. Based on TaqMan method properties, and by coupling TaqMan and ddPCR methods simultaneously on the same type of mosquito specimens, it demonstrated that the TaqMan genotype assays associated with the K-means clustering algorithm could provide a useful semi-quantitative estimate method to investigate the level of allele-specific duplication in mosquito populations.
   Conclusions: Ace-1 gene duplication is evidently far more complex in An. gambiae and An. coluzzii than the better-studied mosquito Culex quinquefasciatus, which consequently can no longer be considered an appropriate model for prediction of phenotypic consequences. These require urgent further evaluation in Anopheles. To maintain the sustained effectiveness carbamates and organophosphates as alternative products to pyrethroids for malaria vector control, monitoring of duplicated resistant alleles in natural populations is essential to guide the rational use of these insecticides.
C1 [Djogbenou, Luc S.; Assogba, Benoit; Makoutode, Michel] Univ Abomey Calavi, Inst Reg Sante Publ Ouidah, Cotonou, Benin.
   [Djogbenou, Luc S.; Essandoh, John; Constant, Edi A. V.; Donnelly, Martin J.; Weetman, David] Univ Liverpool, Liverpool Sch Trop Med, Dept Vector Biol, Liverpool L3 5QA, Merseyside, England.
   [Akogbeto, Martin] Ctr Rech Entomol Cotonou, Cotonou, Benin.
RP Djogbenou, LS (reprint author), Univ Abomey Calavi, Inst Reg Sante Publ Ouidah, Cotonou, Benin.
EM ldjogbenou22002@yahoo.fr
RI Weetman, David/M-1261-2014
OI Weetman, David/0000-0002-5820-1388
FU Wellcome Trust Master's Training Fellowship in Public Health and
   Tropical Medicine [WT093755]
FX We are grateful to Emily Rippon, Keith Steen Stephen Hague (Droplet
   Digital PCR Specialist) for their technical support. We would also like
   to thank the following people; Seth Irish, Audrey Lenhart and Brogdon
   William G. for providing useful comments on earlier versions of the
   manuscript. This work was supported by Wellcome Trust Master's Training
   Fellowship in Public Health and Tropical Medicine Grant WT093755.
NR 34
TC 2
Z9 2
U1 3
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD DEC 18
PY 2015
VL 14
AR 507
DI 10.1186/s12936-015-1026-3
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CZ5MO
UT WOS:000367146900001
PM 26682913
ER

PT J
AU Agossa, FR
   Gnanguenon, V
   Anagonou, R
   Azondekon, R
   Aizoun, N
   Sovi, A
   Oke-Agbo, F
   Sezonlin, M
   Akogbeto, MC
AF Agossa, Fiacre R.
   Gnanguenon, Virgile
   Anagonou, Rodrigue
   Azondekon, Roseric
   Aizoun, Nazaire
   Sovi, Arthur
   Oke-Agbo, Frederic
   Sezonlin, Michel
   Akogbeto, Martin C.
TI Impact of Insecticide Resistance on the Effectiveness of
   Pyrethroid-Based Malaria Vectors Control Tools in Benin: Decreased
   Toxicity and Repellent Effect
SO PLOS ONE
LA English
DT Article
ID ANOPHELES-GAMBIAE-S.L.; WEST-AFRICA; TREATED NETS; BENDIOCARB;
   TRANSMISSION; POPULATIONS; EFFICACY; AREAS
AB Since the first evidence of pyrethroids resistance in 1999 in Benin, mutations have rapidly increased in mosquitoes and it is now difficult to design a study including a control area where malaria vectors are fully susceptible. Few studies have assessed the after effect of resistance on the success of pyrethroid based prevention methods in mosquito populations. We therefore assessed the impact of resistance on the effectiveness of pyrethroids based indoor residual spraying (IRS) in semi-field conditions and long lasting insecticidal nets (LLINs) in laboratory conditions. The results observed showed low repulsion and low toxicity of pyrethroids compounds in the test populations. The toxicity of pyrethroids used in IRS was significantly low with An. gambiae s.l (< 46%) but high for other predominant species such as Mansonia africana (93% to 97%). There were significant differences in terms of the repellent effect expressed as exophily and deterrence compared to the untreated huts (P<0.001). Furthermore, mortality was 23.71% for OlyseNet (R) and 39.06% for PermaNet (R). However, with laboratory susceptible "Kisumu", mortality was 100% for both nets suggesting a resistance within the wild mosquito populations. Thus treatment with pyrethroids at World Health Organization recommended dose will not be effective at reducing malaria in the coming years. Therefore it is necessary to study how insecticide resistance decreases the efficacy of particular pyrethroids used in pyrethroid-based vector control so that a targeted approach can be adopted.
C1 [Agossa, Fiacre R.; Gnanguenon, Virgile; Anagonou, Rodrigue; Azondekon, Roseric; Aizoun, Nazaire; Sovi, Arthur; Oke-Agbo, Frederic; Akogbeto, Martin C.] CREC, Cotonou, Benin.
   [Sezonlin, Michel; Akogbeto, Martin C.] FAST UAC, Lab Evolut Biodiversite Arthropodes & Assainissem, Abomey Calavi, Benin.
RP Agossa, FR (reprint author), CREC, Cotonou, Benin.
EM rofargossa@yahoo.fr
FU Tagros under grant Tagros/CREC/; Tagros
FX The research leading to these results was financially supported by
   Tagros under grant Tagros/CREC/June 12. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.; We are grateful to Tagros which funded
   this study. We acknowledge all volunteers from Malanville for
   participating and facilitating this study. We are also grateful to Simon
   MCollins for language editing.
NR 29
TC 2
Z9 2
U1 6
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 16
PY 2015
VL 10
IS 12
AR e0145207
DI 10.1371/journal.pone.0145207
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CY9JH
UT WOS:000366722700114
PM 26674643
ER

PT J
AU Held, J
   Supan, C
   Salazar, CLO
   Tinto, H
   Bonkian, LN
   Nahum, A
   Moulero, B
   Sie, A
   Coulibaly, B
   Sirima, SB
   Siribie, M
   Otsyula, N
   Otieno, L
   Abdallah, AM
   Kimutai, R
   Bouyou-Akotet, M
   Kombila, M
   Koiwai, K
   Cantalloube, C
   Din-Bell, C
   Djeriou, E
   Waitumbi, J
   Mordmuller, B
   Ter-Minassian, D
   Lell, B
   Kremsner, PG
AF Held, Jana
   Supan, Christian
   Salazar, Carmen L. O.
   Tinto, Halidou
   Bonkian, Lea N.
   Nahum, Alain
   Moulero, Bancole
   Sie, Ali
   Coulibaly, Boubacar
   Sirima, Sodiomon B.
   Siribie, Mohamadou
   Otsyula, Nekoye
   Otieno, Lucas
   Abdallah, Ahmed M.
   Kimutai, Robert
   Bouyou-Akotet, Marielle
   Kombila, Maryvonne
   Koiwai, Kimiko
   Cantalloube, Cathy
   Din-Bell, Chantal
   Djeriou, Elhadj
   Waitumbi, John
   Mordmueller, Benjamin
   Ter-Minassian, Daniel
   Lell, Bertrand
   Kremsner, Peter G.
TI Ferroquine and artesunate in African adults and children with Plasmodium
   falciparum malaria: a phase 2, multicentre, randomised, double-blind,
   dose-ranging, non-inferiority study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID IN-VITRO ACTIVITY; ANTIMALARIAL ACTIVITY;
   DIHYDROARTEMISININ-PIPERAQUINE; UNCOMPLICATED MALARIA; ORAL
   BIOAVAILABILITY; RESISTANT MALARIA; CHLOROQUINE; GABON; DRUG; VIVO
AB Background Artemisinin-based combination therapies (ACTs) are the recommended first-line treatment for uncomplicated Plasmodium falciparum malaria. Ferroquine is a new combination partner for fast-acting ACTs such as artesunate. We aimed to assess different doses of ferroquine in combination with artesunate against uncomplicated P falciparum malaria in a heterogeneous population in Africa.
   Methods We did a phase 2, multicentre, parallel-group, double-blind, randomised, dose-ranging non-inferiority trial at eight African hospitals (two in Gabon, three in Burkina Faso, one in Benin, and two in Kenya). We recruited patients presenting with acute P falciparum monoinfection (1000-200 000 parasites per mu L), and a central body temperature of at least 37.5 degrees C or history of fever in the past 24 h. We assessed patients in two sequential cohorts: cohort 1 contained adults (bodyweight >50 kg) and adolescents (aged >= 14 years, >30 kg), and cohort 2 contained children (aged 2-13 years, 15-30 kg). We randomly assigned patients (1:1:1:1) to receive artesunate 4 mg/kg per day plus ferroquine 2 mg/kg, 4 mg/kg, or 6 mg/kg, given double-blind once per day for 3 days, or ferroquine monotherapy 4 mg/kg per day given single-blind (ie, allocation was only masked from the patient) once per day for 3 days. We did 14 patient visits (screening, 3 treatment days and 48 h post-treatment surveillance, a visit on day 7, then one follow-up visit per week until day 63). The primary endpoint was non-inferiority of treatment in terms of PCR-corrected cure rate against a reference value of 90%, with a 10% non-inferiority margin, assessed in patients treated without major protocol deviations for parasitologically confirmed malaria. We assessed safety in all treated patients. This study is registered with ClinicalTrials.gov, number NCT00988507, and is closed.
   Findings Between Oct 16, 2009, and Sept 22, 2010, we randomly assigned 326 eligible patients to treatment groups, with last follow-up visit on Dec 1, 2010. 284 patients (87%) were available for per-protocol analyses. At day 28, PCR-confirmed cure was noted in 68 (97%, 95% CI 90-100) of 70 patients treated with ferroquine 2 mg/kg plus artesunate, 73 (99%, 93-100) of 74 with ferroquine 4 mg/kg plus artesunate, 71 (99%, 93-100) of 72 with ferroquine 6 mg/kg plus artesunate, and 54 (79%, 68-88) of 68 with ferroquine 4 mg/kg monotherapy. The three dose groups of ferroquine plus artesunate met the non-inferiority hypothesis. The most common adverse events were headache in cohort 1 (30 [19%] of 162 patients) and worsening malaria in cohort 2 (23 [14%] of 164 patients); occurrences were similar between treatment groups.
   Interpretation Ferroquine combined with artesunate was associated with high cure rates and was safe at all doses tested, and could be a promising new drug combination for the treatment of P falciparum malaria. Ferroquine could also partner other drugs to establish
C1 [Held, Jana; Mordmueller, Benjamin; Lell, Bertrand; Kremsner, Peter G.] Univ Klinikum Tubingen, Inst Tropenmed, D-72074 Tubingen, Germany.
   [Held, Jana; Supan, Christian; Salazar, Carmen L. O.; Mordmueller, Benjamin; Lell, Bertrand; Kremsner, Peter G.] Ctr Rech Med Lambarene, Lambarene, Gabon.
   [Held, Jana; Mordmueller, Benjamin; Lell, Bertrand; Kremsner, Peter G.] Heinrich Pette Inst, German Ctr Infect Res, Hamburg, Germany.
   [Tinto, Halidou; Bonkian, Lea N.] Ctr Muraz IRSS, Bobo Dioulasso, Burkina Faso.
   [Nahum, Alain; Moulero, Bancole] Ctr Rech Entomol Cotonou, Cotonou, Benin.
   [Sie, Ali; Coulibaly, Boubacar] Ctr Rech Sante Nouna, Nouna, Burkina Faso.
   [Sirima, Sodiomon B.; Siribie, Mohamadou] Grp Rech Act Sante, Ouagadougou, Burkina Faso.
   [Sirima, Sodiomon B.] Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso.
   [Otsyula, Nekoye; Otieno, Lucas] Kenya Govt Med Res Ctr, US Army Med Res Unit, Nairobi, Kenya.
   [Abdallah, Ahmed M.; Kimutai, Robert] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Bouyou-Akotet, Marielle; Kombila, Maryvonne] Univ Sci Sante, Dept Parasitol, Mycol, Med Trop, Libreville, Gabon.
   [Koiwai, Kimiko; Cantalloube, Cathy; Din-Bell, Chantal; Djeriou, Elhadj; Ter-Minassian, Daniel] Sanofi Res & Dev, Chilly Mazarin, France.
   [Waitumbi, John] Kenya Govt Med Res Ctr, Walter Reed Project, Kisumu, Kenya.
RP Kremsner, PG (reprint author), Univ Klinikum Tubingen, Inst Tropenmed, D-72074 Tubingen, Germany.
EM peter.kremsner@uni-tuebingen.de
RI Mordmuller, Benjamin/A-5749-2010
OI Mordmuller, Benjamin/0000-0001-9101-2768
FU Sanofi
FX Funding Sanofi.
NR 37
TC 11
Z9 11
U1 0
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD DEC
PY 2015
VL 15
IS 12
BP 1409
EP 1419
DI 10.1016/S1473-3099(15)00079-1
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA CW6YQ
UT WOS:000365144800027
PM 26342427
ER

PT J
AU Nouatin, O
   Gbedande, K
   Ibitokou, S
   Vianou, B
   Houngbegnon, P
   Ezinmegnon, S
   Borgella, S
   Akplogan, C
   Cottrell, G
   Varani, S
   Massougbodji, A
   Moutairou, K
   Troye-Blomberg, M
   Deloron, P
   Luty, AJF
   Fievet, N
AF Nouatin, Odilon
   Gbedande, Komi
   Ibitokou, Samad
   Vianou, Bertin
   Houngbegnon, Parfait
   Ezinmegnon, Sem
   Borgella, Sophie
   Akplogan, Carine
   Cottrell, Gilles
   Varani, Stefania
   Massougbodji, Achille
   Moutairou, Kabirou
   Troye-Blomberg, Marita
   Deloron, Philippe
   Luty, Adrian J. F.
   Fievet, Nadine
TI Infants' Peripheral Blood Lymphocyte Composition Reflects Both Maternal
   and Post-Natal Infection with Plasmodium falciparum
SO PLOS ONE
LA English
DT Article
ID REGULATORY T-CELLS; ALPHA-INDUCED APOPTOSIS; HUMAN NK-CELLS; CORD BLOOD;
   MALARIA INFECTION; PLACENTAL MALARIA; IN-UTERO; CYTOKINE RESPONSES;
   IMMUNE-RESPONSES; EARLY-LIFE
AB Maternal parasitoses modulate fetal immune development, manifesting as altered cellular immunological activity in cord blood that may be linked to enhanced susceptibility to infections in early life. Plasmodium falciparum typifies such infections, with distinct placental infection-related changes in cord blood exemplified by expanded populations of parasite antigen-specific regulatory T cells. Here we addressed whether such early-onset cellular immunological alterations persist through infancy. Specifically, in order to assess the potential impacts of P. falciparum infections either during pregnancy or during infancy, we quantified lymphocyte subsets in cord blood and in infants' peripheral blood during the first year of life. The principal age-related changes observed, independent of infection status, concerned decreases in the frequencies of CD4(+), NKdim and NKT cells, whilst CD8(+), Treg and Teff cells' frequencies increased from birth to 12 months of age. P. falciparum infections present at delivery, but not those earlier in gestation, were associated with increased frequencies of Treg and CD8(+) T cells but fewer CD4(+) and NKT cells during infancy, thus accentuating the observed age-related patterns. Overall, P. falciparum infections arising during infancy were associated with a reversal of the trends associated with maternal infection i.e. with more CD4(+) cells, with fewer Treg and CD8(+) cells. We conclude that maternal P. falciparum infection at delivery has significant and, in some cases, year-long effects on the composition of infants' peripheral blood lymphocyte populations. Those effects are superimposed on separate and independent age-as well as infant infection-related alterations that, respectively, either match or run counter to them.
C1 [Nouatin, Odilon; Gbedande, Komi; Ibitokou, Samad; Vianou, Bertin; Houngbegnon, Parfait; Ezinmegnon, Sem; Borgella, Sophie; Akplogan, Carine; Cottrell, Gilles; Massougbodji, Achille; Fievet, Nadine] Univ Abomey Calavi, Fac Sci Sante, CERPAGE, Cotonou, Benin.
   [Nouatin, Odilon; Gbedande, Komi; Ibitokou, Samad; Vianou, Bertin; Houngbegnon, Parfait; Ezinmegnon, Sem; Akplogan, Carine; Moutairou, Kabirou] Univ Abomey Calavi, Fac Sci & Tech, Dept Biochim & Biol Cellulaire, Cotonou, Benin.
   [Borgella, Sophie; Cottrell, Gilles; Deloron, Philippe; Fievet, Nadine] Inst Rech Dev, MERIT UMR Mere & Enfant Face Infect Trop D216, Paris, France.
   [Cottrell, Gilles; Deloron, Philippe; Fievet, Nadine] Univ Paris 05, Fac Pharm, PRES Sorbonne Paris Cite, Paris, France.
   [Varani, Stefania] Univ Bologna, Microbiol Unit, Dept Diagnost Expt & Specialty Med, Bologna, Italy.
   [Troye-Blomberg, Marita] Stockholm Univ, Dept Mol Biosci, Wenner Gren Inst, S-10691 Stockholm, Sweden.
   [Luty, Adrian J. F.] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6525 ED Nijmegen, Netherlands.
RP Fievet, N (reprint author), Univ Abomey Calavi, Fac Sci Sante, CERPAGE, Cotonou, Benin.
EM fievet.nadine@ird.fr
RI Troye-Blomberg, Marita/B-9210-2016; 
OI Troye-Blomberg, Marita/0000-0002-2804-0325; VARANI,
   STEFANIA/0000-0003-0862-4937
FU European 7th Framework Programme [200889]; Ministere des Affaires
   Etrangeres of France (project REFS) [2006-22]; Institut de Recherche
   pour le Developpement; AIRD-DPF; French Ambassy
FX This paper describes work undertaken in the context of the STOPPAM
   project, 'Strategies To Prevent Pregnancy Associated Malaria'
   (www.stoppam.org), a Small & Medium Scale Collaborative Project
   supported by the European 7th Framework Programme under contract number
   200889. This work was also supported by the Ministere des Affaires
   Etrangeres of France (project REFS No. 2006-22), the Institut de
   Recherche pour le Developpement, which contributed to the study
   financially and with research material. Financial support was also
   provided by the AIRD-DPF to SI and KG (PhD research scholarship) and the
   French Ambassy to KG (PhD research scholarship). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 79
TC 1
Z9 1
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 18
PY 2015
VL 10
IS 11
AR e0139606
DI 10.1371/journal.pone.0139606
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CW7CD
UT WOS:000365154600001
PM 26580401
ER

PT J
AU Ngufor, C
   N'Guessan, R
   Fagbohoun, J
   Subramaniam, K
   Odjo, A
   Fongnikin, A
   Akogbeto, M
   Weetman, D
   Rowland, M
AF Ngufor, Corine
   N'Guessan, Raphael
   Fagbohoun, Josias
   Subramaniam, Krishanthi
   Odjo, Abibatou
   Fongnikin, Augustin
   Akogbeto, Martin
   Weetman, David
   Rowland, Mark
TI Insecticide resistance profile of Anopheles gambiae from a phase II
   field station in Cove, southern Benin: implications for the evaluation
   of novel vector control products
SO MALARIA JOURNAL
LA English
DT Article
DE Insecticide resistance; Experimental huts; Cove; Vector control product
   evaluation; Anopheles gambiae sl; Long-lasting insecticidal nets; Indoor
   residual spraying
ID EXPERIMENTAL HUT TRIAL; COTE-DIVOIRE; MOLECULAR-FORMS; TREATED NETS;
   IDENTIFICATION; MOSQUITOS; TANZANIA; EFFICACY; COMPLEX; GHANA
AB Background: Novel indoor residual spraying (IRS) and long-lasting insecticidal net (LLIN) products aimed at improving the control of pyrethroid-resistant malaria vectors have to be evaluated in Phase II semi-field experimental studies against highly pyrethroid-resistant mosquitoes. To better understand their performance it is necessary to fully characterize the species composition, resistance status and resistance mechanisms of the vector populations in the experimental hut sites.
   Methods: Bioassays were performed to assess phenotypic insecticide resistance in the malaria vector population at a newly constructed experimental hut site in Cove, a rice growing area in southern Benin, being used for WHOPES Phase II evaluation of newly developed LLIN and IRS products. The efficacy of standard WHOPES-approved pyrethroid LLIN and IRS products was also assessed in the experimental huts. Diagnostic genotyping techniques and microarray studies were performed to investigate the genetic basis of pyrethroid resistance in the Cove Anopheles gambiae population.
   Results: The vector population at the Cove experimental hut site consisted of a mixture of Anopheles coluzzii and An. gambiae s.s. with the latter occurring at lower frequencies (23 %) and only in samples collected in the dry season. There was a high prevalence of resistance to pyrethroids and DDT (>90 % bioassay survival) with pyrethroid resistance intensity reaching 200-fold compared to the laboratory susceptible An. gambiae Kisumu strain. Standard WHOPES-approved pyrethroid IRS and LLIN products were ineffective in the experimental huts against this vector population (8-29 % mortality). The L1014F allele frequency was 89 %. CYP6P3, a cytochrome P450 validated as an efficient metab-olizer of pyrethroids, was over-expressed.
   Conclusion: Characterizing pyrethroid resistance at Phase II field sites is crucial to the accurate interpretation of the performance of novel vector control products. The strong levels of pyrethroid resistance at the Cove experimental hut station make it a suitable site for Phase II experimental hut evaluations of novel vector control products, which aim for improved efficacy against pyrethroid-resistant malaria vectors to WHOPES standards. The resistance genes identified can be used as markers for further studies investigating the resistance management potential of novel mixture LLIN and IRS products tested at the site.
C1 [Ngufor, Corine; N'Guessan, Raphael; Rowland, Mark] London Sch Hyg & Trop Med, London WC1, England.
   [Ngufor, Corine; N'Guessan, Raphael; Fagbohoun, Josias; Odjo, Abibatou; Fongnikin, Augustin; Akogbeto, Martin] Ctr Rech Entomol Cotonou, Cotonou, Benin.
   [Ngufor, Corine; N'Guessan, Raphael; Rowland, Mark] Pan African Malaria Vector Res Consortium, London, England.
   [Subramaniam, Krishanthi; Weetman, David] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
RP Ngufor, C (reprint author), London Sch Hyg & Trop Med, London WC1, England.
EM corine.ngufor@lshtm.ac.uk
RI Weetman, David/M-1261-2014
OI Weetman, David/0000-0002-5820-1388
FU Bill and Melinda Gates Foundation through the Innovative Vector Control
   Consortium (IVCC)
FX We thank Prof Hilary Ranson (LSTM) for coordinating molecular analysis
   and Damien Todjinou and Achille Oumbouke (CREC) for field assistance.
   The study was funded by the Bill and Melinda Gates Foundation through
   the Innovative Vector Control Consortium (IVCC).
NR 34
TC 4
Z9 4
U1 1
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD NOV 18
PY 2015
VL 14
AR 464
DI 10.1186/s12936-015-0981-z
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CW3PT
UT WOS:000364904900004
PM 26581678
ER

PT J
AU Djenontin, A
   Alou, LPA
   Koffi, A
   Zogo, B
   Duarte, E
   N'Guessan, R
   Moiroux, N
   Pennetier, C
AF Djenontin, Armel
   Alou, Ludovic P. Ahoua
   Koffi, Alphonsine
   Zogo, Barnabas
   Duarte, Elves
   N'Guessan, Raphael
   Moiroux, Nicolas
   Pennetier, Cedric
TI Insecticidal and sterilizing effect of Olyset Duo (R), a permethrin and
   pyriproxyfen mixture net against pyrethroid-susceptible and -resistant
   strains of Anopheles gambiae s.s.: a release-recapture assay in
   experimental huts
SO PARASITE
LA English
DT Article
DE Anopheles gambiae s.s; Pyrethroid; Resistance; Bed net; Insect growth
   regulator
ID CULEX-QUINQUEFASCIATUS MOSQUITOS; TREATED NETS; MALARIA VECTORS;
   AEDES-AEGYPTI; DIPTERA-CULICIDAE; LARVAL HABITATS; COMBINATION NET;
   PERMANET(R) 3.0; EFFICACY; BENIN
AB In the context of the widespread distribution of pyrethroid resistance among malaria vectors, we did a release-recapture trial in experimental huts to investigate the insecticidal and sterilizing effects of a novel long-lasting net (LN), Olyset (R) Duo, incorporating a mixture of permethrin (PER) and the insect growth regulator (IGR), pyriproxyfen (PPF). An LN containing PPF alone and a classic Olyset (R) Net were tested in parallel as positive controls. The effect of progressive number of holes (6, 30, or 150) that may accrue in nets over time was simulated. We used two laboratory Anopheles gambiae s.s. strains: the susceptible Kisumu strain and the pyrethroid-resistant VK-Per strain having solely kdr as resistance mechanism. The effect of these nets on the reproductive success of blood-fed females that survived the different LNs conditions was recorded. Regardless of the mosquito strain, the LNs containing PPF alone with as many as 30 holes drastically reduced the number of eggs laid by females succeeding in feeding, i.e. fecundity by 98% and egg hatching rate (fertility) by 93% relative to untreated control net. Very few of the resistant females blood fed and survived under the Olyset (R) Duo with similar number of holes (up to 30) but of these few, the inhibition of reproductive success was 100%. There was no evidence that the Olyset (R) Duo LN with 150 holes impacted fecundity or fertility of the resistant colony. The efficacy of Olyset (R) Duo is encouraging and clearly illustrates that this new net might be a promising tool for malaria transmission control and resistance management.
C1 [Djenontin, Armel] Univ Abomey Calavi, Fac Sci & Tech, Cotonou, Benin.
   [Djenontin, Armel; Zogo, Barnabas; Duarte, Elves; Pennetier, Cedric] IRD, MIVEGEC, UM CNRS IRD 224 5290, Cotonou, Benin.
   [Djenontin, Armel; Zogo, Barnabas; Duarte, Elves] CREC, Cotonou, Benin.
   [Alou, Ludovic P. Ahoua; Koffi, Alphonsine] INSP, IPR, Bouake, Cote Ivoire.
   [N'Guessan, Raphael] London Sch Hyg & Trop Med, London WC1, England.
   [Moiroux, Nicolas] IRD, MIVEGEC, UM CNRS IRD 224 5290, Montpellier, France.
RP Pennetier, C (reprint author), IRD, MIVEGEC, UM CNRS IRD 224 5290, Cotonou, Benin.
EM cedric.pennetier@ird.fr
RI Pennetier, Cedric/K-2010-2016; 
OI Moiroux, Nicolas/0000-0001-6755-6167
FU Sumitomo Chemical
FX This work was supported financially by Sumitomo Chemical. Funders
   participated in the study design and the decision to publish, but they
   have no role in data collection, analysis, and preparation of the
   manuscript. The authors declare that they have no competing interests.
NR 32
TC 1
Z9 1
U1 0
U2 4
PU EDP SCIENCES S A
PI LES ULIS CEDEX A
PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A,
   FRANCE
SN 1252-607X
EI 1776-1042
J9 PARASITE
JI Parasite
PD OCT 21
PY 2015
VL 22
AR 27
DI 10.1051/parasite/2015027
PG 8
WC Parasitology
SC Parasitology
GA CW8ZL
UT WOS:000365287900001
PM 26489479
ER

PT J
AU Assogba, BS
   Djogbenou, LS
   Milesi, P
   Berthomieu, A
   Perez, J
   Ayala, D
   Chandre, F
   Makoutode, M
   Labbe, P
   Weill, M
AF Assogba, Benoit S.
   Djogbenou, Luc S.
   Milesi, Pascal
   Berthomieu, Arnaud
   Perez, Julie
   Ayala, Diego
   Chandre, Fabrice
   Makoutode, Michel
   Labbe, Pierrick
   Weill, Mylene
TI An ace-1 gene duplication resorbs the fitness cost associated with
   resistance in Anopheles gambiae, the main malaria mosquito
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CULEX-PIPIENS MOSQUITOS; INSENSITIVE ACETYLCHOLINESTERASE ACE-1(R);
   INSECTICIDE RESISTANCE; VECTOR CONTROL; QUINQUEFASCIATUS MOSQUITOS;
   WESTERN KENYA; BURKINA-FASO; COTE-DIVOIRE; CULICIDAE; DIPTERA
AB Widespread resistance to pyrethroids threatens malaria control in Africa. Consequently, several countries switched to carbamates and organophophates insecticides for indoor residual spraying. However, a mutation in the ace-1 gene conferring resistance to these compounds (ace-1(R) allele), is already present. Furthermore, a duplicated allele (ace-1(D)) recently appeared; characterizing its selective advantage is mandatory to evaluate the threat. Our data revealed that a unique duplication event, pairing a susceptible and a resistant copy of the ace-1 gene spread through West Africa. Further investigations revealed that, while ace-1(D) confers less resistance than ace-1(R), the high fitness cost associated with ace-1(R) is almost completely suppressed by the duplication for all traits studied. ace-1 duplication thus represents a permanent heterozygote phenotype, selected, and thus spreading, due to the mosaic nature of mosquito control. It provides malaria mosquito with a new evolutionary path that could hamper resistance management.
C1 [Assogba, Benoit S.; Milesi, Pascal; Berthomieu, Arnaud; Perez, Julie; Labbe, Pierrick; Weill, Mylene] CNRS, IRD, ISEM, UMR 5554, Montpellier, France.
   [Assogba, Benoit S.; Milesi, Pascal; Labbe, Pierrick; Weill, Mylene] Univ Montpellier, F-34059 Montpellier, France.
   [Assogba, Benoit S.; Djogbenou, Luc S.; Makoutode, Michel] IRSP, Ouidah, Benin.
   [Assogba, Benoit S.; Djogbenou, Luc S.; Makoutode, Michel] Univ Abomey Calavi, Cotonou, Benin.
   [Ayala, Diego; Chandre, Fabrice] IRD, CNRS, MIVEGEC, UMR 224 5290, Montpellier, France.
RP Labbe, P (reprint author), CNRS, IRD, ISEM, UMR 5554, Montpellier, France.
EM pierrick.labbe@univ-montp2.fr
OI Labbe, Pierrick/0000-0003-0806-1919; Chandre,
   Fabrice/0000-0002-1994-9705
FU French ANR program (project "AlterNET" SOC ENV); Wellcome Trust
   [WT093755]; IRD
FX We are very grateful to Nicole Pasteur for her helpful comments on the
   manuscript. This work was funded partly by French ANR program (project
   "AlterNET" SOC & ENV 2013-2015) and by Wellcome Trust (grant WT093755).
   Assogba S. Benoit was supported by a fellowship from the IRD. Data used
   in this work were produced through the technical facilities of the
   Environmental Genomic Platform of the Labex Centre Mediterraneen
   Environnement Biodiversite (CeMEB): all sequence data were obtained
   through GenSeq Platform; FISH hybridization was performed through the
   Evolutionary Cytogenomic Plateform. Contribution number 201x-xxx of the
   Institut des Sciences de l'Evolution de Montpellier (UMR CNRS-IRD-UM
   5554).
NR 72
TC 4
Z9 4
U1 1
U2 23
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 5
PY 2015
VL 5
AR 14529
DI 10.1038/srep14529
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS6HM
UT WOS:000362179300001
PM 26434951
ER

PT J
AU Aubouy, A
   Olagnier, D
   Bertin, G
   Ezinmegnon, S
   Majorel, C
   Mimar, S
   Massougbodji, A
   Deloron, P
   Pipy, B
   Coste, A
AF Aubouy, Agnes
   Olagnier, David
   Bertin, Gwladys
   Ezinmegnon, Sem
   Majorel, Clarisse
   Mimar, Saliha
   Massougbodji, Achille
   Deloron, Philippe
   Pipy, Bernard
   Coste, Agnes
TI Nrf2-driven CD36 and HO-1 gene expression in circulating monocytes
   correlates with favourable clinical outcome in pregnancy-associated
   malaria
SO MALARIA JOURNAL
LA English
DT Article
DE Pregnancy-associated malaria; Clinical outcomes; Monocytes; CD36; Nrf2;
   HO-1
ID FALCIPARUM-PARASITIZED ERYTHROCYTES; NECROSIS-FACTOR-ALPHA; HEMOGLOBIN
   SCAVENGER RECEPTOR; CHONDROITIN SULFATE-A; PLASMODIUM-FALCIPARUM;
   INFECTED ERYTHROCYTES; CEREBRAL MALARIA; CARBON-MONOXIDE; HUMAN
   PLACENTA; HEME OXYGENASE-1
AB Background: Pregnancy-associated malaria (PAM) constitutes one of the most severe forms of malaria infection leading to fetal growth restriction and high risk of infant death. The severity of the pathology is largely attributed to the recruitment of monocytes and macrophages in the placenta which is evidenced by dysregulated inflammation found in placental blood. Importantly, CD36(+) monocytes/macrophages are also thought to participate in the tight control of the pro-and anti-inflammatory responses following Plasmodium detection through elimination of apoptotic cells and malaria-infected erythrocytes, internalization and recycling of oxidized forms of low-density lipoprotein and collaboration with TLR2 in pro-inflammatory response. Interestingly, previous work demonstrated that CD36 expression was upregulated on inflammatory macrophages following stimulation of the Nrf2 transcription factor, whilst the PPAR. pathway was inhibited and non-functional in the same inflammatory conditions. This current study examined the possible role of Nrf2-driven gene expression, CD36 and Haem-Oxygenase-1 (HO-1), in PAM clinical outcomes.
   Methods: Clinical data and biological samples including peripheral blood mononuclear cells were collected from 27 women presenting PAM. Polychromatic flow cytometry was used to characterize innate immune cell subpopulations and quantify CD36 protein expression level on monocytes. mRNA levels of CD36, PPAR., Nrf2 and HO-1 were determined by qPCR and related to clinical outcomes. Finally, the capacity of monocytes to modulate CD36 expression upon rosiglitazone or sulforaphane treatment, two respective PPAR. or Nrf2 activators, was also investigated.
   Results: The CD36 receptor, mostly expressed by CD14(+) circulating monocytes, statistically correlated with increased infant birth weights. Interestingly, mRNA levels of the transcription factor Nrf2 and the enzyme HO-1 also correlated with lower parasitaemia and increased infant birth weight, while PPAR. mRNA levels did not. Finally, monocytes isolated from low infant birth weight pregnant women were capable of up-regulating CD36 via the Nrf2 pathway ex vivo.
   Conclusions: Altogether these results suggest that Nrf2-driven CD36 and HO-1 expression on innate immune cells could contribute to a protective and detoxifying mechanism during PAM. More powered and mechanistical studies are however needed to strengthen the conclusions of this study.
C1 [Aubouy, Agnes; Olagnier, David; Majorel, Clarisse; Mimar, Saliha; Pipy, Bernard; Coste, Agnes] Univ Toulouse 3, Inst Rech Dev, UMR Pharma Dev 152, CHU Rangueil, F-31059 Toulouse, France.
   [Bertin, Gwladys; Deloron, Philippe] Univ Paris 05, Inst Rech Dev, PRES Sorbonne Paris Cite, UMR Mere & Enfant Face Infect Trop 216, Paris, France.
   [Ezinmegnon, Sem; Massougbodji, Achille] Ctr Etud & Rech Paludisme Associe Grossesse & Enf, Cotonou, Benin.
RP Aubouy, A (reprint author), Univ Toulouse 3, Inst Rech Dev, UMR Pharma Dev 152, CHU Rangueil, Batiment L1,1 Ave Pr Jean Poulhes, F-31059 Toulouse, France.
EM agnes.aubouy@ird.fr
RI Aubouy, Agnes/J-7792-2015
NR 63
TC 0
Z9 0
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD SEP 18
PY 2015
VL 14
AR 358
DI 10.1186/s12936-015-0888-8
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CR5DG
UT WOS:000361359300002
PM 26385579
ER

PT J
AU Oxborough, RM
   N'Guessan, R
   Kitau, J
   Tungu, PK
   Malone, D
   Mosha, FW
   Rowland, MW
AF Oxborough, Richard M.
   N'Guessan, Raphael
   Kitau, Jovin
   Tungu, Patrick K.
   Malone, David
   Mosha, Franklin W.
   Rowland, Mark W.
TI A new class of insecticide for malaria vector control: evaluation of
   mosquito nets treated singly with indoxacarb (oxadiazine) or with a
   pyrethroid mixture against Anopheles gambiae and Culex quinquefasciatus
SO MALARIA JOURNAL
LA English
DT Article
DE Indoxacarb; Oxadiazine; ITN; Insecticide mixtures; Anopheles gambiae;
   Pyrethroid resistance
ID CROSS-RESISTANCE; BORNE DISEASES; EFFICACY; LEPIDOPTERA; NOCTUIDAE;
   CULICIDAE; DIPTERA; BENIN; AREA
AB Background: Universal coverage with long-lasting insecticidal mosquito nets (LLIN) or indoor residual spraying (IRS) of houses remain the primary strategies for the control of mosquito vectors of malaria. Pyrethroid resistant malaria vectors are widespread throughout sub-Saharan Africa and new insecticides with different modes of action are urgently needed if malaria vector control is to remain effective. Indoxacarb is an oxadiazine insecticide that is effective as an oral and contact insecticide against a broad spectrum of agricultural pests and, due to its unique site of action, no cross-resistance has been detected through mechanisms associated with resistance to insecticides currently used in public health.
   Methods: WHO tunnel tests of host seeking mosquitoes were carried out as a forerunner to experimental hut trials, to provide information on dosage-dependent mortality, repellency, and blood-feeding inhibition. A dosage range of indoxacarb treated netting (100-1000 mg/m(2)) was tested against a pyrethroid susceptible strain of Anopheles gambiae. In addition, efficacy of indoxacarb 500 mg/m(2) was compared with a standard pyrethroid formulation against pyrethroid susceptible and resistant Culex quinquefasciatus. Dosages between 25 and 300 mg/m(2) indoxacarb were tested in tunnel tests and in ball-frame bioassays as mixtures with alphacypermethrin 25 mg/m(2) and were compared with singly applied treatments against an insectary reared pyrethroid resistant strain of Cx. quinquefasciatus originally collected in Cotonou, Benin.
   Results: There was a dosage-dependent response in terms of indoxacarb induced mortality, with dosages > 100 mg/m(2) producing the best mortality response. In tunnel tests indoxacarb 500 mg/m(2) exceeded WHOPES thresholds with > 80 % mortality of adult An. gambiae and blood-feeding inhibition of 75 %. No cross-resistance to indoxacarb was detected through mechanisms associated with resistance to pyrethroid insecticides and was equally effective against susceptible and resistant strains of Cx. quinquefasciatus. Indoxacarb 500 mg/m(2) killed 75 % of pyrethroid resistant Cx. quinquefasciatus compared with only 21 % mortality with alphacypermethrin 40 mg/m(2). Mixtures of indoxacarb with pyrethroid produced an additive response for both mortality and blood-feeding inhibition. The best performing mixture (indoxacarb 200 mg/m(2) + alphacypermethrin 25 mg/m(2)) killed 83 % of pyrethroid resistant Cx. quinquefasciatus and reduced blood-feeding by 88 %, while alphacypermethrin only killed 36 % and inhibited blood-feeding by 50 %.
   Conclusions: New insecticides with different modes of action to those currently used in mosquito vector control are urgently needed. Indoxacarb shows great promise as a mixture with a pyrethroid and should be evaluated in experimental hut trials to determine performance against wild free-flying, pyrethroid resistant An. gambiae and wash-resistant formulations developed.
C1 [Oxborough, Richard M.; N'Guessan, Raphael; Rowland, Mark W.] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England.
   [Oxborough, Richard M.; Kitau, Jovin; Mosha, Franklin W.] Kilimanjaro Christian Med Univ Coll, Dept Entomol & Parasitol, Moshi, Kilimanjaro, Tanzania.
   [N'Guessan, Raphael] Minist Sante, CREC Labs, Ctr Rech Entomol Cotonou, Lab Natl, Cotonou 06, Benin.
   [Oxborough, Richard M.; N'Guessan, Raphael; Kitau, Jovin; Tungu, Patrick K.; Mosha, Franklin W.; Rowland, Mark W.] Pan African Malaria Vector Res Consortium, PAMVERC, Moshi, Tanzania.
   [Tungu, Patrick K.] Natl Inst Med Res, Amani Ctr, Muheza, Tanzania.
   [Malone, David] Innovat Vector Control Consortium, Liverpool L3 5QA, Merseyside, England.
RP Oxborough, RM (reprint author), London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England.
EM oxandbull@hotmail.com
FU Innovative Vector Control Consortium (IVCC, Liverpool, UK)
FX All biological evaluations conducted by PAMVERC were financially
   supported by the Innovative Vector Control Consortium (IVCC, Liverpool,
   UK). The insecticide used in this study were provided by DuPont, USA.
   The authors thank Dr Robert Sloss of IVCC, Liverpool, UK for technical
   and programme support. RMO, RN, CN and MWR are members of the Malaria
   Centre of the London School of Hygiene and Tropical Medicine,
   http:/malaria.lshtm.ac.uk/. We are grateful to E Feston, K Ezekia, R
   Mndeme, R Athuman, and G Chuwa, Department of Entomology and
   Parasitology, Kilimanjaro Christian Medical University College (KCMUCo),
   Tumaini University, Moshi, Kilimanjaro, Tanzania, for insectary and
   laboratory assistance.
NR 38
TC 2
Z9 2
U1 5
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD SEP 17
PY 2015
VL 14
AR 353
DI 10.1186/s12936-015-0890-1
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CR5DB
UT WOS:000361358800009
PM 26377930
ER

PT J
AU Abdulla, S
   Adam, I
   Adjei, GO
   Adjuik, MA
   Alemayehu, B
   Allan, R
   Arinaitwe, E
   Ashley, EA
   Ba, MS
   Barennes, H
   Barnes, KI
   Bassat, Q
   Baudin, E
   Berens-Riha, N
   Bjorkman, A
   Bompart, F
   Bonnet, M
   Borrmann, S
   Bousema, T
   Brasseur, P
   Bukirwa, H
   Checchi, F
   Dahal, P
   D'Alessandro, U
   Desai, M
   Dicko, A
   Djimde, AA
   Dorsey, G
   Doumbo, OK
   Drakeley, CJ
   Duparc, S
   Eshetu, T
   Espie, E
   Etard, JF
   Faiz, AM
   Falade, CO
   Fanello, CI
   Faucher, JF
   Faye, B
   Faye, O
   Filler, S
   Flegg, JA
   Fofana, B
   Fogg, C
   Gadalla, NB
   Gaye, O
   Genton, B
   Gething, PW
   Gil, JP
   Gonzalez, R
   Grandesso, F
   Greenhouse, B
   Greenwood, B
   Grivoyannis, A
   Guerin, PJ
   Guthmann, JP
   Hamed, K
   Hamour, S
   Hay, SI
   Hodel, EM
   Humphreys, GS
   Hwang, J
   Ibrahim, ML
   Jima, D
   Jones, JJ
   Jullien, V
   Juma, E
   Kachur, PS
   Kager, PA
   Kamugisha, E
   Kamya, MR
   Karema, C
   Kayentao, K
   Kiechel, JR
   Kironde, F
   Kofoed, PE
   Kremsner, PG
   Krishna, S
   Lameyre, V
   Lell, B
   Lima, A
   Makanga, M
   Malik, EM
   Marsh, K
   Martensson, A
   Massougbodji, A
   Menan, H
   Menard, D
   Menendez, C
   Mens, PF
   Meremikwu, M
   Moreira, C
   Nabasumba, C
   Nambozi, M
   Ndiaye, JL
   Ngasala, BE
   Nikiema, F
   Nsanzabana, C
   Ntoumi, F
   Oguike, M
   Ogutu, BR
   Olliaro, P
   Omar, SA
   Ouedraogo, JB
   Owusu-Agyei, S
   Penali, LK
   Pene, M
   Peshu, J
   Piola, P
   Plowe, CV
   Premji, Z
   Price, RN
   Randrianarivelojosia, M
   Rombo, L
   Roper, C
   Rosenthal, PJ
   Sagara, I
   Same-Ekobo, A
   Sawa, P
   Schallig, HDFH
   Schramm, B
   Seck, A
   Shekalaghe, SA
   Sibley, CH
   Sinou, V
   Sirima, SB
   Som, FA
   Sow, D
   Staedke, SG
   Stepniewska, K
   Sutherland, CJ
   Swarthout, TD
   Sylla, K
   Talisuna, AO
   Taylor, WRJ
   Temu, EA
   Thwing, JI
   Tine, RCK
   Tinto, H
   Tommasini, S
   Toure, OA
   Ursing, J
   Vaillant, MT
   Valentini, G
   Van den Broek, I
   Van Vugt, M
   Ward, SA
   Winstanley, PA
   Yavo, W
   Yeka, A
   Zolia, YM
   Zongo, I
AF Abdulla, Salim
   Adam, Ishag
   Adjei, George O.
   Adjuik, Martin A.
   Alemayehu, Bereket
   Allan, Richard
   Arinaitwe, Emmanuel
   Ashley, Elizabeth A.
   Ba, Mamadou S.
   Barennes, Hubert
   Barnes, Karen I.
   Bassat, Quique
   Baudin, Elisabeth
   Berens-Riha, Nicole
   Bjoerkman, Anders
   Bompart, Francois
   Bonnet, Maryline
   Borrmann, Steffen
   Bousema, Teun
   Brasseur, Philippe
   Bukirwa, Hasifa
   Checchi, Francesco
   Dahal, Prabin
   D'Alessandro, Umberto
   Desai, Meghna
   Dicko, Alassane
   Djimde, Abdoulaye A.
   Dorsey, Grant
   Doumbo, Ogobara K.
   Drakeley, Chris J.
   Duparc, Stephan
   Eshetu, Teferi
   Espie, Emmanuelle
   Etard, Jean-Francois
   Faiz, Abul M.
   Falade, Catherine O.
   Fanello, Caterina I.
   Faucher, Jean-Francois
   Faye, Babacar
   Faye, Oumar
   Filler, Scott
   Flegg, Jennifer A.
   Fofana, Bakary
   Fogg, Carole
   Gadalla, Nahla B.
   Gaye, Oumar
   Genton, Blaise
   Gething, Peter W.
   Gil, Jose P.
   Gonzalez, Raquel
   Grandesso, Francesco
   Greenhouse, Bryan
   Greenwood, Brian
   Grivoyannis, Anastasia
   Guerin, Philippe J.
   Guthmann, Jean-Paul
   Hamed, Kamal
   Hamour, Sally
   Hay, Simon I.
   Hodel, Eva Maria
   Humphreys, Georgina S.
   Hwang, Jimee
   Ibrahim, Maman L.
   Jima, Daddi
   Jones, Joel J.
   Jullien, Vincent
   Juma, Elizabeth
   Kachur, Patrick S.
   Kager, Piet A.
   Kamugisha, Erasmus
   Kamya, Moses R.
   Karema, Corine
   Kayentao, Kassoum
   Kiechel, Jean-Rene
   Kironde, Fred
   Kofoed, Poul-Erik
   Kremsner, Peter G.
   Krishna, Sanjeev
   Lameyre, Valerie
   Lell, Bertrand
   Lima, Angeles
   Makanga, Michael
   Malik, ElFatih M.
   Marsh, Kevin
   Martensson, Andreas
   Massougbodji, Achille
   Menan, Herve
   Menard, Didier
   Menendez, Clara
   Mens, Petra F.
   Meremikwu, Martin
   Moreira, Clarissa
   Nabasumba, Carolyn
   Nambozi, Michael
   Ndiaye, Jean-Louis
   Ngasala, Billy E.
   Nikiema, Frederic
   Nsanzabana, Christian
   Ntoumi, Francine
   Oguike, Mary
   Ogutu, Bernhards R.
   Olliaro, Piero
   Omar, Sabah A.
   Ouedraogo, Jean-Bosco
   Owusu-Agyei, Seth
   Penali, Louis K.
   Pene, Mbaye
   Peshu, Judy
   Piola, Patrice
   Plowe, Christopher V.
   Premji, Zul
   Price, Ric N.
   Randrianarivelojosia, Milijaona
   Rombo, Lars
   Roper, Cally
   Rosenthal, Philip J.
   Sagara, Issaka
   Same-Ekobo, Albert
   Sawa, Patrick
   Schallig, Henk D. F. H.
   Schramm, Birgit
   Seck, Amadou
   Shekalaghe, Seif A.
   Sibley, Carol H.
   Sinou, Vronique
   Sirima, Sodiomon B.
   Som, Fabrice A.
   Sow, Doudou
   Staedke, Sarah G.
   Stepniewska, Kasia
   Sutherland, Colin J.
   Swarthout, Todd D.
   Sylla, Khadime
   Talisuna, Ambrose O.
   Taylor, Walter R. J.
   Temu, Emmanuel A.
   Thwing, Julie I.
   Tine, Roger C. K.
   Tinto, Halidou
   Tommasini, Silva
   Toure, Offianan A.
   Ursing, Johan
   Vaillant, Michel T.
   Valentini, Giovanni
   Van den Broek, Ingrid
   Van Vugt, Michele
   Ward, Stephen A.
   Winstanley, Peter A.
   Yavo, William
   Yeka, Adoke
   Zolia, Yah M.
   Zongo, Issaka
CA WWARN Artemisinin Based
TI Clinical determinants of early parasitological response to ACTs in
   African patients with uncomplicated falciparum malaria: a literature
   review and meta-analysis of individual patient data
SO BMC MEDICINE
LA English
DT Review
ID RESISTANT PLASMODIUM-FALCIPARUM; PARASITE CLEARANCE;
   ARTEMETHER-LUMEFANTRINE; ARTEMISININ RESISTANCE; COMBINATION THERAPY;
   IN-VIVO; EFFICACY; ARTESUNATE; CHILDREN; CAMBODIA
AB Background: Artemisinin-resistant Plasmodium falciparum has emerged in the Greater Mekong sub-region and poses a major global public health threat. Slow parasite clearance is a key clinical manifestation of reduced susceptibility to artemisinin. This study was designed to establish the baseline values for clearance in patients from Sub-Saharan African countries with uncomplicated malaria treated with artemisinin-based combination therapies (ACTs).
   Methods: A literature review in PubMed was conducted in March 2013 to identify all prospective clinical trials (uncontrolled trials, controlled trials and randomized controlled trials), including ACTs conducted in Sub-Saharan Africa, between 1960 and 2012. Individual patient data from these studies were shared with the WorldWide Antimalarial Resistance Network (WWARN) and pooled using an a priori statistical analytical plan. Factors affecting early parasitological response were investigated using logistic regression with study sites fitted as a random effect. The risk of bias in included studies was evaluated based on study design, methodology and missing data.
   Results: In total, 29,493 patients from 84 clinical trials were included in the analysis, treated with artemether-lumefantrine (n = 13,664), artesunate-amodiaquine (n = 11,337) and dihydroartemisinin-piperaquine (n = 4,492). The overall parasite clearance rate was rapid. The parasite positivity rate (PPR) decreased from 59.7 % (95 % CI: 54.5-64.9) on day 1 to 6.7 % (95 % CI: 4.8-8.7) on day 2 and 0.9 % (95 % CI: 0.5-1.2) on day 3. The 95th percentile of observed day 3 PPR was 5.3 %. Independent risk factors predictive of day 3 positivity were: high baseline parasitaemia (adjusted odds ratio (AOR) = 1.16 (95 % CI: 1.08-1.25); per 2-fold increase in parasite density, P <0.001); fever (>37.5 degrees C) (AOR = 1.50 (95 % CI: 1.06-2.13), P = 0.022); severe anaemia (AOR = 2.04 (95 % CI: 1.21-3.44), P = 0.008); areas of low/moderate transmission setting (AOR = 2.71 (95 % CI: 1.38-5.36), P = 0.004); and treatment with the loose formulation of artesunate-amodiaquine (AOR = 2.27 (95 % CI: 1.14-4.51), P = 0.020, compared to dihydroartemisinin-piperaquine).
   Conclusions: The three ACTs assessed in this analysis continue to achieve rapid early parasitological clearance across the sites assessed in Sub-Saharan Africa. A threshold of 5 % day 3 parasite positivity from a minimum sample size of 50 patients provides a more sensitive benchmark in Sub-Saharan Africa compared to the current recommended threshold of 10 % to trigger further investigation of artemisinin susceptibility.
C1 [Abdulla, Salim; Shekalaghe, Seif A.] Ifakara Hlth Inst, Dar Es Salaam, Tanzania.
   [Adam, Ishag] Univ Khartoum, Fac Med, Khartoum, Sudan.
   [Adjei, George O.] Univ Ghana, Sch Med, Ctr Trop Clin Pharmacol & Therapeut, Accra, Ghana.
   [Adjuik, Martin A.] INDEPTH Network Secretariat, Accra, Ghana.
   [Alemayehu, Bereket] Int Ctr AIDS Care & Treatment Programs, Addis Ababa, Ethiopia.
   [Allan, Richard; Baudin, Elisabeth; Temu, Emmanuel A.] MENTOR Initiat, Crawley, England.
   [Arinaitwe, Emmanuel; Staedke, Sarah G.] Infect Dis Res Collaborat, Kampala, Uganda.
   [Ashley, Elizabeth A.; Checchi, Francesco; Espie, Emmanuelle; Etard, Jean-Francois; Grandesso, Francesco; Nabasumba, Carolyn; Schramm, Birgit] Epictr, Paris, France.
   [Ba, Mamadou S.; Faye, Babacar; Faye, Oumar; Gaye, Oumar; Ndiaye, Jean-Louis; Pene, Mbaye; Sow, Doudou; Sylla, Khadime; Tine, Roger C. K.] Univ Cheikh Anta Diop, Dept Parasitol & Mycol, Fac Med, Dakar, Senegal.
   [Barennes, Hubert; Ouedraogo, Jean-Bosco; Tinto, Halidou] Ctr Muraz, Bobo Dioulasso, Burkina Faso.
   [Barennes, Hubert] French Foreign Affairs, Biarritz, France.
   [Barnes, Karen I.] WorldWide Antimalarial Resistance Network WWARN, Cape Town, South Africa.
   [Barnes, Karen I.] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa.
   [Bassat, Quique; Gonzalez, Raquel; Menendez, Clara] Ctr Invest Saude Manhica, Manhica, Mozambique.
   [Bassat, Quique; Eshetu, Teferi; Gonzalez, Raquel; Menendez, Clara] Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Hosp Clin, Barcelona, Spain.
   [Berens-Riha, Nicole] Univ Munich LMU, Med Ctr, Div Infect Dis & Trop Med, Munich, Germany.
   [Berens-Riha, Nicole] LMU, German Ctr Infect Res DZIF, Munich, Germany.
   [Bjoerkman, Anders; Martensson, Andreas] Karolinska Inst, Dept Microbiol Tumour & Cell Biol, Stockholm, Sweden.
   [Bompart, Francois; Lameyre, Valerie] Sanofi Aventis, Direct Acces Med Access Med, Gentilly, France.
   [Bonnet, Maryline] Epictr, Geneva, Switzerland.
   [Borrmann, Steffen; Marsh, Kevin; Peshu, Judy] Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, Kenya.
   [Borrmann, Steffen; Kremsner, Peter G.; Lell, Bertrand; Ntoumi, Francine] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
   [Borrmann, Steffen; Drakeley, Chris J.] German Ctr Infect Res, Tubingen, Germany.
   [Bousema, Teun; Gadalla, Nahla B.; Oguike, Mary; Sutherland, Colin J.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Infect & Immun, London WC1, England.
   [Bousema, Teun] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Njimegen, Netherlands.
   [Brasseur, Philippe] IRD, Dakar, Senegal.
   [Bukirwa, Hasifa; Yeka, Adoke] Uganda Malaria Surveillance Project, Kampala, Uganda.
   [Dahal, Prabin; Flegg, Jennifer A.; Guerin, Philippe J.; Humphreys, Georgina S.; Moreira, Clarissa; Nsanzabana, Christian; Price, Ric N.; Sibley, Carol H.; Stepniewska, Kasia] WorldWide Antimalarial Resistance Network WWARN, Oxford, England.
   [Dahal, Prabin; Guerin, Philippe J.; Humphreys, Georgina S.; Marsh, Kevin; Moreira, Clarissa; Nsanzabana, Christian; Olliaro, Piero; Price, Ric N.; Stepniewska, Kasia] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England.
   [D'Alessandro, Umberto] Inst Trop Med, Unit Malariol, B-2000 Antwerp, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [D'Alessandro, Umberto; Greenwood, Brian] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Dis Control, London WC1, England.
   [Desai, Meghna; Hwang, Jimee; Kachur, Patrick S.; Thwing, Julie I.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA.
   [Dicko, Alassane; Djimde, Abdoulaye A.; Doumbo, Ogobara K.; Fofana, Bakary; Kayentao, Kassoum; Sagara, Issaka] Univ Bamako, Fac Med Pharm & Dent, Malaria Res & Training Ctr, Bamako, Mali.
   [Dicko, Alassane] Univ Bamako, Fac Med Pharm & Dent, Dept Publ Hlth, Bamako, Mali.
   [Dorsey, Grant; Greenhouse, Bryan; Rosenthal, Philip J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Duparc, Stephan] Med Malaria Venture, Geneva, Switzerland.
   [Eshetu, Teferi] Jimma Univ, Dept Med Lab Sci & Pathol, Jimma, Ethiopia.
   [Etard, Jean-Francois] IRD, Montpellier, France.
   [Faiz, Abul M.] Mahidol Univ, Fac Trop Med, Bangkok, Thailand.
   [Falade, Catherine O.] Univ Ibadan, Coll Med, Dept Pharmacol & Therapeut, Ibadan, Nigeria.
   [Fanello, Caterina I.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Res Unit, Bangkok, Thailand.
   [Faucher, Jean-Francois] IRD, Mother & Child Hlth Trop Res Unit, Paris, France.
   [Faucher, Jean-Francois] Univ Paris 05, PRES Sorbonne Paris Cite, Paris, France.
   [Faucher, Jean-Francois] Univ Besancon, Med Ctr, Dept Infect Dis, F-25030 Besancon, France.
   [Filler, Scott] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland.
   [Flegg, Jennifer A.] Monash Univ, Sch Math Sci, Melbourne, Vic 3004, Australia.
   [Flegg, Jennifer A.] Monash Univ, Monash Acad Cross & Interdisciplinary Math Applic, Melbourne, Vic 3004, Australia.
   [Fogg, Carole] Univ Portsmouth, Portsmouth Hosp NHS Trust, Portsmouth, Hants, England.
   [Gadalla, Nahla B.] Natl Res Ctr, Res Inst Trop Med, Dept Epidemiol, Khartoum, Sudan.
   [Gadalla, Nahla B.] NIAID, Rockville, MD USA.
   [Genton, Blaise; Hodel, Eva Maria; Temu, Emmanuel A.] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland.
   [Genton, Blaise] Univ Lausanne Hosp, Div Infect Dis, Lausanne, Switzerland.
   [Genton, Blaise] Univ Lausanne Hosp, Dept Ambulatory Care & Community Med, Lausanne, Switzerland.
   [Gething, Peter W.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England.
   [Gil, Jose P.] Karolinska Inst, Pharmacogenet Sect, Drug Resistance Unit, Dept Physiol & Pharmacol, Stockholm, Sweden.
   [Gil, Jose P.] Univ Lisbon, Fac Sci, Biosyst & Integrat Sci Inst BioISI, P-1699 Lisbon, Portugal.
   [Gil, Jose P.] SUNY Binghamton, Harpur Coll Arts & Sci, Binghamton, NY USA.
   [Grivoyannis, Anastasia] Univ Washington, Div Emergency Med, Seattle, WA 98195 USA.
   [Guthmann, Jean-Paul] Inst Veille Sanit, Dept Malad Infect, St Maurice, France.
   [Hamed, Kamal] Novartis Pharmaceut, E Hanover, NJ USA.
   [Hamour, Sally] Royal Free Hosp, UCL Ctr Nephrol, London NW3 2QG, England.
   [Hay, Simon I.; Lima, Angeles] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Hay, Simon I.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.
   [Hay, Simon I.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
   [Hodel, Eva Maria] Univ Liverpool, Liverpool Sch Trop Med, Dept Parasitol, Liverpool L3 5QA, Merseyside, England.
   [Hwang, Jimee] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA.
   [Ibrahim, Maman L.] Ctr Rech Med & Sanit, Niamey, Niger.
   [Jima, Daddi] Fed Minist Hlth, Addis Ababa, Ethiopia.
   [Jones, Joel J.; Zolia, Yah M.] Minist Hlth & Social Welf, Natl Malaria Control Programme, Monrovia, Liberia.
   [Jullien, Vincent] Univ Paris 05, AP HP, Paris, France.
   [Juma, Elizabeth] Kenya Govt Med Res Ctr, Nairobi, Kenya.
   [Kager, Piet A.; Mens, Petra F.] Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun Amsterdam CINIMA, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands.
   [Kamugisha, Erasmus] Catholic Univ Hlth & Allied Sci, Mwanza, Tanzania.
   [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Kampala, Uganda.
   [Karema, Corine] Minist Hlth, Malaria & Other Parasit Dis Div RBC, Kigali, Rwanda.
   [Kiechel, Jean-Rene] Drugs Neglected Dis initiat, Geneva, Switzerland.
   [Kironde, Fred] Makerere Univ, Dept Biochem, Kampala, Uganda.
   [Kofoed, Poul-Erik; Ursing, Johan] Projecto Saude Bandim, Bissau, Guinea Bissau.
   [Kofoed, Poul-Erik] Kolding Cty Hosp, Dept Paediat, Kolding, Denmark.
   [Kremsner, Peter G.; Lell, Bertrand] Ctr Rech Med Lambarene, Lambarene, Gabon.
   [Krishna, Sanjeev] Univ London, Inst Infect & Immun, London, England.
   Operat Ctr Barcelona Athens, Med Sans Frontieres, Barcelona, Spain.
   [Makanga, Michael] European & Dev Countries Clin Trials Partnership, Cape Town, South Africa.
   [Malik, ElFatih M.] Fed Minist Hlth, Khartoum, Sudan.
   [Martensson, Andreas] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.
   [Martensson, Andreas] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden.
   [Massougbodji, Achille] Univ Abomey Calavi, FSS, CERPAGE, Cotonou, Benin.
   [Menan, Herve] Univ Cocody, Fac Pharm, Dept Parasitol, Abidjan, Cote Ivoire.
   [Menard, Didier] Inst Pasteur Cambodia, Malaria Mol Epidemiol Unit, Phnom Penh, Cambodia.
   [Mens, Petra F.; Schallig, Henk D. F. H.] KIT Biomed Res, Royal Trop Inst, Amsterdam, Netherlands.
   [Meremikwu, Martin] Univ Calabar, Dept Paediat, Calabar, Nigeria.
   [Meremikwu, Martin] Inst Trop Dis Res & Prevent, Calabar, Nigeria.
   [Nabasumba, Carolyn] Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda.
   [Nambozi, Michael] Trop Dis Res Ctr, Ndola, Zambia.
   [Ngasala, Billy E.; Premji, Zul] Muhimbili Univ Hlth & Allied Sci, Dept Parasitol, Dar Es Salaam, Tanzania.
   [Ngasala, Billy E.; Ursing, Johan] Karolinska Inst, Dept Med Solna, Infect Dis Unit, Malaria Res, Stockholm, Sweden.
   [Nikiema, Frederic; Ouedraogo, Jean-Bosco; Som, Fabrice A.; Tinto, Halidou; Zongo, Issaka] Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso.
   [Ntoumi, Francine] Univ Marien Ngouabi, FCRM, Fac Sci Sante, Brazzaville, Congo.
   [Ogutu, Bernhards R.] United States Army Med Res Unit, Kenya Med Res Inst, Kisumu, Kenya.
   [Olliaro, Piero; Taylor, Walter R. J.] UNICEF UNDP World Bank WHO Special Programme Res, Geneva, Switzerland.
   [Omar, Sabah A.] Kenya Govt Med Res Ctr, Ctr Biotechnol Res & Dev, Nairobi, Kenya.
   [Owusu-Agyei, Seth] Kintampo Hlth Res Ctr, Kintampo, Ghana.
   [Penali, Louis K.; Seck, Amadou] WorldWide Antimalarial Resistance Network WWARN W, Dakar, Senegal.
   [Piola, Patrice] Inst Pasteur Madagascar, Epidemiol Unit, Antananarivo, Madagascar.
   [Plowe, Christopher V.] Univ Maryland, Sch Med, Howard Hughes Med Inst, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [Price, Ric N.] Menzies Sch Hlth Res, Darwin, NT, Australia.
   [Price, Ric N.] Charles Darwin Univ, Darwin, NT 0909, Australia.
   [Randrianarivelojosia, Milijaona] Inst Pasteur Madagascar, Malaria Res Unit, Antananarivo, Madagascar.
   [Rombo, Lars] Karolinska Inst, Karolinska Univ Hosp, Infect Dis Unit, Malaria Res Lab,Dept Med, Stockholm, Sweden.
   [Rombo, Lars] Malarsjukhuset, Dept Infect Dis, S-63188 Eskilstuna, Sweden.
   [Rombo, Lars] Clin Res Ctr, Uppsala, Sweden.
   [Roper, Cally] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Pathogen Mol Biol, London WC1, England.
   [Same-Ekobo, Albert] Ctr Hosp Univ Yaounde, Fac Med & Sci Biomed, Yaounde, Cameroon.
   [Sawa, Patrick] Int Ctr Insect Physiol & Ecol, Human Hlth Div, Mbita, Kenya.
   [Shekalaghe, Seif A.] Kilimanjaro Christian Med Ctr, Kilimanjaro Clin Med Res Inst, Moshi, Tanzania.
   [Sibley, Carol H.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
   [Sinou, Vronique] Aix Marseille Univ, Fac Pharm, UMR MD3, Marseille, France.
   [Sirima, Sodiomon B.] CNRFP, Ouagadougou, Burkina Faso.
   [Staedke, Sarah G.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England.
   [Swarthout, Todd D.; Van den Broek, Ingrid] Med Sans Frontieres, London, England.
   [Talisuna, Ambrose O.] East Africa Reg Ctr, WorldWide Antimalarial Resistance Network WWARN, Nairobi, Kenya.
   [Talisuna, Ambrose O.] Univ Oxford, KEMRI, Wellcome Trust Res Programme, Nairobi, Kenya.
   [Taylor, Walter R. J.] Hop Cantonal Univ Geneva, Serv Med Int & Humanitaire, Geneva, Switzerland.
   [Temu, Emmanuel A.] Univ Basel, Basel, Switzerland.
   [Tommasini, Silva; Valentini, Giovanni] Sigma Tau Ind Farmaceut Riunite SpA, Rome, Italy.
   [Toure, Offianan A.] Inst Pasteur Cote Ivoire, Malariol Dept, Abidjan, Cote Ivoire.
   [Vaillant, Michel T.] CRP Sante, Ctr Hlth Studies, Methodol & Stat Unit, Luxembourg, Luxembourg.
   [Vaillant, Michel T.] Univ Bordeaux 2, Unite Bases Therapeut Inflammat & Infect 3677, F-33076 Bordeaux, France.
   [Van den Broek, Ingrid] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands.
   [Van Vugt, Michele] Univ Amsterdam, Acad Med Ctr, Ctr Trop Med & Travel Med, Div Infect Dis, NL-1012 WX Amsterdam, Netherlands.
   [Ward, Stephen A.] Univ Liverpool, Liverpool Sch Trop Med, Dept Parasitol, Liverpool L3 5QA, Merseyside, England.
   [Winstanley, Peter A.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.
   [Yavo, William] Univ Cocody, Fac Pharmaceut & Biol Sci, Dept Parasitol & Mycol, Abidjan, Cote Ivoire.
   [Yavo, William] Natl Inst Publ Hlth, Malaria Res & Control Ctr, Abidjan, Cote Ivoire.
RP Abdulla, S (reprint author), Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med WorldWide Antimalarial Res, Oxford, England.
RI Roper, Cally/K-2989-2013; Bousema, Teun/N-3574-2014; Ward,
   Steve/G-6003-2015; Hay, Simon/F-8967-2015; 
OI Dahal, Prabin/0000-0002-2158-846X; Price, Richard/0000-0003-2000-2874;
   Roper, Cally/0000-0002-6545-309X; Ward, Steve/0000-0003-2331-3192; Hay,
   Simon/0000-0002-0611-7272; GADALLA, NAHLA/0000-0002-6177-6705; Flegg,
   Jennifer/0000-0002-8809-726X; Gething, Peter/0000-0001-6759-5449
FU Bill & Melinda Gates Foundation
FX WWARN is funded by a Bill & Melinda Gates Foundation grant. The funder
   did not participate in the study protocol development or the writing of
   the paper.
NR 59
TC 0
Z9 0
U1 0
U2 21
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD SEP 7
PY 2015
VL 13
AR 212
DI 10.1186/s12916-015-0445-x
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA CQ7SO
UT WOS:000360804700001
ER

PT J
AU Ruperez, M
   Gonzalez, R
   Mombo-Ngoma, G
   Ouedraogo, S
   Kakolwa, MA
   Abdulla, S
   Accrombessi, M
   Aponte, JJ
   Akerey-Diop, D
   Basra, A
   Briand, V
   Capan, M
   Cot, M
   Kabanywanyi, AM
   Kleine, C
   Kremsner, PG
   Macete, E
   Mackanga, JR
   Massougbodgi, A
   Mayor, A
   Nhacolo, A
   Pahlavan, G
   Ramharter, M
   Sevene, E
   Vala, A
   Zoleko-Manego, R
   Menendez, C
AF Ruperez, M.
   Gonzalez, R.
   Mombo-Ngoma, G.
   Ouedraogo, S.
   Kakolwa, M. A.
   Abdulla, S.
   Accrombessi, M.
   Aponte, J. J.
   Akerey-Diop, D.
   Basra, A.
   Briand, V.
   Capan, M.
   Cot, M.
   Kabanywanyi, A. M.
   Kleine, C.
   Kremsner, P. G.
   Macete, E.
   Mackanga, J. -R.
   Massougbodgi, A.
   Mayor, A.
   Nhacolo, A.
   Pahlavan, G.
   Ramharter, M.
   Sevene, E.
   Vala, A.
   Zoleko-Manego, R.
   Menendez, C.
TI Mortality, morbidity and developmental outcomes in children born to
   women receiving either mefloquine or sulphadoxine-pyrimethamine as
   intermittent preventive treatment of malaria in pregnancy: a randomized
   controlled trial
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Ruperez, M.; Gonzalez, R.; Aponte, J. J.; Mayor, A.; Pahlavan, G.; Menendez, C.] Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain.
   [Ruperez, M.; Gonzalez, R.; Aponte, J. J.; Macete, E.; Mayor, A.; Nhacolo, A.; Sevene, E.; Vala, A.; Menendez, C.] Manhica Hlth Res Ctr CISM, Manhica, Mozambique.
   [Mombo-Ngoma, G.; Akerey-Diop, D.; Basra, A.; Capan, M.; Kleine, C.; Kremsner, P. G.; Mackanga, J. -R.; Ramharter, M.] Ctr Rech Med Lambarene CERMEL, Lamberene, Gabon.
   [Mombo-Ngoma, G.; Akerey-Diop, D.; Basra, A.; Capan, M.; Kleine, C.; Kremsner, P. G.; Mackanga, J. -R.; Ramharter, M.; Zoleko-Manego, R.] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
   [Ouedraogo, S.; Accrombessi, M.; Massougbodgi, A.] Fac Sci Sante, Cotonou, Benin.
   [Ouedraogo, S.; Accrombessi, M.; Briand, V.; Cot, M.] IRD, Paris, France.
   [Kakolwa, M. A.; Abdulla, S.; Kabanywanyi, A. M.] Ifakara Hlth Inst, Dodoma, Tanzania.
   [Briand, V.; Cot, M.] Univ Paris 05, Paris, France.
   [Ramharter, M.] Med Univ Vienna, Div Infect Dis & Trop Med, Dept Med 1, Vienna, Austria.
   [Zoleko-Manego, R.] Ngounie Med Res Ctr, Fougamou, Gabon.
NR 0
TC 0
Z9 0
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2015
VL 20
SU 1
SI SI
BP 97
EP 97
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA CQ7BW
UT WOS:000360758800234
ER

PT J
AU Osse, RA
   Akogbeto, M
AF Osse, R. A.
   Akogbeto, M.
TI Is implementing full coverage of long-lasting insecticidal nets a good
   alternative strategy after indoor residual spraying with bendiocarb
   withdrawal in pyrethroid resistance areas?
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Osse, R. A.] Agr Univ Ketou, CREC, Cotonou, Benin.
   [Akogbeto, M.] Univ Abomey Calavi, CREC, Cotonou, Benin.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2015
VL 20
SU 1
SI SI
MA PS1.045
BP 188
EP 188
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA CQ7BW
UT WOS:000360758801045
ER

PT J
AU Sovi, ADM
   Akogbeto, MC
AF Sovi, A. D. M.
   Akogbeto, M. C.
TI Land use, an environmental risk factor for very high malaria
   transmission
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Sovi, A. D. M.; Akogbeto, M. C.] Ctr Rech Entomol Cotonou, Cotonou, Benin.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2015
VL 20
SU 1
SI SI
MA PS1.138
BP 224
EP 225
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA CQ7BW
UT WOS:000360758801138
ER

PT J
AU Ouedraogo, S
   Bodeau-Livinec, F
   Briand, V
   Huynh, BT
   Koura, GK
   Accrombessi, MMK
   Fievet, N
   Massougbodji, A
   Deloron, P
   Cot, M
AF Ouedraogo, S.
   Bodeau-Livinec, F.
   Briand, V.
   Huynh, B. -T.
   Koura, G. K.
   Accrombessi, M. M. K.
   Fievet, N.
   Massougbodji, A.
   Deloron, P.
   Cot, M.
TI Malaria and gravidity interact to modify maternal haemoglobin
   concentrations during pregnancy
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Ouedraogo, S.] Univ Ouagadougou, Dept Publ Hlth, Fac Hlth Sci, Ouagadougou, Burkina Faso.
   [Bodeau-Livinec, F.; Briand, V.; Huynh, B. -T.; Deloron, P.; Cot, M.] UMR Mere & Enfant Face Infect Trop 216, Paris, France.
   [Koura, G. K.; Fievet, N.] Univ Paris 05, Fac Pharm, Paris, France.
   [Accrombessi, M. M. K.; Massougbodji, A.] Fac Sci Sante, Cotonou, Benin.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2015
VL 20
SU 1
SI SI
MA PS2.177
BP 369
EP 369
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA CQ7BW
UT WOS:000360758802160
ER

PT J
AU Nielsen, MA
   Resende, M
   de Jongh, WA
   Ditlev, SB
   Mordmuller, B
   Houard, S
   Ndam, NT
   Agerbaek, MO
   Hamborg, M
   Massougbodji, A
   Issifou, S
   Strobaek, A
   Poulsen, L
   Leroy, O
   Kremsner, PG
   Chippaux, JP
   Luty, AJF
   Deloron, P
   Theander, TG
   Dyring, C
   Salanti, A
AF Nielsen, Morten A.
   Resende, Mafalda
   de Jongh, Willem A.
   Ditlev, Sisse B.
   Mordmueller, Benjamin
   Houard, Sophie
   Ndam, Nicaise Tuikue
   Agerbaek, Mette O.
   Hamborg, Mette
   Massougbodji, Achille
   Issifou, Saddou
   Strobaek, Anette
   Poulsen, Lars
   Leroy, Odile
   Kremsner, Peter G.
   Chippaux, Jean-Philippe
   Luty, Adrian J. F.
   Deloron, Philippe
   Theander, Thor G.
   Dyring, Charlotte
   Salanti, Ali
TI The Influence of Sub-Unit Composition and Expression System on the
   Functional Antibody Response in the Development of a VAR2CSA Based
   Plasmodium falciparum Placental Malaria Vaccine
SO PLOS ONE
LA English
DT Article
ID PREGNANCY-ASSOCIATED MALARIA; CHONDROITIN SULFATE-A; VARIANT
   SURFACE-ANTIGENS; INFECTED ERYTHROCYTES; ACQUIRED-IMMUNITY; ADHESION;
   PARASITES; EPITOPES; INSIGHT; DOMAINS
AB The disease caused by Plasmodium falciparum (Pf) involves different clinical manifestations that, cumulatively, kill hundreds of thousands every year. Placental malaria (PM) is one such manifestation in which Pf infected erythrocytes (IE) bind to chondroitin sulphate A (CSA) through expression of VAR2CSA, a parasite-derived antigen. Protection against PM is mediated by antibodies that inhibit binding of IE in the placental intervillous space. VAR2CSA is a large antigen incompatible with large scale recombinant protein expression. Vaccines based on sub-units encompassing the functionally constrained receptor-binding domains may, theoretically, circumvent polymorphisms, reduce the risk of escape-mutants and induce cross-reactive antibodies. However, the sub-unit composition and small differences in the borders, may lead to exposure of novel immuno-dominant antibody epitopes that lead to non-functional antibodies, and furthermore influence the folding, stability and yield of expression. Candidate antigens from the pre-clinical development expressed in High-Five insect cells using the baculovirus expression vector system were transitioned into the Drosophila Schneider-2 cell (S2) expression-system compliant with clinical development. The functional capacity of antibodies against antigens expressed in High-Five cells or in S2 cells was equivalent. This enabled an extensive down-selection of S2 insect cell-expressed antigens primarily encompassing the minimal CSA-binding region of VAR2CSA. In general, we found differential potency of inhibitory antibodies against antigens with the same borders but of different var2csa sequences. Likewise, we found that subtle size differences in antigens of the same sequence gave varying levels of inhibitory antibodies. The study shows that induction of a functional response against recombinant subunits of the VAR2CSA antigen is unpredictable, demonstrating the need for large-scale screening in order to identify antigens that induce a broadly strain-transcending antibody response.
C1 [Nielsen, Morten A.; Resende, Mafalda; Ditlev, Sisse B.; Agerbaek, Mette O.; Hamborg, Mette; Theander, Thor G.; Salanti, Ali] Univ Copenhagen, Ctr Med Parasitol, Dept Immunol & Microbiol, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Nielsen, Morten A.; Resende, Mafalda; Ditlev, Sisse B.; Agerbaek, Mette O.; Hamborg, Mette; Theander, Thor G.; Salanti, Ali] Rigshosp, Dept Infect Dis, Copenhagen Univ Hosp, DK-2100 Copenhagen, Denmark.
   [de Jongh, Willem A.; Strobaek, Anette; Poulsen, Lars; Dyring, Charlotte] SCION DTU Sci Pk, Biotechnol ExpreS2, Horsholm, Denmark.
   [Mordmueller, Benjamin; Kremsner, Peter G.] Univ Tubingen, Inst Tropenmed, Tubingen, Germany.
   [Mordmueller, Benjamin; Kremsner, Peter G.] Ctr Rech Med Lambarene, Lambarene, Gabon.
   [Houard, Sophie; Leroy, Odile] Univ Klinikum Heidelberg, European Vaccine Initiat, Heidelberg, Germany.
   [Ndam, Nicaise Tuikue; Chippaux, Jean-Philippe; Luty, Adrian J. F.; Deloron, Philippe] Inst Rech Dev, Mere & Enfant Face Infect Trop UMR216, Paris, France.
   [Ndam, Nicaise Tuikue; Chippaux, Jean-Philippe; Luty, Adrian J. F.; Deloron, Philippe] Univ Paris 05, PRES Sorbonne Paris Cite, Paris, France.
   [Massougbodji, Achille; Issifou, Saddou; Chippaux, Jean-Philippe; Luty, Adrian J. F.] Univ Abomey Calavi, Fac Sci Sante, Ctr Etud & Rech Paludisme Associe Grossesse & Enf, Cotonou, Benin.
RP Nielsen, MA (reprint author), Univ Copenhagen, Ctr Med Parasitol, Dept Immunol & Microbiol, Fac Hlth & Med Sci, Copenhagen, Denmark.
EM mortenn@sund.ku.dk
RI Mordmuller, Benjamin/A-5749-2010; 
OI Mordmuller, Benjamin/0000-0001-9101-2768; Tuikue Ndam,
   Nicaise/0000-0003-2646-2513
FU European Union [304815]; Danish Advanced Technology Foundation
   [005-2011-1]; Expres2ion Biotechnologies
FX The research leading to these results has received funding from the
   European Union Seventh Framework Programme, FP7-HEALTH-2012-INNOVATION
   under grant agreement no 304815
   (http://ec.europa.eu/research/fp7/index_en.cfm?pg=health) and the Danish
   Advanced Technology Foundation under grant number 005-2011-1
   (http://innovationsfonden.dk/en). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. Expres2ion Biotechnologies provided
   support in the form of salaries for authors [WAdeJ, AS, LP, CD], but did
   not have any additional role in the study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. The
   specific roles of these authors are articulated in the 'author
   contributions' section.
NR 30
TC 8
Z9 8
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 1
PY 2015
VL 10
IS 9
AR e0135406
DI 10.1371/journal.pone.0135406
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CQ2NK
UT WOS:000360437700018
PM 26327283
ER

PT J
AU Ibitokou, SA
   Denoeud-Ndam, L
   Ezinmegnon, S
   Ladekpo, R
   Zannou, DM
   Massougbodji, A
   Girard, PM
   Cot, M
   Luty, AJF
   Ndam, NT
AF Ibitokou, Samad A.
   Denoeud-Ndam, Lise
   Ezinmegnon, Sem
   Ladekpo, Rodolphe
   Zannou, Djimon-Marcel
   Massougbodji, Achille
   Girard, Pierre-Marie
   Cot, Michel
   Luty, Adrian J. F.
   Ndam, Nicaise Tuikue
TI Insights Into Circulating Cytokine Dynamics during Pregnancy in
   HIV-Infected Beninese Exposed to Plasmodium falciparum Malaria
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; INTERMITTENT PREVENTIVE TREATMENT;
   NECROSIS-FACTOR-ALPHA; PLACENTAL MALARIA; INTERFERON-GAMMA; IN-VITRO;
   WOMEN; INTERLEUKIN-10; COINFECTION; MACROPHAGES
AB We investigated the circulating plasma levels of Th1- (Interleukin-2 [IL-2], tumor necrosis factor-alpha [TNF-alpha], interferon-gamma [IFN-gamma]) and Th2-type (1L-4, IL-5, IL-10) cytokines in human immunodeficiency virus (HIV)-infected pregnant women living in a malaria-endemic area. We analyzed samples from 200 pregnant women included in the prevention of pregnancy-associated malaria in HIV-infected women: cotrimoxazole prophylaxis versus mefloquine (PACOME) clinical trial who were followed until delivery. Cytokine concentrations were measured by flow cytometry-based multiplex bead array. Significantly elevated levels of IL-10 and lower levels of TNF-alpha were observed at delivery compared with inclusion (P = 0.005). At inclusion, the presence of circulating 1FN-gamma, a higher CD4(+) T cell count and having initiated intermittent preventive treatment of malaria with sulfadoxine pyrimethamine (SP-IPTp) were all associated with a lower likelihood of Plasmodium falciparum infection. At delivery, the inverse relationship between the presence of infection and circulating IFN-gamma persisted, although there was a positive association between the likelihood of infection and the presence of circulating TNF-alpha. Initiation of antiretroviral therapy was associated with elevated IL-5 production. Consistent with our own and others' observations in HIV seronegative subjects, this study shows circulating IL-10 to be a marker of infection with P. falciparum during pregnancy even in HIV-infected women, although plasma IFN-gamma may be a marker of anti-malarial protection in such women.
C1 [Ibitokou, Samad A.; Ladekpo, Rodolphe; Massougbodji, Achille] Univ Abomey Calavi, CERPAGE, Fac Sci Sante, Abomey Calavi, Benin.
   [Denoeud-Ndam, Lise; Cot, Michel; Luty, Adrian J. F.; Ndam, Nicaise Tuikue] Inst Rech Dev, UMR 216, Mere & Enfant Face Infect Trop, Paris, France.
   [Girard, Pierre-Marie] Hop St Antoine, Serv Malad Infect & Trop, F-75571 Paris, France.
RP Ndam, NT (reprint author), Fac Pharm, UMR 216, 4 Ave Observ, F-75006 Paris, France.
EM ibitokou_samad@yahook.fr; lisedenoeud@yahoo.fr; e25sem@yahoo.fr;
   ladekpo@yahoo.fr; djmzannou@yahoo.fr; massougbodjiachille@yahoo.fr;
   pierre-marie.girard@sat.aphp.fr; michel.cot@ird.fr; adrian.luty@ird.fr;
   nicaise.ndam@ird.fr
OI DENOEUD-NDAM, Lise/0000-0002-9482-1461; Tuikue Ndam,
   Nicaise/0000-0003-2646-2513
FU SIDACTION [AI19-3-01528]
FX The PACOME trial received funding from SIDACTION (research grant no.
   AI19-3-01528).
NR 35
TC 0
Z9 1
U1 0
U2 5
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD AUG
PY 2015
VL 93
IS 2
BP 287
EP 292
DI 10.4269/ajtmh.14-0653
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA CO7GK
UT WOS:000359327400018
PM 26101276
ER

PT J
AU Briand, V
   Escolano, S
   Journot, V
   Massougbodji, A
   Cot, M
   Tubert-Bitter, P
AF Briand, Valerie
   Escolano, Sylvie
   Journot, Valerie
   Massougbodji, Achille
   Cot, Michel
   Tubert-Bitter, Pascale
TI Mefloquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive
   Treatment in Pregnancy: A Joint Analysis on Efficacy and Tolerability
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID MULTIPLE END-POINTS; THERAPEUTIC-EFFICACY; CLINICAL-TRIALS;
   BIRTH-WEIGHT; MALARIA; BENIN; CHLOROQUINE; PROPHYLAXIS; FALCIPARUM;
   SAFETY
AB Since there is no ideal candidate to replace sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment (IPTp), alternatives need to be evaluated on basis of their benefit-risk ratio. We reanalyzed the first Beninese trial on mefloquine (MQ) versus SP for IPTp using a multiple outcome approach, which allowed the joint assessment of efficacy and tolerability. Overall superiority of MQ to SP was defined as superiority on at least one efficacy outcome (low birth weight [LBW], placental malaria, or maternal anemia), non-inferiority on all of them as well as on tolerability defined as cutaneous or neuropsychiatric adverse events (AEs) or low compliance with the treatment. The analysis included 1,601 women. MQ was found to be overall superior to SP (P = 0.004). Performing several sensitivity analyses to handle both missing data and stillbirths provided similar results. Using MQ for IPTp as an example, we show that a multiple outcome analysis is a pragmatic way to assess the benefits/disadvantages of one drug compared with another. In the current context of a lack of antimalarials that could be used for IPTp, such a statistical approach could be widely used by institutional policy makers for future recommendations regarding the prevention of malaria in pregnancy (MiP).
C1 [Briand, Valerie; Cot, Michel] IRD, Mere & Enfant Face Infect Trop MERIT UMR216, F-75006 Paris, France.
   [Briand, Valerie; Cot, Michel] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
   [Escolano, Sylvie; Tubert-Bitter, Pascale] INSERM, UMR1181, Biostat Biomath Pharmacoepidemiol & Infect Dis B2, Villejuif, France.
   [Escolano, Sylvie; Tubert-Bitter, Pascale] Inst Pasteur, B2PHI, UMR1181, Paris, France.
   [Escolano, Sylvie; Tubert-Bitter, Pascale] Univ Versailles St Quentin, B2PHI, UMR1181, Villejuif, France.
   [Journot, Valerie] Ctr INSERM U897 Epidemiol Biostat, Bordeaux, France.
   [Massougbodji, Achille] FSS, Lab Parasitol, Cotonou, Benin.
   [Massougbodji, Achille] CERPAGE, Cotonou, Benin.
RP Briand, V (reprint author), IRD, Fac Pharm, MERIT UMR216, 4 Ave Observ, F-75006 Paris, France.
EM valerie.briand@ird.fr; sylvie.escolano@inserm.fr;
   valeric.journot@isped.u-bordeaux2.fr; achille.massougbodji@ird.fr;
   michel.cot@ird.fr; pascalc.tubert@inserm.fr
RI Tubert-Bitter, Pascale/E-6118-2016
FU "Fonds de Solidarite Prioritaire" (French Ministry of Foreign Affairs)
   [2006-22]; Institut de Recherche pour le Developpement; Fondation pour
   la Recherche Medicale [FDM20060907976]; Fondation de France (Fonds
   Inkermann); Fondation Merieux
FX The trial was supported by the "Fonds de Solidarite Prioritaire" (French
   Ministry of Foreign Affairs, project number 2006-22); and the "Institut
   de Recherche pour le Developpement". VB was sponsored by the Fondation
   pour la Recherche Medicale (grant FDM20060907976), the Fondation de
   France (Fonds Inkermann), and the Fondation Merieux.
NR 21
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD AUG
PY 2015
VL 93
IS 2
BP 300
EP 304
DI 10.4269/ajtmh.14.0783
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA CO7GK
UT WOS:000359327400020
PM 26055735
ER

PT J
AU Drame, PM
   Poinsignon, A
   Dechavanne, C
   Cottrell, G
   Farce, M
   Ladekpo, R
   Massougbodji, A
   Cornelie, S
   Courtin, D
   Migot-Nabias, F
   Garcia, A
   Remoue, F
AF Drame, Papa M.
   Poinsignon, Anne
   Dechavanne, Celia
   Cottrell, Gilles
   Farce, Manon
   Ladekpo, Rodolphe
   Massougbodji, Achille
   Cornelie, Sylvie
   Courtin, David
   Migot-Nabias, Florence
   Garcia, Andre
   Remoue, Franck
TI Specific antibodies to Anopheles gSG6-P1 salivary peptide to assess
   early childhood exposure to malaria vector bites
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Salivary proteins; Biomarker of exposure; Anopheles bites;
   Maternal IgG transfer; Infants; Africa
ID IMMUNO-EPIDEMIOLOGIC TOOL; EVALUATING HUMAN EXPOSURE; INFECTION; AFRICA;
   GAMBIAE; TRANSMISSION; ANTIGENS; MARKER; RISK; LIFE
AB Background: The estimates of risk of malaria in early childhood are imprecise given the current entomologic and parasitological tools. Thus, the utility of anti-Anopheles salivary gSG6-P1 peptide antibody responses in measuring exposure to Anopheles bites during early infancy has been assessed.
   Methods: Anti-gSG6-P1 IgG and IgM levels were evaluated in 133 infants (in Benin) at three (M3), six (M6), nine (M9) and 12 (M12) months of age. Specific IgG levels were also assessed in their respective umbilical cord blood (IUCB) and maternal blood (MPB).
   Results: At M3, 93.98 and 41.35% of infants had anti-gSG6-P1 IgG and IgM Ab, respectively. Specific median IgG and IgM levels gradually increased between M3 and M6 (p < 0.0001 and p < 0.001), M6-M9 (p < 0.0001 and p = 0.085) and M9-M12 (p = 0.002 and p = 0.03). These levels were positively associated with the Plasmodium falciparum infection intensity (p = 0.006 and 0.003), and inversely with the use of insecticide-treated bed nets (p = 0.003 and 0.3). Levels of specific IgG in the MPB were positively correlated to those in the IUCB (R = 0.73; p < 0.0001) and those at M3 (R = 0.34; p < 0.0001).
   Conclusion: The exposure level to Anopheles bites, and then the risk of malaria infection, can be evaluated in young infants by assessing anti-gSG6-P1 IgM and IgG responses before and after 6-months of age, respectively. This tool can be useful in epidemiological evaluation and surveillance of malaria risk during the first year of life.
C1 [Drame, Papa M.; Poinsignon, Anne; Farce, Manon; Cornelie, Sylvie; Remoue, Franck] Univ Montpellier I, UMR MIVEGEC, IRD224, CNRS5290, F-34394 Montpellier, France.
   [Drame, Papa M.; Poinsignon, Anne; Farce, Manon; Cornelie, Sylvie; Remoue, Franck] Univ Montpellier 2, IRD, F-34394 Montpellier, France.
   [Drame, Papa M.; Remoue, Franck] Univ Montpellier I, IRD UMR MIVEGEC, IRD224, CNRS5290, Cotonou, Benin.
   [Drame, Papa M.; Remoue, Franck] Univ Montpellier 2, CREC, Cotonou, Benin.
   [Dechavanne, Celia; Cottrell, Gilles; Courtin, David; Migot-Nabias, Florence; Garcia, Andre] IRD, UMR Mere & Enfant Face Infect Trop 216, F-75006 Paris, France.
   [Dechavanne, Celia; Courtin, David; Migot-Nabias, Florence; Garcia, Andre] Univ Paris 05, Sorbonne Paris Cite, Fac Pharm, F-75006 Paris, France.
   [Cottrell, Gilles] Univ Paris 05, Lab Math Appl, F-75006 Paris, France.
   [Ladekpo, Rodolphe; Massougbodji, Achille; Courtin, David] CERPAGE, Cotonou, Benin.
   [Massougbodji, Achille] Univ dAbomey Calavi, Fac Sci Sante, Cotonou, Benin.
RP Drame, PM (reprint author), NIAID, Parasit Dis Lab, NIH, 4 Ctr Dr, Bethesda, MD 20892 USA.
EM papa.drame@nih.gov
RI Garcia, Andre/S-2959-2016; 
OI Garcia, Andre/0000-0002-1808-472X; Dechavanne,
   Celia/0000-0001-8439-9976; courtin, david/0000-0002-5263-4430;
   Migot-Nabias, Florence/0000-0001-9982-594X
FU French Ministry of Foreign Affairs; IRD
FX We thank Thomas B Nutman (NIH) for the language review and re-editing of
   the manuscript. We thank populations of Tori Bossito, especially women,
   for their great support and collaboration. We also thank all the field
   and laboratory staff for their strong commitment to this project.
   Funding received from the French Ministry of Foreign Affairs and the IRD
   provided all of the funds for this study.
NR 50
TC 1
Z9 1
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUL 22
PY 2015
VL 14
AR 285
DI 10.1186/s12936-015-0800-6
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CN2TU
UT WOS:000358275600004
PM 26198354
ER

PT J
AU Kleinschmidt, I
   Mnzava, AP
   Kafy, HT
   Mbogo, C
   Bashir, AI
   Bigoga, J
   Adechoubou, A
   Raghavendra, K
   Knox, TB
   Malik, EM
   Nkuni, ZJ
   Bayoh, N
   Ochomo, E
   Fondjo, E
   Kouambeng, C
   Awono-Ambene, HP
   Etang, J
   Akogbeto, M
   Bhatt, R
   Swain, DK
   Kinyari, T
   Njagi, K
   Muthami, L
   Subramaniam, K
   Bradley, J
   West, P
   Massougbodji, A
   Oke-Sopoh, M
   Hounto, A
   Elmardi, K
   Valecha, N
   Kamau, L
   Mathenge, E
   Donnelly, MJ
AF Kleinschmidt, Immo
   Mnzava, Abraham Peter
   Kafy, Hmooda Toto
   Mbogo, Charles
   Bashir, Adam Ismail
   Bigoga, Jude
   Adechoubou, Alioun
   Raghavendra, Kamaraju
   Knox, Tessa Bellamy
   Malik, Elfatih M.
   Nkuni, Zinga Jose
   Bayoh, Nabie
   Ochomo, Eric
   Fondjo, Etienne
   Kouambeng, Celestin
   Awono-Ambene, Herman Parfait
   Etang, Josiane
   Akogbeto, Martin
   Bhatt, Rajendra
   Swain, Dipak K.
   Kinyari, Teresa
   Njagi, Kiambo
   Muthami, Lawrence
   Subramaniam, Krishanthi
   Bradley, John
   West, Philippa
   Massougbodji, Achile
   Oke-Sopoh, Mariam
   Hounto, Aurore
   Elmardi, Khalid
   Valecha, Neena
   Kamau, Luna
   Mathenge, Evan
   Donnelly, Martin James
TI Design of a study to determine the impact of insecticide resistance on
   malaria vector control: a multi-country investigation
SO MALARIA JOURNAL
LA English
DT Article
ID GAMBIAE-S.L. POPULATIONS; ANOPHELES-GAMBIAE; SOUTH-AFRICA; PYRETHROID
   RESISTANCE; EQUATORIAL-GUINEA; MORTALITY; TRANSMISSION; MOSQUITOS;
   CAMEROON; ZAMBIA
AB Background: Progress in reducing the malaria disease burden through the substantial scale up of insecticide-based vector control in recent years could be reversed by the widespread emergence of insecticide resistance. The impact of insecticide resistance on the protective effectiveness of insecticide-treated nets (ITN) and indoor residual spraying (IRS) is not known. A multi-country study was undertaken in Sudan, Kenya, India, Cameroon and Benin to quantify the potential loss of epidemiological effectiveness of ITNs and IRS due to decreased susceptibility of malaria vectors to insecticides. The design of the study is described in this paper.
   Methods: Malaria disease incidence rates by active case detection in cohorts of children, and indicators of insecticide resistance in local vectors were monitored in each of approximately 300 separate locations (clusters) with high coverage of malaria vector control over multiple malaria seasons. Phenotypic and genotypic resistance was assessed annually. In two countries, Sudan and India, clusters were randomly assigned to receive universal coverage of ITNs only, or universal coverage of ITNs combined with high coverage of IRS. Association between malaria incidence and insecticide resistance, and protective effectiveness of vector control methods and insecticide resistance were estimated, respectively.
   Results: Cohorts have been set up in all five countries, and phenotypic resistance data have been collected in all clusters. In Sudan, Kenya, Cameroon and Benin data collection is due to be completed in 2015. In India data collection will be completed in 2016.
   Discussion: The paper discusses challenges faced in the design and execution of the study, the analysis plan, the strengths and weaknesses, and the possible alternatives to the chosen study design.
C1 [Kleinschmidt, Immo; Bradley, John; West, Philippa] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, MRC Trop Epidemiol Grp, London WC1E 7HT, England.
   [Kafy, Hmooda Toto; Elmardi, Khalid] Fed Minist Hlth, Khartoum, Sudan.
   [Bashir, Adam Ismail] VBDC, Khartoum State Malaria Control Programme, Khartoum, Sudan.
   [Bashir, Adam Ismail] Univ Sains Malaysia, Sch Biol Sci, George Town 11800, Malaysia.
   [Mbogo, Charles] KEMRI Ctr Geog Med Res Coast, Kilifi 80108, Kenya.
   [Bigoga, Jude] Univ Yaounde, Natl Reference Unit NRU Vector Control, Ctr Biotechnol, Yaounde, Cameroon.
   [Adechoubou, Alioun; Oke-Sopoh, Mariam] Minist Sante, Programme Natl Lutte Conte Paludisme PNLP, Cotonou, Benin.
   [Raghavendra, Kamaraju; Bhatt, Rajendra; Swain, Dipak K.; Valecha, Neena] Natl Inst Malaria Res GoI, Dept Hlth Res, Sect 8, Delhi 110077, India.
   [Mnzava, Abraham Peter; Knox, Tessa Bellamy; Nkuni, Zinga Jose] WHO, Global Malaria Programme, CH-1211 Geneva, Switzerland.
   [Bayoh, Nabie; Ochomo, Eric] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu 40100, Kenya.
   [Fondjo, Etienne; Kouambeng, Celestin] Minist Publ Hlth, Natl Malaria Control Programme, Yaounde, Cameroon.
   [Awono-Ambene, Herman Parfait; Etang, Josiane] Org Coordinat Lutte Endemies Afrique Cent OCEAC, Yaounde, Cameroon.
   [Subramaniam, Krishanthi; Donnelly, Martin James] Univ Liverpool Liverpool Sch Trop Med, Dept Vector Biol, Liverpool L3 5QA, Merseyside, England.
   [Malik, Elfatih M.] Minist Hlth, Wad Madani, Gezera State, Sudan.
   [Donnelly, Martin James] Wellcome Trust Sanger Inst, Malaria Programme, Cambridge, England.
   [Kinyari, Teresa] Univ Nairobi, Coll Hlth Sci, Sch Med, Dept Med Physiol, Nairobi, Kenya.
   [Njagi, Kiambo] Minist Hlth, Malaria Control Unit, Nairobi 00202, Kenya.
   [Muthami, Lawrence] KEMRI Ctr Publ Hlth Res, Nairobi, Kenya.
   [Akogbeto, Martin] Ctr Rech Entomol Cotonou, Cotonou, Benin.
   [Kamau, Luna] KEMRI Ctr Biotechnol & Res Dev, Nairobi, Kenya.
   [Mathenge, Evan] KEMRI Eastern & Southern Africa Ctr Int Parasite, Nairobi, Kenya.
   [Etang, Josiane] Univ Douala, Fac Med & Pharmaceut Sci, Douala, Cameroon.
   [Massougbodji, Achile; Hounto, Aurore] Univ Abomey Calavi, Fac Sci Sante, Cotonou, Benin.
   [Kleinschmidt, Immo] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa.
RP Kleinschmidt, I (reprint author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, MRC Trop Epidemiol Grp, Keppel St, London WC1E 7HT, England.
EM Immo.Kleinschmidt@lshtm.ac.uk
FU Medical Research Council; Department for International Development
   [MR/K012126/1]; Bill and Melinda Gates Foundation [48499.01]; World
   Heath Organisation; Global Environmental Facility [GFL/4A2]
FX IK receives support from the Medical Research Council and Department for
   International Development (MR/K012126/1). This study was funded by the
   Bill and Melinda Gates Foundation (Grant Number 48499.01) and the World
   Heath Organisation. The study in Sudan was additionally part-funded by
   the Global Environmental Facility (Grant number GFL/4A2).
NR 38
TC 9
Z9 9
U1 1
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUL 22
PY 2015
VL 14
AR 282
DI 10.1186/s12936-015-0782-4
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CN2TU
UT WOS:000358275600001
PM 26194648
ER

PT J
AU Badaut, C
   Guyonnet, L
   Milet, J
   Renard, E
   Durand, R
   Viwami, F
   Sagbo, G
   Layla, F
   Deloron, P
   Bonnefoy, S
   Migot-Nabias, F
AF Badaut, Cyril
   Guyonnet, Lea
   Milet, Jacqueline
   Renard, Emmanuelle
   Durand, Remy
   Viwami, Firmine
   Sagbo, Gratien
   Layla, Francis
   Deloron, Philippe
   Bonnefoy, Serge
   Migot-Nabias, Florence
TI Immunoglobulin response to Plasmodium falciparum RESA proteins in
   uncomplicated and severe malaria
SO MALARIA JOURNAL
LA English
DT Article
DE Plasmodium falciparum; severe malaria; Ring-infected erythrocyte surface
   antigen; B cell epitope; Benin
ID ERYTHROCYTE SURFACE-ANTIGEN; SICKLE-CELL TRAIT; BLOOD-STAGE ANTIGENS;
   PF155/RESA PROTECT; MEROZOITE INVASION; ANTIBODY-RESPONSE;
   IMMUNE-RESPONSES; IN-VITRO; GENE; INFECTION
AB Background: The three members of the ring-infected erythrocyte surface antigen (RESA) proteins family share high sequence homologies, which impair the detection and assignment to one or another protein of some pathogenic processes inherent to Plasmodium falciparum malaria. The present study was intended to determine if the antibody and inflammatory responses of children living in a malaria-endemic area varied depending on the RESA-1, RESA-2 or RESA-3 proteins and the severity of the disease, two groups of severe and uncomplicated malaria cases being considered.
   Methods: Two synthetic peptides representing predicted B cell epitopes were designed per RESA protein, all located outside of the 3' and 5' repetition blocks, in order to allow an antibody detection specific of each member of the family. Recombinant rRESA-1B and rRESA-3B proteins were also engineered. Two groups of Beninese children admitted to hospital in 2009 for either uncomplicated or severe malaria were compared for their plasma levels of IgG specifically recognizing each recombinant RESA protein or synthetic peptide, and for their plasma inflammatory cytokine levels (IFN-gamma, TNF-alpha and IL-10), taking into account host and parasite genetic factors.
   Results: The absence of IgG cross-reactivity between rRESA proteins and their protein carrier as well as between each RESA peptide and a non-epitopic RESA control peptide validated the use of the engineered recombinant proteins and peptides for the measurement of plasma IgG. Taking into account age, fever duration and parasitaemia, a multiple logistic regression performed on children clustered according to their antibody responses' profiles concluded to an increased risk of severe malaria for P2 (representative of RESA-1) responders (P = 0.007). Increased IL-10 plasma levels were found in children harbouring multiclonal P. falciparum infections on the basis of the T1526G resa2 gene polymorphism (P = 0.004).
   Conclusions: This study provided novel tools to dissect the seroreactivity against the three members of the RESA protein family and to describe its relation to protection against malaria. It suggested the measurement of plasma antibodies raised against specific peptides to serve as predictive immunologic markers for disease severity. Lastly, it reinforced previous observations linking the T1526G resa2 gene mutation to severe malaria.
C1 [Badaut, Cyril] IRBA, Equipe Residente Rech Infectiol Trop, Bretigny Sur Orge, France.
   [Guyonnet, Lea; Milet, Jacqueline; Renard, Emmanuelle; Durand, Remy; Deloron, Philippe; Migot-Nabias, Florence] Inst Rech Dev, UMR Mere & Enfant Face Infect Trop 216, Paris, France.
   [Guyonnet, Lea; Milet, Jacqueline; Renard, Emmanuelle; Durand, Remy; Deloron, Philippe; Migot-Nabias, Florence] Univ Paris 05, COMUE Sorbonne Paris Cite, Fac Sci Pharmaceut & Biol, Paris, France.
   [Durand, Remy] Hop Avicenne, AP HP, Lab Parasitol Mycol, F-93009 Bobigny, France.
   [Viwami, Firmine] CERPAGE, Cotonou, Benin.
   [Sagbo, Gratien; Layla, Francis] Ctr Natl Hosp, Serv Pediat, Cotonou, Benin.
   [Sagbo, Gratien; Layla, Francis] Univ Hubert K Maga, Cotonou, Benin.
   [Bonnefoy, Serge] Inst Pasteur, INSERM, Unite Biol Cellulaire Trypanosomes, U1201, Paris, France.
   [Migot-Nabias, Florence] IRD, Fac Pharm, UMR216, F-75006 Paris, France.
RP Migot-Nabias, F (reprint author), Inst Rech Dev, UMR Mere & Enfant Face Infect Trop 216, Paris, France.
EM florence.migot-nabias@ird.fr
RI Bonnefoy, Serge/B-2466-2014; 
OI Jacqueline, MILET/0000-0003-2710-1517; Migot-Nabias,
   Florence/0000-0001-9982-594X
FU French Agence Nationale de la Recherche [ANR-08-MIE-031]; CNRS
FX We thank the participating children and their families as well as B
   Ayivi and the medical staff at the University Hospital CNHU-HKM. We are
   grateful to A Massougbodji for interceding with local authorities. We
   thank Alice Lebreton for her critical reading of the final manuscript.
   This work was supported by the French Agence Nationale de la Recherche
   under grant MIE (ANR-08-MIE-031) and CNRS.
NR 50
TC 1
Z9 1
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUL 16
PY 2015
VL 14
AR 278
DI 10.1186/s12936-015-0799-8
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CM8VQ
UT WOS:000357980900005
PM 26178656
ER

PT J
AU Zogo, B
   Djenontin, A
   Carolan, K
   Babonneau, J
   Guegan, JF
   Eyangoh, S
   Marion, E
AF Zogo, Barnabas
   Djenontin, Armel
   Carolan, Kevin
   Babonneau, Jeremy
   Guegan, Jean-Francois
   Eyangoh, Sara
   Marion, Estelle
TI A Field Study in Benin to Investigate the Role of Mosquitoes and Other
   Flying Insects in the Ecology of Mycobacterium ulcerans
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID BURULI ULCER; SOUTHEASTERN AUSTRALIA; NAUCORIS-CIMICOIDES; AQUATIC
   INSECTS; MACROLIDE TOXIN; RISK-FACTORS; TRANSMISSION; DISEASE;
   INFECTION; CAMEROON
AB Background
   Buruli ulcer, the third mycobacterial disease after tuberculosis and leprosy, is caused by the environmental mycobacterium M. ulcerans. There is at present no clear understanding of the exact mode(s) of transmission of M. ulcerans. Populations affected by Buruli ulcer are those living close to humid and swampy zones. The disease is associated with the creation or the extension of swampy areas, such as construction of dams or lakes for the development of agriculture. Currently, it is supposed that insects (water bugs and mosquitoes) are host and vector of M. ulcerans. The role of water bugs was clearly demonstrated by several experimental and environmental studies. However, no definitive conclusion can yet be drawn concerning the precise importance of this route of transmission. Concerning the mosquitoes, DNA was detected only in mosquitoes collected in Australia, and their role as host/vector was never studied by experimental approaches. Surprisingly, no specific study was conducted in Africa. In this context, the objective of this study was to investigate the role of mosquitoes (larvae and adults) and other flying insects in ecology of M. ulcerans. This study was conducted in a highly endemic area of Benin.
   Methodology/Principal Findings
   Mosquitoes (adults and larvae) were collected over one year, in Buruli ulcer endemic in Benin. In parallel, to monitor the presence of M. ulcerans in environment, aquatic insects were sampled. QPCR was used to detected M. ulcerans DNA. DNA of M. ulcerans was detected in around 8.7% of aquatic insects but never in mosquitoes (larvae or adults) or in other flying insects.
   Conclusion/Significance
   This study suggested that the mosquitoes don't play a pivotal role in the ecology and transmission of M. ulcerans in the studied endemic areas. However, the role of mosquitoes cannot be excluded and, we can reasonably suppose that several routes of transmission of M. ulcerans are possible through the world.
C1 [Zogo, Barnabas; Djenontin, Armel] IRD CREC Cotonou, Cotonou, Benin.
   [Zogo, Barnabas; Djenontin, Armel] Univ Abomey Calavi, Cotonou, Benin.
   [Carolan, Kevin; Guegan, Jean-Francois] Univ Montpellier I, CNRS, UMR MIVEGEC, IRD, Montpellier, France.
   [Carolan, Kevin; Guegan, Jean-Francois] Univ Montpellier 2, Montpellier, France.
   [Babonneau, Jeremy; Marion, Estelle] Univ Angers, Inserm Avenir Team, ATOMycA, CRCNA,Inserm U892,CNRS 6299, Angers, France.
   [Babonneau, Jeremy; Marion, Estelle] CHU Angers, Angers, France.
   [Eyangoh, Sara] Ctr Pasteur Cameroun, Lab Mycobacteriol, Yaounde, Cameroon.
   [Marion, Estelle] Fdn Raoul Follereau, Ctr Diagnost & Traitement Ulcere Buruli, Pobe, Benin.
RP Marion, E (reprint author), Univ Angers, Inserm Avenir Team, ATOMycA, CRCNA,Inserm U892,CNRS 6299, Angers, France.
EM estelle.marion@inserm.fr
RI Marion, Estelle/G-3437-2016
FU Fondation Raoul Follereau; Institut National de la sante et de la
   recherche Medicale (Inserm Avenir); Agence Nationale de la rcherche
   contre le Sida et les hepatites; Iinstitut de Recherche pour le
   developpement (IRD); Universite d'Angers; Agence Nationale de la
   recherche (ANR)
FX This study was supported by Fondation Raoul Follereau, Institut National
   de la sante et de la recherche Medicale (Inserm Avenir), Agence
   Nationale de la rcherche contre le Sida et les hepatites, Iinstitut de
   Recherche pour le developpement (IRD), Universite d'Angers, and Agence
   Nationale de la recherche (ANR). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 54
TC 2
Z9 2
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUL
PY 2015
VL 9
IS 7
AR e0003941
DI 10.1371/journal.pntd.0003941
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CO3SM
UT WOS:000359079700044
PM 26196901
ER

PT J
AU Ceesay, SJ
   Koivogui, L
   Nahum, A
   Taal, MA
   Okebe, J
   Affara, M
   Kaman, LE
   Bohissou, F
   Agbowai, C
   Tolno, BG
   Amambua-Ngwa, A
   Bangoura, N
   Ahounou, D
   Muhammad, AK
   Duparc, S
   Hamed, K
   Ubben, D
   Bojang, K
   Achan, J
   D'Alessandro, U
AF Ceesay, Serign J.
   Koivogui, Lamine
   Nahum, Alain
   Taal, Makie Abdoulie
   Okebe, Joseph
   Affara, Muna
   Kaman, Lama Eugene
   Bohissou, Francis
   Agbowai, Carine
   Tolno, Benoit Gniouma
   Amambua-Ngwa, Alfred
   Bangoura, Nfaly
   Ahounou, Daniel
   Muhammad, Abdul Khalie
   Duparc, Stephan
   Hamed, Kamal
   Ubben, David
   Bojang, Kalifa
   Achan, Jane
   D'Alessandro, Umberto
TI Malaria Prevalence among Young Infants in Different Transmission
   Settings, Africa
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; RETROSPECTIVE SURVEILLANCE; NEONATAL
   MALARIA; AGE; EPIDEMIOLOGY; PARASITEMIA; PREGNANCY; EXPOSURE; CHILDREN;
   RECORDS
AB The prevalence and consequences of malaria among infants are not well characterized and may be underestimated. A better understanding of the risk for malaria in early infancy is critical for drug development and informed decision making. In a cross-sectional survey in Guinea, The Gambia, and Benin, countries with different malaria transmission intensities, the overall prevalence of malaria among infants <= 6 months of age was 11.8% (Guinea, 21.7%; The Gambia, 3.7%; and Benin, 10.2%). Seroprevalence ranged from 5.7% in The Gambia to 41.6% in Guinea. Mean parasite densities in infants were significantly lower than those in children 1-9 years of age in The Gambia (p<0.0001) and Benin (p = 0.0021). Malaria in infants was significantly associated with fever or recent history of fever (p = 0.007) and anemia (p = 0.001). Targeted preventive interventions, adequate drug formulations, and treatment guidelines are needed to address the sizeable prevalence of malaria among young infants in malaria-endemic countries.
C1 [Ceesay, Serign J.; Okebe, Joseph; Affara, Muna; Amambua-Ngwa, Alfred; Muhammad, Abdul Khalie; Bojang, Kalifa; Achan, Jane; D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [Koivogui, Lamine; Kaman, Lama Eugene; Tolno, Benoit Gniouma] Inst Natl Sante Publ, Conakry, Guinea.
   [Nahum, Alain; Bohissou, Francis; Agbowai, Carine; Ahounou, Daniel] Ctr Rech Entomol Cotonou, Cotonou, Benin.
   [Taal, Makie Abdoulie] Natl Publ Hlth Lab, Kotu, Gambia.
   [Bangoura, Nfaly] Prefectoral Sante Faranah, Faranah, Guinea.
   [Duparc, Stephan; Ubben, David] Med Malaria Venture, Geneva, Switzerland.
   [Hamed, Kamal] Novartis Pharmaceut, E Hanover, NJ USA.
   [D'Alessandro, Umberto] London Sch Hyg & Trop Med, London WC1, England.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
RP D'Alessandro, U (reprint author), MRC, POB 273, Banjul, Gambia.
EM Udalessandro@mrc.gm
FU Medicines for Malaria Venture; Novartis Pharma AG
FX This study was funded by Medicines for Malaria Venture and Novartis
   Pharma AG.
NR 33
TC 3
Z9 3
U1 0
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUL
PY 2015
VL 21
IS 7
BP 1114
EP 1121
DI 10.3201/eid2107.142036
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CL5KF
UT WOS:000356998100003
PM 26079062
ER

PT J
AU Akogbeto, MC
   Aikpon, RY
   Azondekon, R
   Padonou, GG
   Osse, RA
   Agossa, FR
   Beach, R
   Sezonlin, M
AF Akogbeto, Martin C.
   Aikpon, Rock Y.
   Azondekon, Roseric
   Padonou, Gil G.
   Osse, Razaki A.
   Agossa, Fiacre R.
   Beach, Raymond
   Sezonlin, Michel
TI Six years of experience in entomological surveillance of indoor residual
   spraying against malaria transmission in Benin: lessons learned,
   challenges and outlooks
SO MALARIA JOURNAL
LA English
DT Article
DE Indoor residual spraying; Lessons learned; Benin
ID INSECTICIDAL MOSQUITO NETS; GAMBIAE-S.L. POPULATIONS; ANOPHELES-GAMBIAE;
   WEST-AFRICA; PYRETHROID RESISTANCE; VECTOR CONTROL; BENDIOCARB;
   MANAGEMENT; CARBAMATE; EFFICACY
AB Background: From 2008 to 2013, a prevention intervention against malaria based on indoor residual spraying (IRS) was implemented in Benin. From 2008 to 2012, Ficam M(R), a bendiocarb-containing product was used for house spraying, in association with pirimiphos methyl EC (Actellic EC) in 2013. This operation aimed to strengthen the effectiveness of treated nets so as to expedite the achievement of Millennium Development Goals (MDGs): the reduction of morbidity and mortality due to malaria by 75 % from 2000 to 2015.
   Methods: Monitoring and evaluation (M&E) was implemented in order to evaluate the impact of IRS intervention on malaria transmission. Anopheles gambiae s.l. populations were sampled by human landing catch. In addition, window exit traps and pyrethrum spray catches were performed to assess exophagic behaviour of Anopheles vectors the main malaria vector in the treated areas. The residual activity of insecticide in the treated walls was also assessed using WHO bioassay test.
   Results: The purpose of this project was to draw attention to new challenges and future prospects for the success of IRS in Benin. The main strength of the intervention was a large-scale operation in which more than 80 % of the houses were treated due to the strong adhesion of population. In addition, a significant reduction of the EIR in areas under IRS were observed. However, there were many challenges including the high cost of IRS implementation and the identification of suitable areas to implement IRS. This was because of the low and short residual effect of the insecticides recommended for IRS and the management strategy for vector resistance to insecticides. This indicated that challenges are accompanied by suggested solutions. For the cost of IRS to be accessible to states, then local organizations need to be created in partnership with the National Malaria Control Programme (NMCP) in order to ensure relevant planning and implementation of IRS.
   Conclusion: As an anticipatory measure against vector resistance, this paper proposes various methods, such as periodic IRS based on a combination of two or three insecticides of different classes used in rotation every two or three years.
C1 [Akogbeto, Martin C.; Aikpon, Rock Y.; Azondekon, Roseric; Padonou, Gil G.; Osse, Razaki A.; Agossa, Fiacre R.] CREC, Cotonou, Benin.
   [Akogbeto, Martin C.; Aikpon, Rock Y.; Padonou, Gil G.; Agossa, Fiacre R.; Sezonlin, Michel] Univ dAbomey Calavi, Fac Sci & Tech, Cotonou, Benin.
   [Azondekon, Roseric] Univ Massachusetts, Amherst, MA 01003 USA.
   [Osse, Razaki A.] Univ Agr Ketou, Ketou, Benin.
   [Beach, Raymond] Ctr Dis Control, Atlanta, GA 30333 USA.
RP Aikpon, RY (reprint author), CREC, 06 BP 2604, Cotonou, Benin.
EM rockypremier@yahoo.fr
FU President's Malaria Initiative of the US Government
FX The research leading to these results was financially supported by The
   President's Malaria Initiative of the US Government. We acknowledge The
   President's Malaria Initiative through USAID Cotonou, Benin
NR 30
TC 1
Z9 1
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUN 12
PY 2015
VL 14
AR 242
DI 10.1186/s12936-015-0757-5
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CK4VH
UT WOS:000356220900001
PM 26063497
ER

PT J
AU Accrombessi, M
   Ouedraogo, S
   Agbota, GC
   Gonzalez, R
   Massougbodji, A
   Menendez, C
   Cot, M
AF Accrombessi, Manfred
   Ouedraogo, Smaila
   Agbota, Gino Cedric
   Gonzalez, Raquel
   Massougbodji, Achille
   Menendez, Clara
   Cot, Michel
TI Malaria in Pregnancy Is a Predictor of Infant Haemoglobin Concentrations
   during the First Year of Life in Benin, West Africa
SO PLOS ONE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM INFECTION; PLACENTAL MALARIA; IRON-DEFICIENCY;
   YOUNG-CHILDREN; RISK-FACTORS; ANEMIA; SUSCEPTIBILITY; ANTIGENS; MALAWI;
   WOMEN
AB Background
   Anaemia is an increasingly recognized health problem in Africa, particularly in infants and pregnant women. Although malaria is known to be the main risk factor of anaemia in both groups, the consequences of maternal factors, particularly malaria in pregnancy (MiP), on infant haemoglobin (Hb) concentrations during the first months of life are still unclear.
   Methods
   We followed-up a cohort of 1005 Beninese pregnant women from the beginning of pregnancy until delivery. A subsample composed of the first 400 offspring of these women were selected at birth and followed until the first year of life. Placental histology and blood smear at 1st clinical antenatal visit (ANC), 2nd ANC and delivery were used to assess malaria during pregnancy. Infant Hb concentrations were measured at birth, 6, 9 and 12 months of age. A mixed multi-level model was used to assess the association between MiP and infant Hb variations during the first 12 months of life.
   Results
   Placental malaria (difference mean [dm] = -2.8 g/L, 95% CI [-5.3, -0.3], P = 0.03) and maternal peripheral parasitaemia at delivery (dm = -4.6 g/L, 95% CI [-7.9, -1.3], P = 0.007) were the main maternal factors significantly associated with infant Hb concentrations during the first year of life. Poor maternal nutritional status and malaria infection during infancy were also significantly associated with a decrease in infant Hb.
   Conclusion
   Antimalarial control and nutritional interventions before and during pregnancy should be reinforced to reduce specifically the incidence of infant anaemia, particularly in SubSaharan countries.
C1 [Accrombessi, Manfred; Agbota, Gino Cedric; Cot, Michel] IRD, Mere & Enfant Face Infect Trop UMR216, Paris, France.
   [Accrombessi, Manfred; Agbota, Gino Cedric; Cot, Michel] Univ Paris 05, PRES Paris Sorbonne Cite, Paris, France.
   [Accrombessi, Manfred; Agbota, Gino Cedric; Massougbodji, Achille] Univ Abomey Calavi, Fac Med Cotonou, Cotonou, Benin.
   [Ouedraogo, Smaila] Univ Ouagadougou, Unite Format & Rech Sci Sante, Ouagadougou, Burkina Faso.
   [Gonzalez, Raquel; Menendez, Clara] Univ Barcelona, Hosp Clin, ISGlobal, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain.
   [Gonzalez, Raquel; Menendez, Clara] Manhica Hlth Res Ctr CISM, Manhica, Mozambique.
RP Accrombessi, M (reprint author), IRD, Mere & Enfant Face Infect Trop UMR216, Paris, France.
EM accrombessimanfred@yahoo.fr
FU Malaria in Pregnancy consortium; Bill and Melinda Gates Foundation;
   EDCTP [EDCTP-IP.07.31080.002]; Institut de Recherche pour le
   Developpement grant
FX This study was supported by the Malaria in Pregnancy consortium, which
   is funded through a grant from the Bill and Melinda Gates Foundation to
   the Liverpool School of Tropical Medicine. The MiPPAD study was
   supported by the EDCTP (EDCTP-IP.07.31080.002). Manfred Accrombessi was
   supported by an Institut de Recherche pour le Developpement grant while
   writing this paper.
NR 41
TC 0
Z9 0
U1 2
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 8
PY 2015
VL 10
IS 6
AR UNSP e0129510
DI 10.1371/journal.pone.0129510
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK1GM
UT WOS:000355955300134
PM 26052704
ER

PT J
AU Marie, A
   Ronca, R
   Poinsignon, A
   Lombardo, F
   Drame, PM
   Cornelie, S
   Besnard, P
   Le Mire, J
   Fiorentino, G
   Fortes, F
   Carnevale, P
   Remoue, F
   Arca, B
AF Marie, Alexandra
   Ronca, Raffaele
   Poinsignon, Anne
   Lombardo, Fabrizio
   Drame, Papa M.
   Cornelie, Sylvie
   Besnard, Patrick
   Le Mire, Jacques
   Fiorentino, Gabriella
   Fortes, Filomeno
   Carnevale, Pierre
   Remoue, Franck
   Arca, Bruno
TI The Anopheles gambiae cE5 salivary protein: a sensitive biomarker to
   evaluate the efficacy of insecticide-treated nets in malaria vector
   control
SO MICROBES AND INFECTION
LA English
DT Article
DE cE5 salivary protein; Anopheles gambiae; Malaria; Biomarker; Vector
   exposure; Insecticide-treated nets
ID IMMUNO-EPIDEMIOLOGIC TOOL; HUMAN-ANTIBODY RESPONSE; LOW-LEVEL
   INFESTATION; HUMAN EXPOSURE; TRIATOMA-INFESTANS; VISCERAL LEISHMANIASIS;
   GLAND PROTEINS; WEST-AFRICA; BITES; ANTIGENS
AB Evaluation of vector control is crucial for improving malaria containment and, according to World Health Organization, new complementary indicators would be very valuable. In this study the IgG response to the Anopheles-specific cE5 salivary protein was tested as a tool to evaluate the efficacy of insecticide-treated nets in reducing human exposure to malaria vectors. Sera collected during a longitudinal study carried out in Angola, and including entomological and parasitological data, were used to assess the IgG response to the Anopheles gambiae cE5 in both children and adults, before and after the application of insecticide-treated nets. Seasonal fluctuation of specific IgG antibody levels according to exposure was only found in children (up to approximate to 14 years old) whose anti-cE5 IgG response dropped after bed nets installation. These results were fully consistent with previous findings obtained with the same set of sera and indicating a substantial reduction of human-vector contact shortly after nets implementation. Overall, children IgG response to the cE5 protein appeared a very sensitive biomarker, which allowed for the detection of even weak exposure to Anopheles bites, indicating it may represent a reliable additional tool to evaluate the efficacy of vector control interventions. (C) 2015 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
C1 [Marie, Alexandra; Poinsignon, Anne; Drame, Papa M.; Cornelie, Sylvie; Remoue, Franck] CNRS 5290, MIVEGEC, UMR IRD 224, UM1 UM2, F-34394 Montpellier 5, France.
   [Ronca, Raffaele; Fiorentino, Gabriella] Univ Naples Federico II, Dept Biol, I-80126 Naples, Italy.
   [Lombardo, Fabrizio; Arca, Bruno] Univ Roma La Sapienza, Parasitol Sect, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy.
   [Cornelie, Sylvie] MIVEGEC IRD CREC, Cotonou, Benin.
   [Besnard, Patrick; Le Mire, Jacques] SONAMET Clin, Malaria Control Program, Lobito, Angola.
   [Fortes, Filomeno] Minist Publ Hlth, Malaria Control Program, Luanda, Angola.
   [Carnevale, Pierre] IRD, Montpellier, France.
RP Marie, A (reprint author), CNRS 5290, MIVEGEC, UMR IRD 224, UM1 UM2, 911 Av Agropolis, F-34394 Montpellier 5, France.
EM alexandra.marie@ird.fr; bruno.arca@uniroma1.it
RI Lombardo, Fabrizio/J-8511-2014; 
OI Lombardo, Fabrizio/0000-0002-8563-0612; Arca, Bruno/0000-0002-4029-0984;
   FIORENTINO, Gabriella/0000-0002-4089-3822; Ronca,
   Raffaele/0000-0003-2217-3378
FU Institut de Recherche pour le Developpement (IRD; Departement de
   Valorisation au Sud); European Community's Seventh Framework 415
   Programme (FP7) (EviMalaR) [242095]; EviMalaR scholarship
FX The authors gratefully acknowledge the population of the Bella Vista
   area (Lobito, Angola) for their participation in this study, the
   technical personal of the Malaria Control Program team, especially Maria
   Chilombo (SONAMET Lobito) and Dr Jean-Francois Foucher from Acer-Energy
   (ACERGY) Company. This work was supported by the Institut de Recherche
   pour le Developpement (IRD; Departement de Valorisation au Sud) and the
   European Community's Seventh Framework 415 Programme (FP7) (grant
   agreement No 242095, EviMalaR). Alexandra Marie was supported by an
   EviMalaR scholarship.
NR 47
TC 0
Z9 0
U1 4
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD JUN
PY 2015
VL 17
IS 6
BP 409
EP 416
DI 10.1016/j.micinf.2015.01.002
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CL5FU
UT WOS:000356986000003
PM 25637950
ER

PT J
AU Weetman, D
   Mitchell, SN
   Wilding, CS
   Birks, DP
   Yawson, AE
   Essandoh, J
   Mawejje, HD
   Djogbenou, LS
   Steen, K
   Rippon, EJ
   Clarkson, CS
   Field, SG
   Rigden, DJ
   Donnelly, MJ
AF Weetman, David
   Mitchell, Sara N.
   Wilding, Craig S.
   Birks, Daniel P.
   Yawson, Alexander E.
   Essandoh, John
   Mawejje, Henry D.
   Djogbenou, Luc S.
   Steen, Keith
   Rippon, Emily J.
   Clarkson, Christopher S.
   Field, Stuart G.
   Rigden, Daniel J.
   Donnelly, Martin J.
TI Contemporary evolution of resistance at the major insecticide target
   site gene Ace-1 by mutation and copy number variation in the malaria
   mosquito Anophelesgambiae
SO MOLECULAR ECOLOGY
LA English
DT Article
DE Ace-1 G119S; Acetylcholinesterase; gene duplication; malaria mosquito;
   purifying selection
ID DROSOPHILA-MELANOGASTER; SELECTIVE SWEEPS; ORGANOPHOSPHATE RESISTANCE;
   ACETYLCHOLINESTERASE GENE; DIFFERENTIATION MEASURE; POSITIVE SELECTION;
   STANDING VARIATION; POPULATION-SIZE; MOLECULAR-FORMS; CULEX-PIPIENS
AB Functionally constrained genes are ideal insecticide targets because disruption is often fatal, and resistance mutations are typically costly. Synaptic acetylcholinesterase (AChE) is an essential neurotransmission enzyme targeted by insecticides used increasingly in malaria control. In Anopheles and Culex mosquitoes, a glycine-serine substitution at codon 119 of the Ace-1 gene confers both resistance and fitness costs, especially for 119S/S homozygotes. G119S in Anophelesgambiae from Accra (Ghana) is strongly associated with resistance, and, despite expectations of cost, resistant 119S alleles are increasing significantly in frequency. Sequencing of Accra females detected only a single Ace-1 119S haplotype, whereas 119G diversity was high overall but very low at non-synonymous sites, evidence of strong purifying selection driven by functional constraint. Flanking microsatellites showed reduced diversity, elevated linkage disequilibrium and high differentiation of 119S, relative to 119G homozygotes across up to two megabases of the genome. Yet these signals of selection were inconsistent and sometimes weak tens of kilobases from Ace-1. This unexpected finding is attributable to apparently ubiquitous amplification of 119S alleles as part of a large copy number variant (CNV) far exceeding the size of the Ace-1 gene, whereas 119G alleles were unduplicated. Ace-1 CNV was detectable in archived samples collected when the 119S allele was rare in Ghana. Multicopy amplification of resistant alleles has not been observed previously and is likely to underpin the recent increase in 119S frequency. The large CNV compromised localization of the strong selective sweep around Ace-1, emphasizing the need to integrate CNV analysis into genome scans for selection.
C1 [Weetman, David; Birks, Daniel P.; Steen, Keith; Rippon, Emily J.; Clarkson, Christopher S.; Donnelly, Martin J.] Univ Liverpool, Liverpool Sch Trop Med, Dept Vector Biol, Liverpool L3 5QA, Merseyside, England.
   [Mitchell, Sara N.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Wilding, Craig S.] Liverpool John Moores Univ, Sch Nat Sci & Psychol, Liverpool L3 5UX, Merseyside, England.
   [Yawson, Alexander E.] Ghana Atom Energy Commiss, Biotechnol & Nucl Agr Res Inst, Kwabenya, Accra, Ghana.
   [Yawson, Alexander E.] Univ Cape Coast, Dept Mol Biol & Biotechnol, Cape Coast, Ghana.
   [Essandoh, John] Univ Cape Coast, Dept Wildlife & Entomol, Cape Coast, Ghana.
   [Mawejje, Henry D.] Infect Dis Res Collaborat, Kampala, Uganda.
   [Djogbenou, Luc S.] Inst Reg Sante Publ Ouidah, Ouidah, Benin.
   [Djogbenou, Luc S.] Univ Abomey Calavi, Cotonou, Benin.
   [Field, Stuart G.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   [Rigden, Daniel J.] Univ Liverpool, Inst Integrat Biol, Liverpool L69 3BX, Merseyside, England.
   [Donnelly, Martin J.] Wellcome Trust Sanger Inst, Malaria Programme, Cambridge, England.
RP Weetman, D (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Dept Vector Biol, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.
EM david.weetman@lstmed.ac.uk
RI Wilding, Craig/C-5500-2012; 
OI Wilding, Craig/0000-0001-5818-2706; Rigden, Daniel/0000-0002-7565-8937;
   Mitchell, Sara/0000-0002-7926-1881
FU National Institutes of Health [R01AI082734]; Innovative Vector Control
   Consortium; BBSRC; Wellcome Trust [094960/Z/10/Z, WT093755]
FX This work was funded by the National Institutes of Health (R01AI082734);
   the Innovative Vector Control Consortium; a BBSRC PhD studentship to
   SNM; a Wellcome Trust Master's Fellowship in Public Health and Tropical
   Medicine 094960/Z/10/Z to JE; and a Wellcome Trust Training Fellowship
   in Public Health and Tropical Medicine WT093755 to LSD. We are grateful
   to Mike Osae (Ghana Atomic Energy Commission) for help with sampling and
   to three anonymous reviewers for helpful comments and suggestions.
NR 79
TC 7
Z9 7
U1 4
U2 22
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1083
EI 1365-294X
J9 MOL ECOL
JI Mol. Ecol.
PD JUN
PY 2015
VL 24
IS 11
BP 2656
EP 2672
DI 10.1111/mec.13197
PG 17
WC Biochemistry & Molecular Biology; Ecology; Evolutionary Biology
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology;
   Evolutionary Biology
GA CJ1FS
UT WOS:000355228800007
PM 25865270
ER

PT J
AU Anstey, NM
   Price, RN
   Davis, TME
   Karunajeewa, HA
   Mueller, I
   Karunajeewa, HA
   D'Alessandro, U
   Massougbodji, A
   Nikiema, F
   Ouedraogo, JB
   Tinto, H
   Zongo, I
   Ouedraogo, JB
   Tinto, H
   Same-Ekobo, A
   Kone, M
   Menan, H
   Toure, AO
   Yavo, W
   Yavo, W
   Kofoed, PE
   Alemayehu, BH
   Jima, D
   Baudin, E
   Espie, E
   Nabasumba, C
   Pinoges, L
   Schramm, B
   Cot, M
   Deloron, P
   Faucher, JF
   Cot, M
   Deloron, P
   Faucher, JF
   Faucher, JF
   Guthmann, JP
   Lell, B
   Borrmann, S
   Lell, B
   Adjei, GO
   Kofoed, PE
   Ursing, J
   Tjitra, E
   Borrmann, S
   Marsh, K
   Peshu, J
   Juma, E
   Ogutu, BR
   Omar, SA
   Sawa, P
   Talisuna, AO
   Talisuna, AO
   Khanthavong, M
   Mayxay, M
   Newton, PN
   Mayxay, M
   Piola, P
   Djimde, AA
   Doumbo, OK
   Fofana, B
   Sagara, I
   Bassat, Q
   Gonzalez, R
   Menendez, C
   Smithuis, F
   Smithuis, F
   Bousema, T
   Kager, PA
   Mens, PF
   Mens, PF
   Schallig, HDFH
   Van den Broek, I
   Van Vugt, M
   Ibrahim, ML
   Falade, CO
   Meremikwu, M
   Meremikwu, M
   Gil, JP
   Karema, C
   Ba, MS
   Faye, B
   Faye, O
   Gaye, O
   Ndiaye, JL
   Pene, M
   Sow, D
   Sylla, K
   Tine, RCK
   Penali, LK
   Barnes, KI
   Workman, LJ
   Barnes, KI
   Workman, LJ
   Bassat, Q
   Gonzalez, R
   Menendez, C
   Mueller, I
   Lima, A
   Adam, I
   Gadalla, NB
   Malik, EFM
   Bjorkman, A
   Gil, JP
   Martensson, A
   Ngasala, BE
   Ursing, J
   Rombo, L
   Rombo, L
   Rombo, L
   Aliu, P
   Duparc, S
   Filler, S
   Genton, B
   Genton, B
   Hodel, EM
   Olliaro, P
   Abdulla, S
   Kamugisha, E
   Ngasala, BE
   Premji, Z
   Shekalaghe, SA
   Shekalaghe, SA
   Ashley, EA
   Carrara, VI
   McGready, R
   Nosten, F
   Ashley, EA
   Faiz, AM
   Lee, SJ
   White, NJ
   Carrara, VI
   Dondorp, AM
   Smith, JJ
   D'Alessandro, U
   Tarning, J
   Achan, J
   Bukirwa, H
   Yeka, A
   Arinaitwe, E
   Staedke, SG
   Kamya, MR
   Kironde, F
   Nabasumba, C
   Bousema, T
   Drakeley, CJ
   Gadalla, NB
   Oguike, M
   Sutherland, CJ
   Checchi, F
   Dahal, P
   Flegg, JA
   Guerin, PJ
   Moreira, C
   Newton, PN
   Nsanzabana, C
   Price, RN
   Sibley, CH
   Stepniewska, K
   Tarning, J
   Dahal, P
   Dondorp, AM
   Flegg, JA
   Guerin, PJ
   Lee, SJ
   Marsh, K
   McGready, R
   Moreira, C
   Newton, PN
   Nosten, F
   Nsanzabana, C
   Olliaro, P
   Price, RN
   Tarning, J
   White, NJ
   Gething, PW
   Hay, SI
   Greenwood, B
   Hodel, EM
   Ward, SA
   Staedke, SG
   Van den Broek, I
   Winstanley, PA
   Dorsey, G
   Greenhouse, B
   Rosenthal, PJ
   Gadalla, NB
   Gil, JP
   Grivoyannis, A
   Hamed, K
   Hwang, J
   Kachur, PS
   Hwang, J
   Sibley, CH
   Nambozi, M
AF Anstey, N. M.
   Price, R. N.
   Davis, T. M. E.
   Karunajeewa, H. A.
   Mueller, I.
   Karunajeewa, H. A.
   D'Alessandro, U.
   Massougbodji, A.
   Nikiema, F.
   Ouedraogo, J-B
   Tinto, H.
   Zongo, I.
   Ouedraogo, J-B
   Tinto, H.
   Same-Ekobo, A.
   Kone, M.
   Menan, H.
   Toure, A. O.
   Yavo, W.
   Yavo, W.
   Kofoed, P-E
   Alemayehu, B. H.
   Jima, D.
   Baudin, E.
   Espie, E.
   Nabasumba, C.
   Pinoges, L.
   Schramm, B.
   Cot, M.
   Deloron, P.
   Faucher, J-F
   Cot, M.
   Deloron, P.
   Faucher, J-F
   Faucher, J-F
   Guthmann, J-P
   Lell, B.
   Borrmann, S.
   Lell, B.
   Adjei, G. O.
   Kofoed, P-E
   Ursing, J.
   Tjitra, E.
   Borrmann, S.
   Marsh, K.
   Peshu, J.
   Juma, E.
   Ogutu, B. R.
   Omar, S. A.
   Sawa, P.
   Talisuna, A. O.
   Talisuna, A. O.
   Khanthavong, M.
   Mayxay, M.
   Newton, P. N.
   Mayxay, M.
   Piola, P.
   Djimde, A. A.
   Doumbo, O. K.
   Fofana, B.
   Sagara, I.
   Bassat, Q.
   Gonzalez, R.
   Menendez, C.
   Smithuis, F.
   Smithuis, F.
   Bousema, T.
   Kager, P. A.
   Mens, P. F.
   Mens, P. F.
   Schallig, H. D. F. H.
   Van den Broek, I.
   Van Vugt, M.
   Ibrahim, M. L.
   Falade, C. O.
   Meremikwu, M.
   Meremikwu, M.
   Gil, J. P.
   Karema, C.
   Ba, M. S.
   Faye, B.
   Faye, O.
   Gaye, O.
   Ndiaye, J-L
   Pene, M.
   Sow, D.
   Sylla, K.
   Tine, R. C. K.
   Penali, L. K.
   Barnes, K. I.
   Workman, L. J.
   Barnes, K. I.
   Workman, L. J.
   Bassat, Q.
   Gonzalez, R.
   Menendez, C.
   Mueller, I.
   Lima, A.
   Adam, I.
   Gadalla, N. B.
   Malik, E. F. M.
   Bjorkman, A.
   Gil, J. P.
   Martensson, A.
   Ngasala, B. E.
   Ursing, J.
   Rombo, L.
   Rombo, L.
   Rombo, L.
   Aliu, P.
   Duparc, S.
   Filler, S.
   Genton, B.
   Genton, B.
   Hodel, E. M.
   Olliaro, P.
   Abdulla, S.
   Kamugisha, E.
   Ngasala, B. E.
   Premji, Z.
   Shekalaghe, S. A.
   Shekalaghe, S. A.
   Ashley, E. A.
   Carrara, V. I.
   McGready, R.
   Nosten, F.
   Ashley, E. A.
   Faiz, A. M.
   Lee, S. J.
   White, N. J.
   Carrara, V. I.
   Dondorp, A. M.
   Smith, J. J.
   D'Alessandro, U.
   Tarning, J.
   Achan, J.
   Bukirwa, H.
   Yeka, A.
   Arinaitwe, E.
   Staedke, S. G.
   Kamya, M. R.
   Kironde, F.
   Nabasumba, C.
   Bousema, T.
   Drakeley, C. J.
   Gadalla, N. B.
   Oguike, M.
   Sutherland, C. J.
   Checchi, F.
   Dahal, P.
   Flegg, J. A.
   Guerin, P. J.
   Moreira, C.
   Newton, P. N.
   Nsanzabana, C.
   Price, R. N.
   Sibley, C. H.
   Stepniewska, K.
   Tarning, J.
   Dahal, P.
   Dondorp, A. M.
   Flegg, J. A.
   Guerin, P. J.
   Lee, S. J.
   Marsh, K.
   McGready, R.
   Moreira, C.
   Newton, P. N.
   Nosten, F.
   Nsanzabana, C.
   Olliaro, P.
   Price, R. N.
   Tarning, J.
   White, N. J.
   Gething, P. W.
   Hay, S. I.
   Greenwood, B.
   Hodel, E. M.
   Ward, S. A.
   Staedke, S. G.
   Van den Broek, I.
   Winstanley, P. A.
   Dorsey, G.
   Greenhouse, B.
   Rosenthal, P. J.
   Gadalla, N. B.
   Gil, J. P.
   Grivoyannis, A.
   Hamed, K.
   Hwang, J.
   Kachur, P. S.
   Hwang, J.
   Sibley, C. H.
   Nambozi, M.
CA Worldwide Antimalarial Resistance
TI The effect of dose on the antimalarial efficacy of
   artemether-lumefantrine: a systematic review and pooled analysis of
   individual patient data
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
ID PLASMODIUM-FALCIPARUM MALARIA; POPULATION PHARMACOKINETICS;
   UNCOMPLICATED MALARIA; AFRICAN INFANTS; CHILDREN; SAFETY;
   PHARMACODYNAMICS; CHLOROQUINE; ARTESUNATE; RESISTANCE
AB Background Artemether-lumefantrine is the most widely used artemisinin-based combination therapy for malaria, although treatment failures occur in some regions. We investigated the effect of dosing strategy on efficacy in a pooled analysis from trials done in a wide range of malaria-endemic settings.
   Methods We searched PubMed for clinical trials that enrolled and treated patients with artemether-lumefantrine and were published from 1960 to December, 2012. We merged individual patient data from these trials by use of standardised methods. The primary endpoint was the PCR-adjusted risk of Plasmodium falciparum recrudescence by day 28. Secondary endpoints consisted of the PCR-adjusted risk of P falciparum recurrence by day 42, PCR-unadjusted risk of P falciparum recurrence by day 42, early parasite clearance, and gametocyte carriage. Risk factors for PCR-adjusted recrudescence were identified using Cox's regression model with frailty shared across the study sites.
   Findings We included 61 studies done between January, 1998, and December, 2012, and included 14 327 patients in our analyses. The PCR-adjusted therapeutic efficacy was 97.6% (95% CI 97.4-97.9) at day 28 and 96.0% (95.6-96.5) at day 42. After controlling for age and parasitaemia, patients prescribed a higher dose of artemether had a lower risk of having parasitaemia on day 1 (adjusted odds ratio [OR] 0.92, 95% CI 0.86-0.99 for every 1 mg/kg increase in daily artemether dose; p=0.024), but not on day 2 (p=0.69) or day 3 (0.087). In Asia, children weighing 10-15 kg who received a total lumefantrine dose less than 60 mg/kg had the lowest PCR-adjusted efficacy (91.7%, 95% CI 86.5-96.9). In Africa, the risk of treatment failure was greatest in malnourished children aged 1-3 years (PCR-adjusted efficacy 94.3%, 95% CI 92.3-96.3). A higher artemether dose was associated with a lower gametocyte presence within 14 days of treatment (adjusted OR 0.92, 95% CI 0.85-0.99; p=0.037 for every 1 mg/kg increase in total artemether dose).
   Interpretation The recommended dose of artemether-lumefantrine provides reliable efficacy in most patients with uncomplicated malaria. However, therapeutic efficacy was lowest in young children from Asia and young underweight children from Africa; a higher dose regimen should be assessed in these groups.
C1 [Anstey, N. M.; Price, R. N.] Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia.
   [Anstey, N. M.] Charles Darwin Univ, Darwin, NT 0909, Australia.
   [Davis, T. M. E.] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia.
   [Karunajeewa, H. A.; Mueller, I.] Walter & Eliza Hall Inst Med Res, Infect & Immun Div, Melbourne, Vic, Australia.
   Western Hlth, Div Med, Melbourne, Vic, Australia.
   [D'Alessandro, U.] Inst Trop Med, Unit Malariol, B-2000 Antwerp, Belgium.
   [Massougbodji, A.] Univ dAbomey Calavi, Fac Sci Sante, Ctr Etud & Rech Paludisme Associe Grossesse & Enf, Cotonou, Benin.
   [Nikiema, F.; Ouedraogo, J-B; Tinto, H.] Inst Rech Sci Sante, Direct Reg Ouest, Bobo Dioulasso, Burkina Faso.
   Ctr Muraz, Bobo Dioulasso, Burkina Faso.
   [Same-Ekobo, A.] Univ Yaounde, Ctr Hosp, Fac Med & Sci Biomed, Yaounde, Cameroon.
   [Kone, M.; Menan, H.; Yavo, W.] Univ Cocody, Fac Pharm, Dept Parasitol & Mycol, Abidjan, Cote Ivoire.
   [Toure, A. O.] Inst Pasteur Cote Ivoire, Malariol Dept, Abidjan, Cote Ivoire.
   [Yavo, W.] Natl Inst Publ Hlth, Malaria Res & Control Ctr, Abidjan, Cote Ivoire.
   [Kofoed, P-E] Kolding Cty Hosp, Dept Paediat, Kolding, Denmark.
   [Alemayehu, B. H.] Int Ctr AIDS Care & Treatment Programs, Addis Ababa, Ethiopia.
   [Jima, D.] Fed Minist Hlth, Addis Ababa, Ethiopia.
   [Baudin, E.; Espie, E.; Nabasumba, C.; Pinoges, L.; Schramm, B.] Epictr, Paris, France.
   [Cot, M.; Deloron, P.; Faucher, J-F] Inst Rech Dev, Mother & Child Hlth Trop Res Unit, Paris, France.
   [Cot, M.; Deloron, P.; Faucher, J-F] Univ Paris 05, Sorbonne Paris Cite, PRES, Paris, France.
   [Faucher, J-F] Univ Besancon, Med Ctr, Dept Infect Dis, F-25030 Besancon, France.
   [Guthmann, J-P] Inst Veille Sanit, Dept Malad Infect, St Maurice, France.
   [Lell, B.] Ctr Rech Med Lambarene, Lambarene, Gabon.
   [Lell, B.; Borrmann, S.] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
   [Adjei, G. O.] Univ Ghana, Sch Med, Ctr Trop Clin Pharmacol & Therapeut, Accra, Ghana.
   [Kofoed, P-E] Projecto Saude Bandim, Bissau, Guinea Bissau.
   [Tjitra, E.] Minist Hlth, Natl Inst Hlth Res & Dev, Jakarta, Indonesia.
   [Borrmann, S.; Marsh, K.; Peshu, J.] Kenya Govt Med Res Ctr, Kilifi, Kenya.
   [Borrmann, S.; Marsh, K.; Peshu, J.] Wellcome Trust Res Programme, Kilifi, Kenya.
   [Juma, E.] Kenya Govt Med Res Ctr, Nairobi, Kenya.
   [Ogutu, B. R.] Kenya Govt Med Res Ctr, Kisumu, Kenya.
   [Ogutu, B. R.] US Army Med Res Unit, Kisumu, Kenya.
   [Omar, S. A.; Sawa, P.] Int Ctr Insect Physiol & Ecol, Human Hlth Div, Mbita Point, Kenya.
   [Talisuna, A. O.] WWARN East Africa Reg Ctr, Nairobi, Kenya.
   [Talisuna, A. O.] Univ Oxford, KEMRI, Oxford OX3 7LJ, England.
   [Talisuna, A. O.] Wellcome Trust Res Programme, Nairobi, Kenya.
   [Khanthavong, M.] Ctr Malariol Parasitol & Entomol, Viangchan, Laos.
   [Mayxay, M.; Newton, P. N.] Oxford Univ Trop Med Res Collaborat, Mahosot Hosp, Wellcome Trust Mahosot Hosp, Viangchan, Laos.
   [Mayxay, M.] Natl Univ Laos, Fac Med Sci, Viangchan, Laos.
   [Piola, P.] Inst Pasteur Madagascar, Antananarivo, Madagascar.
   [Djimde, A. A.; Doumbo, O. K.; Fofana, B.; Sagara, I.] Univ Bamako, Fac Med Pharm & Odontostomatol, Dept Epidemiol Parasit Dis, Malaria Res & Training Ctr, Bamako, Mali.
   [Bassat, Q.; Gonzalez, R.; Menendez, C.] Ctr Invest Saude Manhica, Manhica, Mozambique.
   [Smithuis, F.] Myanmar Oxford Clin Res Unit, Yangon, Myanmar.
   [Smithuis, F.] Myanmar & Med Act Myanmar, Yangon, Myanmar.
   [Bousema, T.] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Njimegen, Netherlands.
   [Kager, P. A.; Mens, P. F.] Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun Amsterdam CINEMA, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands.
   [Mens, P. F.; Schallig, H. D. F. H.] Royal Trop Inst, KIT Biomed Res, NL-1105 AZ Amsterdam, Netherlands.
   [Van den Broek, I.] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands.
   [Van Vugt, M.] Univ Amsterdam, Acad Med Ctr, Ctr Trop Med & Travel Med, Div Infect Dis, NL-1012 WX Amsterdam, Netherlands.
   [Ibrahim, M. L.] Ctr Rech Med & Sanit, Niamey, Niger.
   [Falade, C. O.] Univ Ibadan, Coll Med, Ibadan, Nigeria.
   [Meremikwu, M.] Univ Calabar, Dept Paediat, Calabar, Nigeria.
   Inst Trop Dis Res & Prevent, Calabar, Nigeria.
   [Gil, J. P.] Univ Lisbon, Fac Ciencias, Ctr Biodivers Funct & Integrat Genom, Drug Resistance & Pharmacogenet, P-1699 Lisbon, Portugal.
   [Karema, C.] Minist Hlth, Malaria & Other Parasit Dis Div RBC, Kigali, Rwanda.
   [Ba, M. S.; Faye, B.; Faye, O.; Gaye, O.; Ndiaye, J-L; Pene, M.; Sow, D.; Sylla, K.; Tine, R. C. K.] Univ Cheikh Anta Diop, Fac Med, Dept Parasitol & Mycol, Dakar, Senegal.
   [Penali, L. K.] WWARN West Africa Reg Ctr, Dakar, Senegal.
   [Barnes, K. I.; Workman, L. J.] WWARN, Pharmacol Module, Cape Town, South Africa.
   [Barnes, K. I.; Workman, L. J.] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa.
   [Bassat, Q.; Gonzalez, R.; Menendez, C.] Ctr Recerca Salut Int Barcelona, Barcelona, Spain.
   [Lima, A.] Medecins Sans Frontieres Operat Ctr Barcelona Ath, Barcelona, Spain.
   [Adam, I.] Univ Khartoum, Fac Med, Khartoum, Sudan.
   [Gadalla, N. B.] Natl Res Ctr, Res Inst Trop Med, Dept Epidemiol, Khartoum, Sudan.
   [Malik, E. F. M.] Fed Minist Hlth, Khartoum, Sudan.
   [Bjorkman, A.] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Infect Dis Unit, Stockholm, Sweden.
   [Gil, J. P.] Karolinska Inst, Dept Physiol & Pharmacol, Drug Resistance Unit, Pharmacogenet Sect, Stockholm, Sweden.
   [Ursing, J.; Martensson, A.; Ngasala, B. E.] Karolinska Inst, Dept Med Solna, Infect Dis Unit, Malaria Res, Stockholm, Sweden.
   [Martensson, A.] Karolinska Inst, Dept Publ Hlth Sci, Div Global Hlth, Stockholm, Sweden.
   [Rombo, L.] Karolinska Univ Hosp, Dept Med, Malaria Res Lab, Infect Dis Unit, Stockholm, Sweden.
   [Rombo, L.] Dept Infect Dis, Eskilstuna, Sweden.
   [Rombo, L.] Sormland Cty Council, Clin Res Ctr, Sormland, Sweden.
   [Aliu, P.] Novartis Pharma AG, Basel, Switzerland.
   [Duparc, S.] Med Malaria Venture, Geneva, Switzerland.
   [Filler, S.] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland.
   [Genton, B.] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland.
   [Genton, B.] Univ Lausanne Hosp, Div Infect Dis, Lausanne, Switzerland.
   [Genton, B.] Univ Lausanne Hosp, Dept Ambulatory Care & Community Med, Lausanne, Switzerland.
   [Hodel, E. M.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Olliaro, P.] UNDP, UNICEF, World Bank, Geneva, Switzerland.
   [Olliaro, P.] WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland.
   [Abdulla, S.] Ifakara Hlth Inst, Dar Es Salaam, Tanzania.
   [Kamugisha, E.] Catholic Univ Hlth & Allied Sci, Mwanza, Tanzania.
   [Ngasala, B. E.; Premji, Z.] Muhimbili Univ Hlth & Allied Sci, Dept Parasitol, Dar Es Salaam, Tanzania.
   [Shekalaghe, S. A.] Kilimanjaro Christian Med Ctr, Kilimanjaro Clin Med Res Inst, Moshi, Tanzania.
   [Shekalaghe, S. A.] Ifakara Hlth Inst, Bagamoyo, Tanzania.
   [Ashley, E. A.; Carrara, V. I.; McGready, R.; Nosten, F.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Shoklo Malaria Res Unit, Mae Sot, Thailand.
   [Ashley, E. A.; Faiz, A. M.; Lee, S. J.; White, N. J.] Mahidol Univ, Fac Trop Med, Bangkok, Thailand.
   [Carrara, V. I.; Dondorp, A. M.] Mahidol Univ, Mahidol Oxford Univ Res Unit, Bangkok, Thailand.
   [Smith, J. J.] WWARN Asia Reg Ctr, Bangkok, Thailand.
   MRC Unit, Fajara, Gambia.
   [Tarning, J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.
   [Achan, J.; Bukirwa, H.; Yeka, A.] Uganda Malaria Surveillance Project, Kampala, Uganda.
   [Arinaitwe, E.; Staedke, S. G.] Infect Dis Res Collaborat, Kampala, Uganda.
   [Kamya, M. R.] Makerere Univ, Coll Hlth Sci, Kampala, Uganda.
   [Kironde, F.] Makerere Univ, Dept Biochem, Kampala, Uganda.
   [Nabasumba, C.] Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda.
   [Bousema, T.; Gadalla, N. B.; Drakeley, C. J.; Oguike, M.; Sutherland, C. J.] London Sch Hyg & Trop Med, Immunol & Infect Dept, London WC1, England.
   [Checchi, F.] Save Children, Humanitarian Dept, London, England.
   [Newton, P. N.; Tarning, J.; Dahal, P.; Flegg, J. A.; Guerin, P. J.; Moreira, C.; Nsanzabana, C.; Sibley, C. H.; Stepniewska, K.] Worldwide Antimalarial Resistance Network, Oxford, England.
   [Marsh, K.; Newton, P. N.; Olliaro, P.; McGready, R.; Nosten, F.; Lee, S. J.; White, N. J.; Dondorp, A. M.; Tarning, J.; Dahal, P.; Flegg, J. A.; Guerin, P. J.; Moreira, C.; Nsanzabana, C.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England.
   [Gething, P. W.; Hay, S. I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford, England.
   [Greenwood, B.] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England.
   [Hodel, E. M.; Ward, S. A.] Univ Liverpool, Liverpool Sch Trop Med, Dept Parasitol, Liverpool L3 5QA, Merseyside, England.
   [Staedke, S. G.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England.
   [Van den Broek, I.] Medecins Sans Frontieres, London, England.
   [Winstanley, P. A.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.
   [Dorsey, G.; Greenhouse, B.; Rosenthal, P. J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Gadalla, N. B.] NIAID, Rockville, MD USA.
   [Gil, J. P.] SUNY Binghamton, Harpur Coll Arts & Sci, Binghamton, NY USA.
   [Grivoyannis, A.] Univ Washington, Div Emergency Med, Seattle, WA 98195 USA.
   [Hamed, K.] Novartis, E Hanover, NJ USA.
   [Hwang, J.; Kachur, P. S.] US Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Hwang, J.] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA.
   [Sibley, C. H.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
   [Nambozi, M.] Trop Dis Res Ctr, Ndola, Zambia.
RP Price, RN (reprint author), Univ Oxford, Ctr Trop Med & Global Hlth, Worldwide Antimalarial Resistance Network, S Parks Rd, Oxford OX3 7LJ, England.
EM ric.price@wwarn.org; christian.nsanzabana@wwarn.org
RI Hodel, Eva Maria/E-1258-2014; Bousema, Teun/N-3574-2014; Ward,
   Steve/G-6003-2015; Hay, Simon/F-8967-2015; 
OI Price, Richard/0000-0003-2000-2874; Hodel, Eva
   Maria/0000-0001-5821-1685; Ward, Steve/0000-0003-2331-3192; Hay,
   Simon/0000-0002-0611-7272; GADALLA, NAHLA/0000-0002-6177-6705; Guerin,
   Philippe/0000-0002-6008-2963; Dahal, Prabin/0000-0002-2158-846X; Flegg,
   Jennifer/0000-0002-8809-726X; Gething, Peter/0000-0001-6759-5449;
   Nosten, Francois/0000-0002-7951-0745; McGready, Rose/0000-0003-1621-3257
FU Bill & Melinda Gates Foundation
FX Bill & Melinda Gates Foundation.
NR 32
TC 13
Z9 13
U1 1
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUN
PY 2015
VL 15
IS 6
BP 692
EP 702
DI 10.1016/S1473-3099(15)70024-1
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA CI3HI
UT WOS:000354638000034
ER

PT J
AU Cottrell, G
   Moussiliou, A
   Luty, AJF
   Cot, M
   Fievet, N
   Massougbodji, A
   Deloron, P
   Ndam, NT
AF Cottrell, Gilles
   Moussiliou, Azizath
   Luty, Adrian J. F.
   Cot, Michel
   Fievet, Nadine
   Massougbodji, Achille
   Deloron, Philippe
   Ndam, Nicaise Tuikue
TI Submicroscopic Plasmodium falciparum Infections Are Associated With
   Maternal Anemia, Premature Births, and Low Birth Weight
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE malaria; PCR; submicroscopic; pregnancy; Plasmodium falciparum
ID INTERMITTENT PREVENTIVE TREATMENT; SUB-SAHARAN AFRICA; PREGNANT-WOMEN;
   MALARIA TRANSMISSION; BENIN; MICROSCOPY; GRAVIDITY; DIAGNOSIS; PLACENTA;
   IMPACT
AB Background. Molecular, as opposed to microscopic, detection measures the real prevalence of Plasmodium falciparum infections. Such occult infections are common during pregnancy but their impact on pregnancy outcomes is unclear. We performed a longitudinal study to describe that impact.
   Methods. In a cohort of 1037 Beninese pregnant women, we used ultrasound to accurately estimate gestational ages. Infection with P. falciparum, hemoglobin concentration, use of intermittent preventive treatment during pregnancy (IPTp) for malaria, and other parameters were recorded during pregnancy. Using multivariate analyses, we evaluated the impact of submicroscopic infections on maternal anemia, premature birth, and low birth weight.
   Results. At inclusion, polymerase chain reaction (PCR) and microscopy detected infection in 40% and 16% of women, respectively. The proportion infected declined markedly after 2 doses of IPTp but rebounded to 34% (by PCR) at delivery. Submicroscopic infections during pregnancy were associated with lower mean hemoglobin irrespective of gravidity, and with increased anemia risk in primigravidae (odds ratio [OR], 2.23; 95% confidence interval [CI], .98-5.07). Prospectively, submicroscopic infections at inclusion were associated with significantly increased risks of low birth weight in primigravidae (OR, 6.09; 95% CI, 1.16-31.95) and premature births in multigravidae (OR, 2.25; 95% CI, 1.13-4.46).
   Conclusions. In this detailed longitudinal study, we document the deleterious impact of submicroscopic P. falciparum parasitemia during pregnancy on multiple pregnancy outcomes. Parasitemia occurs frequently during pregnancy, but routine microscopic and rapid diagnostic tests fail to detect the vast majority of episodes. Our findings imply caution in any revision of the current strategies for prevention of pregnancy-associated malaria.
C1 [Cottrell, Gilles; Luty, Adrian J. F.; Cot, Michel; Fievet, Nadine; Deloron, Philippe; Ndam, Nicaise Tuikue] Univ Paris 05, Fac Pharm, PRES Sorbonne Paris Cite, Paris, France.
   [Cottrell, Gilles; Moussiliou, Azizath; Luty, Adrian J. F.; Cot, Michel; Fievet, Nadine; Deloron, Philippe; Ndam, Nicaise Tuikue] Inst Rech Dev, MERIT UMR216, F-75270 Paris, France.
   [Moussiliou, Azizath] Univ Paris 06, Paris, France.
   [Massougbodji, Achille] Univ Abomey Calavi, Ctr Etud & Rech Paludisme Associe Grossesse & Enf, Cotonou, Benin.
RP Cottrell, G (reprint author), Inst Rech Dev, MERIT UMR216, 4 Ave Observ, F-75270 Paris, France.
EM gilles.cottrell@ird.fr
OI Tuikue Ndam, Nicaise/0000-0003-2646-2513
FU European 7th Framework Programme [200889, 304815]; Islamic Development
   Bank
FX This article describes work undertaken in the context of the STOPPAM
   (Strategies to Prevent Pregnancy Associated Malaria) and PLACMALVAC
   (Clinical Development of a VAR2CSA-Based Placental Malaria Vaccine)
   projects. STOPPAM and PLACMALVAC are small- and medium- scale
   collaborative projects supported by the European 7th Framework Programme
   (contract numbers 200889 and 304815). A. Mo. was supported by PhD
   studentships from the Islamic Development Bank.
NR 33
TC 18
Z9 18
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2015
VL 60
IS 10
BP 1481
EP 1488
DI 10.1093/cid/civ122
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CH0ON
UT WOS:000353721300006
PM 25694651
ER

PT J
AU Moussiliou, A
   Alao, MJ
   Denoeud-Ndam, L
   Tahar, R
   Ezimegnon, S
   Sagbo, G
   Amoussou, A
   Luty, AJF
   Deloron, P
   Ndam, NT
AF Moussiliou, Azizath
   Alao, Maroufou J.
   Denoeud-Ndam, Lise
   Tahar, Rachida
   Ezimegnon, Sem
   Sagbo, Gratien
   Amoussou, Annick
   Luty, Adrian J. F.
   Deloron, Philippe
   Ndam, Nicaise Tuikue
TI High Plasma Levels of Soluble Endothelial Protein C Receptor Are
   Associated With Increased Mortality Among Children With Cerebral Malaria
   in Benin
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE plasmodium; cerebral malaria; EPCR; sEPCR; protein C
ID AFRICAN CHILDREN; EPCR GENE; FALCIPARUM; THROMBOSIS; BINDING; SEPCR;
   RISK
AB Loss of endothelial protein C receptor (EPCR) occurs at the sites of Plasmodium falciparum-infected erythrocyte sequestration in patients with or who died from cerebral malaria. In children presenting with different clinical syndromes of malaria, we assessed the relationships between endogenous plasma soluble EPCR (sEPCR) levels and clinical presentation or mortality. After adjustment for age, for treatment before admission, and for a known genetic factor, sEPCR level at admission was positively associated with cerebral malaria (P = .011) and with malaria-related mortality (P = .0003). Measuring sEPCR levels at admission could provide an early biological marker of the outcome of cerebral malaria.
C1 [Moussiliou, Azizath; Denoeud-Ndam, Lise; Tahar, Rachida; Luty, Adrian J. F.; Deloron, Philippe; Ndam, Nicaise Tuikue] Univ Paris 05, Fac Pharm, PRES Sorbonne Paris Cite, Paris, France.
   [Moussiliou, Azizath; Denoeud-Ndam, Lise; Tahar, Rachida; Luty, Adrian J. F.; Deloron, Philippe; Ndam, Nicaise Tuikue] IRD, UMR216, MERIT, F-75006 Paris, France.
   [Moussiliou, Azizath] Univ Paris 06, Paris, France.
   [Alao, Maroufou J.] Hop Mere Enfant Lagune, Dept Pediat, Cotonou, Benin.
   [Ezimegnon, Sem] Univ Abomey Calavi, Ctr Etud & Rech Paludisme Associe Grossesse & Enf, Cotonou, Benin.
   [Sagbo, Gratien] Ctr Natl Hosp Univ, Serv Pediat, Cotonou, Benin.
   [Amoussou, Annick] Hop Zone Suru Lere, Serv Pediat, Cotonou, Benin.
RP Ndam, NT (reprint author), IRD, UMR216, 4 Ave Observ, F-75006 Paris, France.
EM nicaise.ndam@ird.fr
OI DENOEUD-NDAM, Lise/0000-0002-9482-1461; Tuikue Ndam,
   Nicaise/0000-0003-2646-2513
FU Agence Inter-etablissement de Recherche pour le Developpement
   (PEERS-EPIVAC grant); Islamic Development Bank
FX This work was supported by the Agence Inter-etablissement de Recherche
   pour le Developpement (PEERS-EPIVAC grant) and Islamic Development Bank
   (PhD studentship to A. M.).
NR 14
TC 5
Z9 5
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 1
PY 2015
VL 211
IS 9
BP 1484
EP 1488
DI 10.1093/infdis/jiu661
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CI4LZ
UT WOS:000354722000017
PM 25425698
ER

PT J
AU Ndam, NT
   Denoeud-Ndam, L
   Doritchamou, J
   Viwami, F
   Salanti, A
   Nielsen, MA
   Fievet, N
   Massougbodji, A
   Luty, AJF
   Deloron, P
AF Ndam, Nicaise Tuikue
   Denoeud-Ndam, Lise
   Doritchamou, Justin
   Viwami, Firmine
   Salanti, Ali
   Nielsen, Morten A.
   Fievet, Nadine
   Massougbodji, Achille
   Luty, Adrian J. F.
   Deloron, Philippe
TI Protective Antibodies against Placental Malaria and Poor Outcomes during
   Pregnancy, Benin
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID FALCIPARUM-INFECTED ERYTHROCYTES; CHONDROITIN SULFATE-A; CROSS-REACTIVE
   ANTIBODIES; PLASMODIUM-FALCIPARUM; VAR2CSA PROTEIN; BIRTH-WEIGHT;
   BINDING; ADHESION; DOMAINS; WOMEN
AB Placental malaria is caused by Plasmodium falciparum infected erythrocytes that bind to placental tissue. Binding is mediated by VAR2CSA, a parasite antigen coded by the var gene, which interacts with chondroitin sulfate A (CSA). Consequences include maternal anemia and fetal growth retardation. Antibody-mediated immunity to placental malaria is acquired during successive pregnancies, but the target of VAR2CSA-specific protective antibodies is unclear. We assessed VAR2CSA-specific antibodies in pregnant women and analyzed their relationships with protection against placental infection, preterm birth, and low birthweight. Antibody responses to the N-terminal region of VAR2CSA during early pregnancy were associated with reduced risks for infections and low birthweight. Among women infected during pregnancy, an increase in CSA binding inhibition was associated with reduced risks for placental infection, preterm birth, and low birthweight. These data suggest that antibodies against VAR2CSA N-terminal region mediate immunity to placental malaria and associated outcomes. Our results validate current vaccine development efforts with VAR2CSA N-terminal constructs.
C1 [Ndam, Nicaise Tuikue; Denoeud-Ndam, Lise; Doritchamou, Justin; Fievet, Nadine; Luty, Adrian J. F.; Deloron, Philippe] Inst Rech Dev, F-75006 Paris, France.
   [Ndam, Nicaise Tuikue; Fievet, Nadine; Luty, Adrian J. F.; Deloron, Philippe] Pole Rech & Enseignement Super, Sorbonne Paris Cite, Paris, France.
   [Viwami, Firmine; Massougbodji, Achille; Luty, Adrian J. F.] Univ Abomey Calavi, Cotonou, Benin.
   [Salanti, Ali; Nielsen, Morten A.] Univ Copenhagen, Copenhagen, Denmark.
RP Ndam, NT (reprint author), Inst Rech Dev, Fac Pharm, Parasitol Lab, Unites Mixtes Rech Mere & Enfants Face Infect Tro, 4 Ave Observ, F-75006 Paris, France.
EM nicaise.ndam@ird.fr
OI Nielsen, Morten Agertoug/0000-0003-2668-4992; Tuikue Ndam,
   Nicaise/0000-0003-2646-2513; DENOEUD-NDAM, Lise/0000-0002-9482-1461
FU European 7th Framework Program [200889]; Agence Inter-etablissements de
   Recherche pour le Developement
FX This study was supported by the European 7th Framework Program (contract
   no. 200889 for the Small & Medium Scale Collaborative Project Strategies
   To Prevent Pregnancy-Associated Malaria). J. D. was supported by a PhD
   studentship from Agence Inter-etablissements de Recherche pour le
   Developement.
NR 38
TC 13
Z9 13
U1 0
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD MAY
PY 2015
VL 21
IS 5
BP 813
EP 823
DI 10.3201/eid2105.141626
PG 11
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CG9BW
UT WOS:000353610400010
PM 25898123
ER

PT J
AU Sicuri, E
   Fernandes, S
   Macete, E
   Gonzalez, R
   Mombo-Ngoma, G
   Massougbodgi, A
   Abdulla, S
   Kuwawenaruwa, A
   Katana, A
   Desai, M
   Cot, M
   Ramharter, M
   Kremsner, P
   Slustker, L
   Aponte, J
   Hanson, K
   Menendez, C
AF Sicuri, Elisa
   Fernandes, Silke
   Macete, Eusebio
   Gonzalez, Raquel
   Mombo-Ngoma, Ghyslain
   Massougbodgi, Achille
   Abdulla, Salim
   Kuwawenaruwa, August
   Katana, Abraham
   Desai, Meghna
   Cot, Michel
   Ramharter, Michael
   Kremsner, Peter
   Slustker, Laurence
   Aponte, John
   Hanson, Kara
   Menendez, Clara
TI Economic Evaluation of an Alternative Drug to Sulfadoxine-Pyrimethamine
   as Intermittent Preventive Treatment of Malaria in Pregnancy
SO PLOS ONE
LA English
DT Article
ID SUB-SAHARAN AFRICA; EFFECTIVENESS ACCEPTABILITY CURVES;
   COST-EFFECTIVENESS ANALYSIS; PLASMODIUM-FALCIPARUM; CONTROLLED-TRIAL;
   HIV-INFECTION; WEST-AFRICA; IMPACT; MORTALITY; WOMEN
AB Background
   Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in HIV-negative women to avert malaria, while this relies on cotrimoxazole prophylaxis (CTXp) in HIV-positive women. Alternative antimalarials are required in areas where parasite resistance to antifolate drugs is high. The cost-effectiveness of IPTp with alternative drugs is needed to inform policy.
   Methods
   The cost-effectiveness of 2-dose IPTp-mefloquine (MQ) was compared with IPTp-SP in HIV-negative women (Benin, Gabon, Mozambique and Tanzania). In HIV-positive women the cost-effectiveness of 3-dose IPTp-MQ added to CTXp was compared with CTXp alone (Kenya, Mozambique and Tanzania). The outcomes used were maternal clinical malaria, anaemia at delivery and non-obstetric hospital admissions. The poor tolerability to MQ was included as the value of women's loss of working days. Incremental cost-effectiveness ratios (ICERs) were calculated and threshold analysis undertaken.
   Results
   For HIV-negative women, the ICER for IPTp-MQ versus IPTp-SP was 136.30 US$ (2012 US$) (95%,CI 131.41; 141.18) per disability-adjusted life-year (DALY) averted, or 237.78 US$ (95%CI 230.99; 244.57), depending on whether estimates from Gabon were included or not. For HIV-positive women, the ICER per DALY averted for IPTp-MQ added to CTXp, versus CTXp alone was 6.96 US$ (95%CI 4.22; 9.70). In HIV-negative women, moderate shifts of variables such as malaria incidence, drug cost, and IPTp efficacy increased the ICERs above the cost-effectiveness threshold. In HIV-positive women the intervention remained cost-effective for a substantial (up to 21 times) increase in cost per tablet.
   Conclusions
   Addition of IPTp with an effective antimalarial to CTXp was very cost-effective in HIV-positive women. IPTp with an efficacious antimalarial was more cost-effective than IPTp-SP in HIV-negative women. However, the poor tolerability of MQ does not favour its use as IPTp. Regardless of HIV status, prevention of malaria in pregnancy with a highly efficacious, well tolerated antimalarial would be cost-effective despite its high price.
C1 [Sicuri, Elisa; Gonzalez, Raquel; Aponte, John; Menendez, Clara] Univ Barcelona, Hosp Clin Barcelona, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain.
   [Fernandes, Silke; Hanson, Kara] London Sch Hyg & Trop Med, London WC1, England.
   [Macete, Eusebio; Gonzalez, Raquel; Aponte, John; Menendez, Clara] Manhica Hlth Res Ctr CISM, Manhica, Mozambique.
   [Mombo-Ngoma, Ghyslain; Ramharter, Michael; Kremsner, Peter] Albert Schweitzer Hosp, Ctr Rech Med Lambarene CERMEL, Lambarene, Gabon.
   [Mombo-Ngoma, Ghyslain; Ramharter, Michael; Kremsner, Peter] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
   [Massougbodgi, Achille] Univ Abomey Calavi, Fac Sci Sante, Cotonou, Benin.
   [Abdulla, Salim; Kuwawenaruwa, August] Ifakara Hlth Inst, Dar Es Salaam, Tanzania.
   [Katana, Abraham] Kenya Med Res Inst KEMRI, Ctr Global Hlth Res, Kisumu, Kenya.
   [Desai, Meghna; Slustker, Laurence] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA.
   [Desai, Meghna; Slustker, Laurence] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Kisumu, Kenya.
   [Cot, Michel] Inst Rech Dev, Paris, France.
   [Cot, Michel] Univ Paris 05, Paris, France.
   [Ramharter, Michael] Med Univ Vienna, Dept Med 1, Div Infect Dis & Trop Med, Vienna, Austria.
RP Sicuri, E (reprint author), Univ Barcelona, Hosp Clin Barcelona, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain.
EM elisa.sicuri@cresib.cat
RI Sicuri, Elisa/L-8012-2014; Ramharter, Michael/C-5273-2013
OI Sicuri, Elisa/0000-0002-2499-2732; Ramharter,
   Michael/0000-0002-9259-1885
FU MiP Consortium - Bill & Melinda Gates Foundation
FX This study was supported by MiP Consortium, which is funded through a
   grant from the Bill & Melinda Gates Foundation to the Liverpool School
   of Tropical Medicine.
NR 69
TC 2
Z9 2
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 27
PY 2015
VL 10
IS 4
AR e0125072
DI 10.1371/journal.pone.0125072
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG9SB
UT WOS:000353659100094
PM 25915616
ER

PT J
AU Tiono, AB
   Tinto, H
   Alao, MJ
   Meremikwu, M
   Tshefu, A
   Ogutu, B
   Ouedraogo, A
   Lingani, M
   Cousin, M
   Lefevre, G
   Jain, JP
   Duparc, S
   Hamed, K
AF Tiono, Alfred B.
   Tinto, Halidou
   Alao, Maroufou J.
   Meremikwu, Martin
   Tshefu, Antoinette
   Ogutu, Bernhards
   Ouedraogo, Alphonse
   Lingani, Moussa
   Cousin, Marc
   Lefevre, Gilbert
   Jain, Jay Prakash
   Duparc, Stephan
   Hamed, Kamal
TI Increased systemic exposures of artemether and dihydroartemisinin in
   infants under 5 kg with uncomplicated Plasmodium falciparum malaria
   treated with artemether-lumefantrine (Coartem (R))
SO MALARIA JOURNAL
LA English
DT Article
DE Artemether-lumefantrine; Dispersible; Efficacy; Infants;
   Pharmacokinetics; Safety; < 5 kg body weight
ID AFRICAN INFANTS; 6-DOSE REGIMEN; CHILDREN; EFFICACY; SAFETY;
   PHARMACOKINETICS; NEUROTOXICITY; ARTEMISININS; TABLETS; TRIAL
AB Background: Artemether-lumefantrine (AL) dispersible formulation was developed for the treatment of uncomplicated Plasmodium falciparum malaria in infants and children weighing 5 to <35 kg. However, there are no clinical studies with artemisinin-based combination therapy in infants <5 kg.
   Methods: This multicentre, open-label, single-arm study evaluated the efficacy, safety and pharmacokinetics of AL dispersible in infants aged >28 days and <5 kg of body weight, who were treated with one AL dispersible tablet (20 mg artemether/120 mg lumefantrine) given twice-daily for three days and followed up for six weeks (core follow-up) and at 12 months of age (long-term follow-up).
   Results: A total of 20 patients were enrolled and completed the six-week core study follow-up. In the per protocol population, PCR-corrected cure rate at days 28 and 42 was 100% (95% CI: 79.4, 100). AL dispersible was well tolerated with reported adverse events of mild to moderate severity. Pharmacokinetic data showed that lumefantrine levels were similar, however, artemether and dihydroartemisinin levels were on average two-to three-fold greater than historical values in infants and children >= 5 kg.
   Conclusions: A three-day regimen of AL dispersible formulation was efficacious and generally well tolerated in infants weighing <5 kg with uncomplicated P. falciparum malaria, but artemether and dihydroartemisinin exposures could not be supported by the preclinical safety margins for neurotoxicity. Hence, dosing recommendations cannot be made in infants <5 kg as implications for toxicity are unknown.
C1 [Tiono, Alfred B.; Ouedraogo, Alphonse] Minist Sante, Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso.
   [Tinto, Halidou; Lingani, Moussa] IRSS CRUN, Unitr Rech Clin Nanoro, Ouagadougou, Burkina Faso.
   [Alao, Maroufou J.] Hop Mere & Enfant Lagune, Serv Pediat, Cotonou 01107, Benin.
   [Meremikwu, Martin] Univ Calabar, Teaching Hosp, Inst Trop Dis Res & Prevent, Calabar 1278, Nigeria.
   [Tshefu, Antoinette] Univ Kinshasa, Kinshasa Sch Publ Hlth, Kinshasa 11850, Zaire.
   [Ogutu, Bernhards] Kenya Govt Med Res Ctr, Clin Res Ctr, Nairobi, Kenya.
   [Cousin, Marc; Lefevre, Gilbert] Novartis Pharma AG, CH-4002 Basel, Switzerland.
   [Jain, Jay Prakash] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India.
   [Duparc, Stephan] MMV, CH-1215 Meyrin, Switzerland.
   [Hamed, Kamal] Novartis Pharmaceut, E Hanover, NJ 07936 USA.
RP Hamed, K (reprint author), Novartis Pharmaceut, One Hlth Plaza, E Hanover, NJ 07936 USA.
EM kamal.hamed@novartis.com
FU Novartis Pharma AG; Medicines for Malaria Venture (MMV)
FX The authors thank Sarfaraz Sayyed (Novartis Healthcare Private Limited)
   for assistance with statistical analysis. We also thank the study
   participants, and local health facility and laboratory staff. Novartis
   Pharma AG and Medicines for Malaria Venture (MMV) provided funding for
   this study. The sponsors of the study were involved in study design,
   data analysis, data interpretation, and writing of the report.
NR 24
TC 1
Z9 1
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD APR 15
PY 2015
VL 14
AR UNSP 157
DI 10.1186/s12936-015-0682-7
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CG5IQ
UT WOS:000353325100001
PM 25886021
ER

PT J
AU Gnanguenon, V
   Agossa, FR
   Badirou, K
   Govoetchan, R
   Anagonou, R
   Oke-Agbo, F
   Azondekon, R
   AgbanrinYoussouf, R
   Attolou, R
   Tokponnon, FT
   Aikpon, R
   Osse, R
   Akogbeto, MC
AF Gnanguenon, Virgile
   Agossa, Fiacre R.
   Badirou, Kefilath
   Govoetchan, Renaud
   Anagonou, Rodrigue
   Oke-Agbo, Frederic
   Azondekon, Roseric
   AgbanrinYoussouf, Ramziath
   Attolou, Roseline
   Tokponnon, Filemon T.
   Aikpon, Rock
   Osse, Razaki
   Akogbeto, Martin C.
TI Malaria vectors resistance to insecticides in Benin: current trends and
   mechanisms involved
SO PARASITES & VECTORS
LA English
DT Article
DE Pyrethroids resistance; Bendiocarb resistance; Insensitive
   acetylcholinesterase-1; Knock-down resistance; Resistance map
ID ANOPHELES-GAMBIAE-S.L.; RESIDUAL SPRAYING IRS; WEST-AFRICA; MOLECULAR
   CHARACTERIZATION; PLASMODIUM-FALCIPARUM; KDR MUTATION; BURKINA-FASO;
   TREATED NETS; TRANSMISSION; IMPACT
AB Background: Insecticides are widely used to control malaria vectors and have significantly contributed to the reduction of malaria-caused mortality. In addition, the same classes of insecticides were widely introduced and used in agriculture in Benin since 1980s. These factors probably contributed to the selection of insecticide resistance in malaria vector populations reported in several localities in Benin. This insecticide resistance represents a threat to vector control tool and should be monitored. The present study reveals observed insecticide resistance trends in Benin to help for a better management of insecticide resistance.
   Methods: Mosquito larvae were collected in eight sites and reared in laboratory. Bioassays were conducted on the adult mosquitoes upon the four types of insecticide currently used in public health in Benin. Knock-down resistance, insensitive acetylcholinesterase-1 resistance, and metabolic resistance analysis were performed in the mosquito populations based on molecular and biochemical analysis. The data were mapped using Geographical Information Systems (GIS) with Arcgis software.
   Results: Mortalities observed with Deltamethrin (pyrethroid class) were less than 90% in 5 locations, between 90-97% in 2 locations, and over 98% in one location. Bendiocarb (carbamate class) showed mortalities ranged 90-97% in 2 locations and were over 98% in the others locations. A complete susceptibility to Pirimiphos methyl and Fenitrothion (organophosphate class) was observed in all locations with 98-100% mortalities. Knock-down resistance frequencies were high (0.78-0.96) and similar between Anopheles coluzzii, Anopheles gambiae, Anopheles arabiensis, and Anopheles melas. Insensitive acetylcholinesterase-1 was rare (0.002-0.1) and only detected in Anopheles gambiae in concomitance with Knock-down resistance mutation. The maps showed a large distribution of Deltamethrin resistance, Knock-down mutation and metabolic resistance throughout the country, a suspected resistance to Bendiocarb and detection of insensitive acetylcholinesterase-1 from northern Benin, and a wide distribution of susceptible vectors to Pirimiphos methyl and Fenitrothion.
   Conclusion: This study showed a widespread resistance of malaria vectors to pyrethroid previously located in southern Benin, an early emergence of carbamates resistance from northern Benin and a full susceptibility to organophosphates. Several resistance mechanisms were detected in vectors with a potential cross resistance to pyrethroids through Knock-down and metabolic resistance mechanisms.
C1 [Gnanguenon, Virgile; Agossa, Fiacre R.; Badirou, Kefilath; Govoetchan, Renaud; Anagonou, Rodrigue; Oke-Agbo, Frederic; Azondekon, Roseric; AgbanrinYoussouf, Ramziath; Attolou, Roseline; Aikpon, Rock; Osse, Razaki; Akogbeto, Martin C.] Ctr Rech Entomol Cotonou, Cotonou, Benin.
   [Gnanguenon, Virgile; Agossa, Fiacre R.; Badirou, Kefilath; Govoetchan, Renaud; Anagonou, Rodrigue; AgbanrinYoussouf, Ramziath; Attolou, Roseline; Aikpon, Rock; Akogbeto, Martin C.] Univ Abomey Calavi, Fac Sci & Tech, Abomey Calavi, Benin.
   [Osse, Razaki] Univ Agr Ketou, Ketou, Benin.
   [Tokponnon, Filemon T.] Programme Natl Lutte Paludisme, Cotonou, Benin.
RP Gnanguenon, V (reprint author), Ctr Rech Entomol Cotonou, Cotonou, Benin.
EM amerusangel@yahoo.fr
NR 51
TC 5
Z9 5
U1 2
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD APR 12
PY 2015
VL 8
AR 223
DI 10.1186/s13071-015-0833-2
PG 14
WC Parasitology
SC Parasitology
GA CF8YZ
UT WOS:000352849400001
PM 25886599
ER

PT J
AU Diop, MM
   Moiroux, N
   Chandre, F
   Martin-Herrou, H
   Milesi, P
   Boussari, O
   Porciani, A
   Duchon, S
   Labbe, P
   Pennetier, C
AF Diop, Malal M.
   Moiroux, Nicolas
   Chandre, Fabrice
   Martin-Herrou, Hadrien
   Milesi, Pascal
   Boussari, Olayide
   Porciani, Angelique
   Duchon, Stephane
   Labbe, Pierrick
   Pennetier, Cedric
TI Behavioral Cost & Overdominance in Anopheles gambiae
SO PLOS ONE
LA English
DT Article
ID PYRETHROID INSECTICIDES; CULEX-QUINQUEFASCIATUS; MALARIA CONTROL;
   RESISTANCE; SELECTION; MUTATION; KDR; DUPLICATIONS; PROPORTIONS;
   ACTIVATION
AB In response to the widespread use of control strategies such as Insecticide Treated Nets (ITN), Anopheles mosquitoes have evolved various resistance mechanisms. Kdr is a mutation that provides physiological resistance to the pyrethroid insecticides family (PYR). In the present study, we investigated the effect of the Kdr mutation on the ability of female An. gambiae to locate and penetrate a 1cm-diameter hole in a piece of netting, either treated with insecticide or untreated, to reach a bait in a wind tunnel. Kdr homozygous, PYR-resistant mosquitoes were the least efficient at penetrating an untreated damaged net, with about 51% [39-63] success rate compared to 80% [70-90] and 78% [65-91] for homozygous susceptible and heterozygous respectively. This reduced efficiency, likely due to reduced host- seeking activity, as revealed by mosquito video-tracking, is evidence of a recessive behavioral cost of the mutation. Kdr heterozygous mosquitoes were the most efficient at penetrating nets treated with PYR insecticide, thus providing evidence for overdominance, the rarely-described case of heterozygote advantage conveyed by a single locus. The study also highlights the remarkable capacity of female mosquitoes, whether PYR-resistant or not, to locate holes in bed-nets.
C1 [Diop, Malal M.; Boussari, Olayide; Porciani, Angelique; Pennetier, Cedric] IRD, UM1 UM2 CNRS 5290 IRD 224, MiVEGEC, Cotonou, Benin.
   [Diop, Malal M.; Boussari, Olayide; Porciani, Angelique; Pennetier, Cedric] Ctr Rech Entomol Cotonou, Cotonou, Benin.
   [Moiroux, Nicolas; Chandre, Fabrice; Martin-Herrou, Hadrien; Duchon, Stephane] IRD, UM1 UM2 CNRS 5290 IRD 224, MiVEGEC, Montpellier, France.
   [Milesi, Pascal; Labbe, Pierrick] ISEM, CNRS 5554 UM2, Montpellier, France.
RP Pennetier, C (reprint author), IRD, UM1 UM2 CNRS 5290 IRD 224, MiVEGEC, Cotonou, Benin.
EM cedric.pennetier@ird.fr
RI Pennetier, Cedric/K-2010-2016; 
OI Diop, Malal/0000-0002-9985-158X; Labbe, Pierrick/0000-0003-0806-1919;
   Moiroux, Nicolas/0000-0001-6755-6167; Chandre,
   Fabrice/0000-0002-1994-9705
FU Institut de Recherche pour le Developpement (IRD); IRD
FX This work has been funded by Institut de Recherche pour le Developpement
   (IRD). MMD is supported by an IRD PhD fellowship. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
NR 49
TC 1
Z9 1
U1 2
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 1
PY 2015
VL 10
IS 4
AR UNSP e0121755
DI 10.1371/journal.pone.0121755
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CE9AM
UT WOS:000352135600082
PM 25831058
ER

PT J
AU Adjuik, MA
   Allan, R
   Anvikar, AR
   Ashley, EA
   Ba, MS
   Barennes, H
   Barnes, KI
   Bassat, Q
   Baudin, E
   Bjoorkman, A
   Bompart, F
   Bonnet, M
   Borrmann, S
   Brasseur, P
   Bukirwa, H
   Checchi, F
   Cot, M
   Dahal, P
   D'Alessandro, U
   Deloron, P
   Desai, M
   Diap, G
   Djimde, AA
   Dorsey, G
   Doumbo, OK
   Espiee, E
   Etard, JF
   Fanello, CI
   Faucher, JF
   Faye, B
   Flegg, JA
   Gaye, O
   Gething, PW
   Gonzalez, R
   Grandesso, F
   Guerin, PJ
   Guthmann, JP
   Hamour, S
   Hasugian, AR
   Hay, SI
   Humphreys, GS
   Jullien, V
   Juma, E
   Kamya, MR
   Karema, C
   Kiechel, JR
   Kremsner, PG
   Krishna, S
   Lameyre, V
   Ibrahim, LM
   Lee, SJ
   Lell, B
   Martensson, A
   Massougbodji, A
   Menan, H
   Menard, D
   Menendez, C
   Meremikwu, M
   Moreira, C
   Nabasumba, C
   Nambozi, M
   Ndiaye, JL
   Nikiema, F
   Nsanzabana, C
   Ntoumi, F
   Ogutu, BR
   Olliaro, P
   Osorio, L
   Ouedraogo, JB
   Penali, LK
   Pene, M
   Pinoges, L
   Piola, P
   Price, RN
   Roper, C
   Rosenthal, PJ
   Rwagacondo, CE
   Same-Ekobo, A
   Schramm, B
   Seck, A
   Sharma, B
   Sibley, CH
   Sinou, V
   Sirima, SB
   Smith, JJ
   Smithuis, F
   Some, FA
   Sow, D
   Staedke, SG
   Stepniewska, K
   Swarthout, TD
   Sylla, K
   Talisuna, AO
   Tarning, J
   Taylor, WRJ
   Temu, EA
   Thwing, JI
   Tjitra, E
   Tine, RCK
   Tinto, H
   Vaillant, MT
   Valecha, N
   Van den Broek, I
   White, NJ
   Yeka, A
   Zongo, I
AF Adjuik, Martin A.
   Allan, Richard
   Anvikar, Anupkumar R.
   Ashley, Elizabeth A.
   Ba, Mamadou S.
   Barennes, Hubert
   Barnes, Karen I.
   Bassat, Quique
   Baudin, Elisabeth
   Bjorkman, Anders
   Bompart, Francois
   Bonnet, Maryline
   Borrmann, Steffen
   Brasseur, Philippe
   Bukirwa, Hasifa
   Checchi, Francesco
   Cot, Michel
   Dahal, Prabin
   D'Alessandro, Umberto
   Deloron, Philippe
   Desai, Meghna
   Diap, Graciela
   Djimde, Abdoulaye A.
   Dorsey, Grant
   Doumbo, Ogobara K.
   Espie, Emmanuelle
   Etard, Jean-Francois
   Fanello, Caterina I.
   Faucher, Jean-Francois
   Faye, Babacar
   Flegg, Jennifer A.
   Gaye, Oumar
   Gething, Peter W.
   Gonzalez, Raquel
   Grandesso, Francesco
   Guerin, Philippe J.
   Guthmann, Jean-Paul
   Hamour, Sally
   Hasugian, Armedy Ronny
   Hay, Simon I.
   Humphreys, Georgina S.
   Jullien, Vincent
   Juma, Elizabeth
   Kamya, Moses R.
   Karema, Corine
   Kiechel, Jean R.
   Kremsner, Peter G.
   Krishna, Sanjeev
   Lameyre, Valerie
   Ibrahim, Laminou M.
   Lee, Sue J.
   Lell, Bertrand
   Martensson, Andreas
   Massougbodji, Achille
   Menan, Herve
   Menard, Didier
   Menendez, Clara
   Meremikwu, Martin
   Moreira, Clarissa
   Nabasumba, Carolyn
   Nambozi, Michael
   Ndiaye, Jean-Louis
   Nikiema, Frederic
   Nsanzabana, Christian
   Ntoumi, Francine
   Ogutu, Bernhards R.
   Olliaro, Piero
   Osorio, Lyda
   Ouedraogo, Jean-Bosco
   Penali, Louis K.
   Pene, Mbaye
   Pinoges, Loretxu
   Piola, Patrice
   Price, Ric N.
   Roper, Cally
   Rosenthal, Philip J.
   Rwagacondo, Claude Emile
   Same-Ekobo, Albert
   Schramm, Birgit
   Seck, Amadou
   Sharma, Bhawna
   Sibley, Carol Hopkins
   Sinou, Veronique
   Sirima, Sodiomon B.
   Smith, Jeffery J.
   Smithuis, Frank
   Some, Fabrice A.
   Sow, Doudou
   Staedke, Sarah G.
   Stepniewska, Kasia
   Swarthout, Todd D.
   Sylla, Khadime
   Talisuna, Ambrose O.
   Tarning, Joel
   Taylor, Walter R. J.
   Temu, Emmanuel A.
   Thwing, Julie I.
   Tjitra, Emiliana
   Tine, Roger C. K.
   Tinto, Halidou
   Vaillant, Michel T.
   Valecha, Neena
   Van den Broek, Ingrid
   White, Nicholas J.
   Yeka, Adoke
   Zongo, Issaka
CA WorldWide Antimalarial Resistance
TI The effect of dosing strategies on the therapeutic efficacy of
   artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of
   individual patient data
SO BMC Medicine
LA English
DT Article
DE Malaria; Plasmodium falciparum; Drug resistance; Artesunate;
   Amodiaquine; Dosing; Efficacy
ID PLASMODIUM-FALCIPARUM MALARIA; PLUS SULFADOXINE-PYRIMETHAMINE;
   CHLOROQUINE-RESISTANCE TRANSPORTER; FIXED-DOSE COMBINATION;
   ARTEMISININ-BASED COMBINATIONS; ANTIMALARIAL-DRUG RESISTANCE;
   MULTICENTER CLINICAL-TRIALS; NON-INFERIORITY TRIAL;
   ARTEMETHER-LUMEFANTRINE; IN-VIVO
AB Background: Artesunate-amodiaquine (AS-AQ) is one of the most widely used artemisinin-based combination therapies (ACTs) to treat uncomplicated Plasmodium falciparum malaria in Africa. We investigated the impact of different dosing strategies on the efficacy of this combination for the treatment of falciparum malaria.
   Methods: Individual patient data from AS-AQ clinical trials were pooled using the WorldWide Antimalarial Resistance Network (WWARN) standardised methodology. Risk factors for treatment failure were identified using a Cox regression model with shared frailty across study sites.
   Results: Forty-three studies representing 9,106 treatments from 1999-2012 were included in the analysis; 4,138 (45.4%) treatments were with a fixed dose combination with an AQ target dose of 30 mg/kg (FDC), 1,293 (14.2%) with a non-fixed dose combination with an AQ target dose of 25 mg/kg (loose NFDC-25), 2,418 (26.6%) with a non-fixed dose combination with an AQ target dose of 30 mg/kg (loose NFDC-30), and the remaining 1,257 (13.8%) with a co-blistered non-fixed dose combination with an AQ target dose of 30 mg/kg (co-blistered NFDC). The median dose of AQ administered was 32.1 mg/kg [IQR: 25.9-38.2], the highest dose being administered to patients treated with co-blistered NFDC (median = 35.3 mg/kg [IQR: 30.6-43.7]) and the lowest to those treated with loose NFDC-25 (median = 25.0 mg/kg [IQR: 22.7-25.0]). Patients treated with FDC received a median dose of 32.4 mg/kg [IQR: 27-39.0]. After adjusting for reinfections, the corrected antimalarial efficacy on day 28 after treatment was similar for co-blistered NFDC (97.9% [95% confidence interval (CI): 97.0-98.8%]) and FDC (98.1% [95% CI: 97.6%-98.5%]; P = 0.799), but significantly lower for the loose NFDC-25 (93.4% [95% CI: 91.9%-94.9%]), and loose NFDC-30 (95.0% [95% CI: 94.1%-95.9%]) (P < 0.001 for all comparisons). After controlling for age, AQ dose, baseline parasitemia and region; treatment with loose NFDC-25 was associated with a 3.5-fold greater risk of recrudescence by day 28 (adjusted hazard ratio, AHR = 3.51 [95% CI: 2.02-6.12], P < 0.001) compared to FDC, and treatment with loose NFDC-30 was associated with a higher risk of recrudescence at only three sites.
   Conclusions: There was substantial variation in the total dose of amodiaquine administered in different AS-AQ combination regimens. Fixed dose AS-AQ combinations ensure optimal dosing and provide higher antimalarial treatment efficacy than the loose individual tablets in all age categories.
C1 [Adjuik, Martin A.] INDEPTH NETWORK Secretariat, Accra, Ghana.
   [Allan, Richard] MENTOR Initiat, Crawley, England.
   [Anvikar, Anupkumar R.; Valecha, Neena] Natl Inst Malaria Res, New Delhi, India.
   [Ashley, Elizabeth A.; Baudin, Elisabeth; Checchi, Francesco; Guthmann, Jean-Paul; Pinoges, Loretxu] Epictr, Paris, France.
   [Ba, Mamadou S.; Faye, Babacar; Ndiaye, Jean-Louis; Pene, Mbaye; Sow, Doudou; Tine, Roger C. K.] Univ Cheikh Anta Diop, Fac Med, Dept Parasitol, Dakar, Senegal.
   [Barennes, Hubert] Ctr Muraz, Unite Epidemiol Intervent, Bobo Dioulasso, Burkina Faso.
   [Barennes, Hubert] French Foreign Affairs, Biarritz, France.
   [Barnes, Karen I.; Yeka, Adoke] WWARN, Pharmacol Module, Cape Town, South Africa.
   [Barnes, Karen I.] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa.
   [Bassat, Quique; Gonzalez, Raquel; Menendez, Clara] Ctr Invest Saude Manhica, Manhica, Mozambique.
   [Bassat, Quique; Gonzalez, Raquel; Menendez, Clara] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain.
   [Bjorkman, Anders; Martensson, Andreas] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.
   [Bompart, Francois] Direct AccEs Med Access Med, Gentilly, France.
   [Bonnet, Maryline] Epictr, Geneva, Switzerland.
   [Borrmann, Steffen] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
   [Borrmann, Steffen] German Ctr Infect Res, Tubingen, Germany.
   [Brasseur, Philippe] IRD, Dakar, Senegal.
   [Bukirwa, Hasifa; Yeka, Adoke] Uganda Malaria Surveillance Project, Kampala, Uganda.
   [Cot, Michel; Deloron, Philippe] IRD, Mother & Child Hlth Trop Res Unit, Paris, France.
   [Cot, Michel; Deloron, Philippe] Univ Paris 05, Sorbonne Paris Cite, PRES, Paris, France.
   [Dahal, Prabin; Flegg, Jennifer A.; Guerin, Philippe J.; Humphreys, Georgina S.; Moreira, Clarissa; Nsanzabana, Christian; Sibley, Carol Hopkins; Stepniewska, Kasia] WWARN, Oxford, England.
   [Dahal, Prabin; Fanello, Caterina I.; Guerin, Philippe J.; Humphreys, Georgina S.; Lee, Sue J.; Moreira, Clarissa; Nsanzabana, Christian; Olliaro, Piero; Price, Ric N.; Tarning, Joel; White, Nicholas J.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
   [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia.
   [Desai, Meghna; Thwing, Julie I.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA.
   [Diap, Graciela; Kiechel, Jean R.] Drugs Neglected Dis initiat, Geneva, Switzerland.
   [Djimde, Abdoulaye A.] Univ Bamako, Fac Med Pharm & Odontostomatol, Dept Epidemiol Parasit Dis, Malaria Res & Training Ctr, Bamako, Mali.
   [Dorsey, Grant; Rosenthal, Philip J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Espie, Emmanuelle] Inst Pasteur, Dakar, Senegal.
   [Etard, Jean-Francois] IRD, Montpellier, France.
   [Fanello, Caterina I.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit MORU, Bangkok 10700, Thailand.
   [Faucher, Jean-Francois] Basancon Univ, Med Ctr, Dept Infect Dis, Besancon, France.
   [Flegg, Jennifer A.] Monash Univ, Sch Math Sci, Melbourne, Vic 3004, Australia.
   [Flegg, Jennifer A.] Monash Univ, Monash Acad Cross & Interdisciplinary Math Applic, Melbourne, Vic 3004, Australia.
   [Gething, Peter W.; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford, England.
   [Hamour, Sally] Royal Free Hosp, UCL Ctr Nephrol, London NW3 2QG, England.
   [Hasugian, Armedy Ronny; Tjitra, Emiliana] Nat Inst Hlth Res & Dev, Minist Hlth, Jakarta, Indonesia.
   [Jullien, Vincent] Univ Paris 05, Assistance Publ Hop Paris, Paris, France.
   [Juma, Elizabeth] Kenya Govt Med Res Ctr, Clin Res Ctr, Nairobi, Kenya.
   [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Kampala, Uganda.
   [Karema, Corine] Minist Hlth, Malaria & Other Parasit Dis Div RBC, Kigali, Rwanda.
   [Kremsner, Peter G.; Lell, Bertrand] Ctr Rech Med Lambarene, Lambarene, Gabon.
   [Kremsner, Peter G.; Lell, Bertrand; Ntoumi, Francine] Univ Tubingen, Inst Tropenmed, Tubingen, Germany.
   [Krishna, Sanjeev] Univ London, Inst Infect & Immun St Georges, London, England.
   [Ibrahim, Laminou M.] Ctr Rech Med & Sanitaire, Niamey, Niger.
   [Martensson, Andreas] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.
   [Martensson, Andreas] Uppsala Univ, Ctr Clin Res Sormland, S-75105 Uppsala, Sweden.
   [Massougbodji, Achille] Univ Abomey Calavi, FSS, CERPAGE, Cotonou, Benin.
   [Menan, Herve] Univ Cocody, Fac Pharm, Dept Parasitol, Abidjan, Cote Ivoire.
   [Menard, Didier] Inst Pasteur Cambodge, Unite Epidemiol Mol Paludisme, Phnom Penh, Cambodia.
   [Meremikwu, Martin] Univ Calabar, Dept Paediat, Calabar, Nigeria.
   [Meremikwu, Martin] Inst Trop Dis Res & Prevent, Calabar, Nigeria.
   [Nabasumba, Carolyn] Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda.
   [Nambozi, Michael] Trop Dis Res Ctr, Ndola, Zambia.
   [Nikiema, Frederic; Ouedraogo, Jean-Bosco; Tinto, Halidou; Zongo, Issaka] Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso.
   [Ntoumi, Francine] Univ Marien Ngouabi, Fac Sci Sante, FCRM, Brazzaville, Congo.
   [Ogutu, Bernhards R.] Kenya Govt Med Res Ctr, United States Army Med Res Unit, Kisumu, Kenya.
   [Olliaro, Piero; Taylor, Walter R. J.] UNDP, UNICEF, World Bank WHO Special Programme, Res & Training Trop Dis TDR, Geneva, Switzerland.
   [Osorio, Lyda] Int Ctr Med Res & Training CIDEIM, Cali, Colombia.
   [Ouedraogo, Jean-Bosco; Tinto, Halidou] Ctr Muraz, Bobo Dioulasso, Burkina Faso.
   [Penali, Louis K.; Seck, Amadou] WWARN, West Africa Reg Ctr, Dakar, Senegal.
   [Piola, Patrice] Inst Pasteur Madagascar, Antananarivo, Madagascar.
   [Price, Ric N.] Menzies Sch Hlth Res, Darwin, NT, Australia.
   [Price, Ric N.] Charles Darwin Univ, Darwin, NT 0909, Australia.
   [Roper, Cally] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Pathogen Mol Biol, London WC1, England.
   [Rwagacondo, Claude Emile] UNICEF WCARO, RBM Focal Point, Dakar, Senegal.
   [Same-Ekobo, Albert] Univ Yaounde, Ctr Hosp, Yaounde, Cameroon.
   [Sharma, Bhawna] Drugs Neglected Dis initiat, New Delhi, India.
   [Sibley, Carol Hopkins] Univ Washington, Dept Gen Sci, Seattle, WA 98195 USA.
   [Sinou, Veronique] Aix Marseille Univ, Fac Pharm, UMR MD3, Marseille, France.
   [Sirima, Sodiomon B.] CNRFP, Ouagadougou, Burkina Faso.
   [Smith, Jeffery J.; Tarning, Joel] WWARN, Asia Reg Ctr, Bangkok, Thailand.
   [Smith, Jeffery J.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [Smithuis, Frank] Med Sans Frontieres Holland, Yangon, Myanmar.
   [Smithuis, Frank] Med Act Myanmar, Yangon, Myanmar.
   [Staedke, Sarah G.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England.
   [Staedke, Sarah G.] Infect Dis Res Collaborat, Kampala, Uganda.
   [Swarthout, Todd D.] Med Sans Frontieres, London, England.
   [Talisuna, Ambrose O.] WWARN, East Africa Reg Ctr, Nairobi, Kenya.
   [Talisuna, Ambrose O.] Univ Oxford, KEMRI, Wellcome Trust Res Programme, Nairobi, Kenya.
   [Taylor, Walter R. J.] Hop Univ Geneva, Serv Med Int & Humanitaire, Geneva, Switzerland.
   [Temu, Emmanuel A.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Temu, Emmanuel A.] Univ Basel, Basel, Switzerland.
   [Vaillant, Michel T.] CRP Sante, Ctr Hlth Studies, Methodol & Stat Unit, Luxembourg, Luxembourg.
   [Vaillant, Michel T.] Univ Victor Segalen Bordeaux 2, Bases Therapeut Inflammat & Infect, Unite 3677, Bordeaux, France.
   [Van den Broek, Ingrid] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands.
   [Yeka, Adoke] Makerere Univ, Sch Publ Hlth, Kampala, Uganda.
RP Guerin, PJ (reprint author), Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England.
EM philippe.guerin@wwarn.org; christian.nsanzabana@wwarn.org
RI Roper, Cally/K-2989-2013; Hay, Simon/F-8967-2015; 
OI Roper, Cally/0000-0002-6545-309X; Hay, Simon/0000-0002-0611-7272; Flegg,
   Jennifer/0000-0002-8809-726X; Gething, Peter/0000-0001-6759-5449; Dahal,
   Prabin/0000-0002-2158-846X; Krishna, Sanjeev/0000-0003-0066-0634; Price,
   Richard/0000-0003-2000-2874
FU Bill and Melinda Gates Foundation
FX WWARN is funded by a Bill and Melinda Gates Foundation grant. The funder
   did not participate in the study protocol development and the writing of
   the paper.
NR 78
TC 0
Z9 0
U1 2
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD MAR 31
PY 2015
VL 13
AR 66
DI 10.1186/s12916-015-0301-z
PG 19
WC Medicine, General & Internal
SC General & Internal Medicine
GA CG8CY
UT WOS:000353536000001
ER

PT J
AU Oxborough, RM
   N'Guessan, R
   Jones, R
   Kitau, J
   Ngufor, C
   Malone, D
   Mosha, FW
   Rowland, MW
AF Oxborough, Richard M.
   N'Guessan, Raphael
   Jones, Rebecca
   Kitau, Jovin
   Ngufor, Corine
   Malone, David
   Mosha, Franklin W.
   Rowland, Mark W.
TI The activity of the pyrrole insecticide chlorfenapyr in mosquito
   bioassay: towards a more rational testing and screening of
   non-neurotoxic insecticides for malaria vector control
SO MALARIA JOURNAL
LA English
DT Article
DE Chlorfenapyr; ITN; Anopheles gambiae; Vector control; Bioassay;
   Insecticide; Malaria
ID RESISTANT ANOPHELES-GAMBIAE; CULEX-QUINQUEFASCIATUS MOSQUITOS; CIRCADIAN
   FLIGHT ACTIVITY; PYRETHROID-RESISTANT; BED NETS; PERMETHRIN; CULICIDAE;
   DIPTERA; ARABIENSIS; TEMPERATURE
AB Background: The rapid selection of pyrethroid resistance throughout sub-Saharan Africa is a serious threat to malaria vector control. Chlorfenapyr is a pyrrole insecticide which shows no cross resistance to insecticide classes normally used for vector control and is effective on mosquito nets under experimental hut conditions. Unlike neurotoxic insecticides, chlorfenapyr owes its toxicity to disruption of metabolic pathways in mitochondria that enable cellular respiration. A series of experiments explored whether standard World Health Organization (WHO) guidelines for evaluation of long-lasting insecticidal nets, developed through testing of pyrethroid insecticides, are suitable for evaluation of non-neurotoxic insecticides.
   Methods: The efficacy of WHO recommended cone, cylinder and tunnel tests was compared for pyrethroids and chlorfenapyr. To establish bioassay exposure times predictive of insecticide-treated net (ITN) efficacy in experimental hut trials, standard three-minute bioassays of pyrethroid and chlorfenapyr ITNs were compared with longer exposures. Mosquito behaviour and response to chlorfenapyr ITN in bioassays conducted at night were compared to day and across a range of temperatures representative of highland and lowland transmission.
   Results: Standard three-minute bioassay of chlorfenapyr produced extremely low levels of mortality compared to pyrethroids. Thirty-minute day-time bioassay produced mortality closer to hut efficacy of chlorfenapyr ITN but still fell short of the WHO threshold. Overnight tunnel test with chlorfenapyr produced 100% mortality and exceeded the WHO threshold of 80%. The endogenous circadian activity rhythm of anophelines results in inactivity by day and raised metabolism and flight activity by night. A model which explains improved toxicity of chlorfenapyr ITN when tested at night, and during the day at higher ambient temperature, is that activation of chlorfenapyr and disruption of respiratory pathways is enhanced when the insect is more metabolically and behaviourally active.
   Conclusions: Testing according to current WHO guidelines is not suitable for certain types of non-neurotoxic insecticide which, although highly effective in field trials, would be overlooked at the screening stage of evaluation through bioassay. Testing methods must be tailored to the characteristics and mode of action of each insecticide class. The WHO tunnel test on night-active anophelines is the most reliable bioassay for identifying the toxicity of novel insecticides.
C1 [Oxborough, Richard M.; N'Guessan, Raphael; Jones, Rebecca; Ngufor, Corine; Rowland, Mark W.] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England.
   [Oxborough, Richard M.; Kitau, Jovin; Mosha, Franklin W.] Kilimanjaro Christian Med Univ Coll, Dept Entomol & Parasitol, Moshi, Kilimanjaro, Tanzania.
   [N'Guessan, Raphael; Ngufor, Corine] Minist Sante, Lab Natl, Ctr Rech Entomol Cotonou, CREC Labs, Cotonou 06, Benin.
   [Oxborough, Richard M.; N'Guessan, Raphael; Kitau, Jovin; Ngufor, Corine; Mosha, Franklin W.; Rowland, Mark W.] Pan African Malaria Vector Res Consortium PAMVERC, Moshi, Tanzania.
   [Malone, David] Univ Liverpool Liverpool Sch Trop Med, IVCC, Liverpool L3 5QA, Merseyside, England.
RP Oxborough, RM (reprint author), London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England.
EM oxandbull@hotmail.com
FU Innovative Vector Control Consortium (IVCC, Liverpool, UK)
FX All biological evaluations conducted by PAMVERC were financially
   supported by the Innovative Vector Control Consortium (IVCC, Liverpool,
   UK). The nets used in this study were provided by BASF Professional &
   Specialty Solutions, Public Health (Germany). The authors thank Drs
   Susanne Stutz, Egon Weinmueller and Wolfgang Paulus of BASF SE,
   Limbergerhof, Germany, Dr James Austin of BASF Corporation, North
   Carolina, USA for technical input, insecticides and LLINs. The authors
   thank Robert Sloss of IVCC, Liverpool, UK and Dr Robert Farlow of Robert
   Farlow Consulting LLC, Texas, USA for technical and programme support.
   RMO, RN, CN and MR are members of the Malaria Centre of the London
   School of Hygiene and Tropical Medicine, http:/malaria.lshtm.ac.uk/. We
   are grateful to K Ezekia, R Mndeme, R Athuman, C Masenga, H Temba, G
   Chuwa, O Mohammed, A Msapalla, A Tumaini, A Mtui, E Philipo, E Tilya, P
   Anthony, S Mushiro, J Mpuya, E Kessy, L Mollel, F Temba, E Mushi for
   insectary, laboratory and administrative assistance.
NR 34
TC 6
Z9 6
U1 2
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAR 24
PY 2015
VL 14
AR 124
DI 10.1186/s12936-015-0639-x
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CF0WR
UT WOS:000352265600001
PM 25879231
ER

PT J
AU Moya-Alvarez, V
   Cottrell, G
   Ouedraogo, S
   Accrombessi, M
   Massougbodgi, A
   Cot, M
AF Moya-Alvarez, Violeta
   Cottrell, Gilles
   Ouedraogo, Smaila
   Accrombessi, Manfred
   Massougbodgi, Achille
   Cot, Michel
TI Does Iron Increase the Risk of Malaria in Pregnancy?
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE iron levels; pregnancy-associated malaria
ID PLASMODIUM-FALCIPARUM INFECTION; MATERNAL ANEMIA; ENDOTHELIAL
   ACTIVATION; WESTERN KENYA; BIRTH-WEIGHT; ENDEMIC AREA; PREVENTION;
   WOMEN; SUPPLEMENTATION; METAANALYSIS
AB Background. Pregnancy-associated malaria (PAM) remains a significant health concern in sub-Saharan Africa. Cross-sectional studies report that iron might be associated with increased malaria morbidity, raising fears that current iron supplementation policies will cause harm in the present context of increasing resistance against intermittent preventive treatment in pregnancy (IPTp). Therefore, it is necessary to assess the relation of iron levels with malaria risk during the entire pregnancy.
   Methods. To investigate the association of maternal iron levels on malaria risk in the context of an IPTp clinical trial, 1005 human immunodeficiency virus-negative, pregnant Beninese women were monitored throughout their pregnancy between January 2010 and May 2011. Multilevel models with random intercept at the individual levels and random slope for gestational age were used to analyze the factors associated with increased risk of a positive blood smear and increased Plasmodium falciparum density.
   Results. During the follow-up, 29% of the women had at least 1 episode of malaria. On average, women had 0.52 positive smears (95% confidence interval [CI], 0.44-0.60). High iron levels (measured by the log(10) of ferritin corrected on inflammation) were significantly associated with increased risk of a positive blood smear (adjusted odds ratio = 1.75; 95% CI, 1.46-2.11; P < .001) and high P falciparum density (beta estimate = 0.22; 95% CI, 0.18-0.27; P < .001) during the follow-up period adjusted on pregnancy parameters, comorbidities, environmental and socioeconomic indicators, and IPTp regime. Furthermore, iron-deficient women were significantly less likely to have a positive blood smear and high P falciparum density (P < .001 in both cases).
   Conclusions. Iron levels were positively associated with increased PAM during pregnancy in the context of IPTp. Supplementary interventional studies are needed to determine the benefits and risks of differently dosed iron and folate supplements in malaria-endemic regions.
C1 [Moya-Alvarez, Violeta; Cottrell, Gilles; Cot, Michel] Inst Rech Dev, MERIT Mere & Enfant Face Infect Trop, Paris, France.
   [Moya-Alvarez, Violeta; Accrombessi, Manfred] Univ Paris 06, Paris, France.
   [Moya-Alvarez, Violeta] Ecole Hautes Etud Sante Publ, Reseau Doctoral, Rennes, France.
   [Moya-Alvarez, Violeta; Cottrell, Gilles; Ouedraogo, Smaila; Accrombessi, Manfred; Cot, Michel] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
   [Ouedraogo, Smaila] Inst Rech Dev, MERIT Mere & Enfant Face Infect Trop, Cotonou, Benin.
   [Ouedraogo, Smaila] Univ Ouagadougou, Unite Format & Rech Sci Sante, Ouagadougou, Burkina Faso.
   [Ouedraogo, Smaila] Ctr Hosp Univ Yalgado Ouedraogo, Publ Hlth Dept, Ouagadougou, Burkina Faso.
   [Massougbodgi, Achille] Univ Abomey Calavi, Fac Sci Sante, Cotonou, Benin.
RP Moya-Alvarez, V (reprint author), Univ Paris 05, MERIT, IRD, UMR 216, 4 Ave Observ, F-75270 Paris 06, France.
EM vmoyaalvarez@gmail.com
NR 44
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD SPR
PY 2015
VL 2
IS 2
DI 10.1093/ofid/ofv038
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA CX6BM
UT WOS:000365786200033
ER

EF